Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection by Bøtker, HE et al.
Vol.:(0123456789) 
Basic Research in Cardiology  (2018) 113:39  
https://doi.org/10.1007/s00395-018-0696-8
PRACTICAL GUIDELINE
Practical guidelines for rigor and reproducibility in preclinical 
and clinical studies on cardioprotection
Hans Erik Bøtker1  · Derek Hausenloy2,3,4,5,6 · Ioanna Andreadou7 · Salvatore Antonucci8 · Kerstin Boengler9 · 
Sean M. Davidson2 · Soni Deshwal8 · Yvan Devaux10 · Fabio Di Lisa8 · Moises Di Sante8 · Panagiotis Efentakis7 · 
Saveria Femminò11 · David García‑Dorado12 · Zoltán Giricz13,14 · Borja Ibanez15 · Efstathios Iliodromitis16 · 
Nina Kaludercic8 · Petra Kleinbongard17 · Markus Neuhäuser18,19 · Michel Ovize20,21 · Pasquale Pagliaro11 · 
Michael Rahbek‑Schmidt1 · Marisol Ruiz‑Meana12 · Klaus‑Dieter Schlüter9 · Rainer Schulz9 · Andreas Skyschally17 · 
Catherine Wilder2 · Derek M. Yellon2 · Peter Ferdinandy13,14 · Gerd Heusch17 
Received: 30 May 2018 / Revised: 18 July 2018 / Accepted: 3 August 2018 
© The Author(s) 2018
An initiative of the European Union—CARDIOPROTECTION 
COST ACTION CA16225 “Realising the therapeutic potential of 
novel cardioprotective therapies” (www.cardi oprot ectio n.eu).
Hans Erik Bøtker, Derek Hausenloy, Peter Ferdinandy and Gerd 
Heusch are joint first and last authors, as per COST ACTION policy.
Professors Michael V. Cohen, MD, and James M. Downey, PhD, 
Dept. of Physiology, University of South Alabama, Mobile, 
Alabama, USA, served as guest editors for this article and were 
responsible for all editorial decisions, including selection of 
reviewers. Such transfer policy to guest editor(s) applies to all 
manuscripts with authors from the editor’s institution.
 * Hans Erik Bøtker 
 haboet@rm.dk
 * Gerd Heusch 
 gerd.heusch@uk‑essen.de
1 Department of Cardiology, Aarhus University Hospital, 
Palle‑Juul Jensens Boulevard 99, 8200 Aarhus N, Denmark
2 The Hatter Cardiovascular Institute, University College London, 
67 Chenies Mews, London WC1E 6HX, UK
3 The National Institute of Health Research, University College 
London Hospitals Biomedial Research Centre, Research 
and Development, London, UK
4 National Heart Research Institute Singapore, National Heart 
Centre, Singapore, Singapore
5 Yon Loo Lin School of Medicine, National University Singapore, 
Singapore, Singapore
6 Cardiovascular and Metabolic Disorders Program, Duke‑National 
University of Singapore, 8 College Road, Singapore 169857, 
Singapore
7 Laboratory of Pharmacology, Faculty of Pharmacy, National 
and Kapodistrian University of Athens, Athens, Greece
8 Department of Biomedical Sciences, CNR Institute 
of Neuroscience, University of Padova, Via Ugo Bassi 58/B, 
35121 Padua, Italy
9 Institute for Physiology, Justus‑Liebig University Giessen, 
Giessen, Germany
10 Cardiovascular Research Unit, Luxembourg Institute of Health, 
Strassen, Luxembourg
11 Department of Clinical and Biological Sciences, University 
of Torino, Turin, Italy
12 Experimental Cardiology, Vall d’Hebron Institut de Recerca 
(VHIR), Hospital Universitari Vall d’Hebron, Pg. Vall d’Hebron 
119‑129, 08035 Barcelona, Spain
13 Department of Pharmacology and Pharmacotherapy, Semmelweis 
University, Budapest, Hungary
14 Pharmahungary Group, Szeged, Hungary
15 Centro Nacional de Investigaciones Cardiovasculares Carlos III 
(CNIC), IIS‑Fundación Jiménez Díaz, CIBERCV, Madrid, Spain
16 Second Department of Cardiology, Faculty of Medicine, Attikon 
University Hospital, National and Kapodistrian University 
of Athens, Athens, Greece
17 Institute for Pathophysiology, West German Heart and Vascular 
Center, University of Essen Medical School, Essen, Germany
18 Department of Mathematics and Technology, Koblenz University 
of Applied Science, Remagen, Germany
19 Institute for Medical Informatics, Biometry, and Epidemiology, 
University Hospital Essen, Essen, Germany
20 Explorations Fonctionnelles Cardiovasculaires, Hôpital Louis 
Pradel, Lyon, France
21 UMR, 1060 (CarMeN), Université Claude Bernard, Lyon1, 
Villeurbanne, France
 Basic Research in Cardiology  (2018) 113:39 
1 3
39  Page 2 of 73
Abbreviations
ADP  Adenosine diphosphate
ANOVA  Analysis of variance
ATP  Adenosine triphosphate
CK  Creatine kinase
CK‑MB  Creatine kinase‑muscle/brain
CMR  Cardiac magnetic resonance imaging
CsA  Cyclosporine A
ECG  Electrocardiogram
EGTA  Ethylene glycol‑bis(β‑aminoethyl ether)‑
N,N,N’,N’‑tetraacetic acid
FCCP  Carbonyl cyanide‑4‑(trifluoromethoxy)
phenylhydrazone
FCS  Fetal calf serum
HEPES  4‑(2‑hydroxyethyl)‑1‑piperazineethanesul‑
fonic acid
ICH  International conference on harmonization
IFM  Interfibrillar mitochondria
JC‑1  Tetraethyl‑benzimidazolyl‑carbocyanine 
iodide
KHB  Krebs–Henseleit buffer
LDH  Lactate dehydrogenase
LGE  Late gadolinium enhancement
LOCF  Last observation carried forward
MACCE  Major adverse cardiac and cerebral events
MOPS  3‑(N‑morpholino)propanesulfonic acid
mPTP  Mitochondrial permeability transition pore
MTT  (3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphe‑
nyltetrazolium bromide) tetrazolium
PPCI  Primary percutaneous coronary 
intervention
RNA  Ribonucleic acid
ROS  Reactive oxygen species
SPECT  Single‑photon emission computed 
tomography
SSM  Subsarcolemmal mitochondria
STEMI  ST segment elevation myocardial infarction
T2w‑CMR  T2‑weighted cardiac magnetic resonance 
imaging
TMRE  Ethyl ester of tetramethylrhodamine
TMRM  Methyl ester of tetramethylrhodamine
TTC  2,3,5‑triphenyl tetrazolium chloride
Acronyms
ARRIVE  Animal research: reporting of in vivo 
experiments
CAESAR  Consortium for preclinical assessment of 
cardioprotective therapies
CONDI‑2  Effect of remote ischemic conditioning 
on clinical outcomes in STEMI patients 
undergoing pPCI
ERIC‑PPCI  Effect of remote ischemic condition‑
ing on clinical outcomes in ST‑segment 
elevation myocardial infarction patients 
undergoing primary percutaneous coronary 
intervention
EuroSCORE  European system for cardiac operative risk 
evaluation
TIMI  Thrombolysis in myocardial infarction
Introduction
The potential for ischemic preconditioning to reduce infarct 
size was first recognized more than 30 years ago [180]. 
Despite extension of the concept to ischemic postcondition‑
ing [460] and remote ischemic conditioning [202, 344] and 
literally thousands of experimental studies in various spe‑
cies and models which identified a multitude of signaling 
steps [199], so far there is only a single and very recent 
study, which has unequivocally translated cardioprotection 
to improved clinical outcome as the primary endpoint in 
patients [155, 200]. Many potential reasons for this disap‑
pointing lack of clinical translation of cardioprotection have 
been proposed, including lack of rigor and reproducibility in 
preclinical studies [54, 195], and poor design and conduct of 
clinical trials [196, 206]. There is, however, universal agree‑
ment that robust preclinical data are a mandatory prerequi‑
site to initiate a meaningful clinical trial. In this context, it 
is disconcerting that the CAESAR consortium (Consortium 
for preclinicAl assESsment of cARdioprotective therapies) 
in a highly standardized multi‑center approach of preclini‑
cal studies identified only ischemic preconditioning, but not 
nitrite or sildenafil, when given as adjunct to reperfusion, to 
reduce infarct size [230]. However, ischemic precondition‑
ing—due to its very nature—can only be used in elective 
interventions, and not in acute myocardial infarction [181, 
197, 203]. Therefore, better strategies to identify robust and 
reproducible strategies of cardioprotection, which can sub‑
sequently be tested in clinical trials must be developed [184]. 
We refer to the recent guidelines for experimental models of 
myocardial ischemia and infarction [279], and aim to pro‑
vide now practical guidelines to ensure rigor and reproduc‑
ibility in preclinical and clinical studies on cardioprotection. 
In line with the above guidelines [279], we define rigor as 
standardized state‑of‑the‑art design, conduct and reporting 
of a study, which is then a prerequisite for reproducibility, 
i.e. replication of results by another laboratory when per‑
forming exactly the same experiment.
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Randomization, blinding, power analysis 
and statistics
Study design, randomization, blinding, power 
analysis, statistics
The ICH (International Conference on Harmonization) E9 
guideline [168] is the most prominent guideline for sta‑
tistical principles in clinical trials. In some analogy, the 
ARRIVE (Animal Research: Reporting of In vivo Experi‑
ments) guidelines make recommendations for reporting ani‑
mal research [94, 212, 249], notably study design, including 
power analysis and sample size planning, randomization of 
study groups, blinding of investigators, and adequate statisti‑
cal procedures to evaluate and interpret the data [345]. Some 
journals [54, 176] have established additional guidelines for 
planning, performing and reporting experimental studies and 
the respective data. For clinical trials, the ICH E6 guide‑
line for Good Clinical Practice (see http://www.ich.org/filea 
dmin/Publi c_Web_Site/ICH_Produ cts/Guide lines /Effic acy/
E6/E6_R2__Step_4_2016_1109.pdf) must be considered. 
This guideline addresses various issues related to quality 
control, including monitoring before, during, and after the 
trial. In addition, there are clinical trial registries to provide 
better transparency of and access to clinical trials. Similar 
registries would also be useful for preclinical trials.
Here, we aim to provide a pragmatic framework for study 
design, including power analysis, randomization, blinding 
and statistical data analysis for the presentation of preclinical 
and clinical studies (for clinical trials see also http://www.
conso rt‑state ment.org/) on acute myocardial infarction and 
cardioprotection.
Exploratory vs. prospective studies
The gold standard for clinical trial design is a prospective, 
randomized, blinded, controlled study. The bias of such pro‑
spective studies is lowest, and their data are most robust. 
However, most studies on cardioprotection fall into the 
category of observational/exploratory study; other studies 
retrospectively analyze previously recorded data. The selec‑
tion of the design (observational/exploratory vs. prospec‑
tive) for a given project always represents a compromise of a 
most rigorous approach vs. limited resources and feasibility. 
Clearly, an exploratory study, while aiming for novelty, is 
associated with a greater risk of false‑positive findings due 
to confounding factors, whereas a prospective study aims 
for an existing specific hypothesis but provides more robust 
data.
Study design
Selection of variables/endpoints
According to the ICH E9 guideline [168], the primary vari‑
able “should be the variable capable of providing the most 
relevant and convincing evidence directly related to the pri‑
mary objective of the trial”. This is also true for experimen‑
tal studies, and ideally there is only one primary endpoint. 
Infarct size is the gold standard primary endpoint; ventricu‑
lar function or release of biomarkers during reperfusion may 
also be used as endpoints of cardioprotection.
When infarct size is used as the primary endpoint, sec‑
ondary endpoints can be hemodynamics such as coronary 
blood flow or ventricular function. Further, secondary end‑
points can be mitochondrial function or expression or acti‑
vation of signaling proteins. Material from biopsies is often 
analyzed at only one time point, mostly at the end of the 
experiment.
Number of experimental groups
The simplest design of a cardioprotection study has only 
two groups (control/placebo with myocardial infarction 
without intervention versus the verum group with myocar‑
dial infarction and with cardioprotective intervention). This 
basic model can be extended to other groups, e.g. myocardial 
infarction with cardioprotective intervention and blocking 
agents or another cardioprotective intervention, etc. Clearly, 
the choice and, therefore, the number of groups depend on 
the aim of the experiment. The primary endpoint must be 
measured in all groups. When there are more than two 
groups and/or more than one endpoint, one has to carry out 
more than one statistical test. As a consequence, the mul‑
tiplicity of tests must be considered to control for the rate 
of false‑positive conclusions at an acceptable level. When 
a significant difference in at least one endpoint is sufficient 
to claim an effect, the significance level α can be adjusted 
using the Bonferroni correction, where P values are com‑
pared with α/k instead of α when performing k statistical 
tests. For instance, if α = 0.05 (as usual) and there are four 
endpoints, a P value has to be smaller than 0.05/4 = 0.0125 
for achieving significance. The Bonferroni correction is the 
easiest adjustment; there are more sophisticated and more 
efficient alternatives [319]. When the decision rule is that 
statistical significance is needed for all primary variables, 
no special method such as the Bonferroni adjustment to 
consider for the multiplicity of tests is needed. All tests can 
be performed with the unadjusted α‑level, but all single P 
values have to be ≤ α for significance. This procedure inflates 
the type II error rate, which must be taken into account for 
sample size determination.
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Inclusion and exclusion criteria
Inclusion and exclusion criteria must be specified in advance 
and reported as transparently and as detailed as possible [54, 
94, 176, 212, 249]. Individual animals from one breeder 
with comparable baseline characteristics (age, gender, body 
weight, etc.) should be included. When genetic variants are 
analyzed in one experimental group, their wild‑type litter‑
mates or animals with a comparable genetic background must 
serve as controls. All factors aside from the intervention (age, 
sex and housing conditions of the animals, but also the indi‑
vidual investigator), should be kept unchanged. Major devia‑
tions, as defined in advance, must result in exclusion from 
analysis in experimental studies. Exclusion is particularly 
mandatory for factors known to impact on the intervention 
itself (e.g. use of blocking agent from different batches, dif‑
ferent procedures and algorithms of the protective interven‑
tion, etc.) and for factors known to impact on the endpoints 
(e.g. temperature, etc.). However, in prospective preclinical 
and clinical trials all randomized preparations/individuals 
(patients/animals) must be included in the intention‑to‑treat 
analysis. An additional per‑protocol analysis excluding prep‑
arations/animals/patients who seriously violated the protocol 
(see ICH E9 guideline [168]) is frequently of scientific rel‑
evance. A similar procedure with two separate analyses is 
also possible when potentially interfering variables become 
apparent only in retrospect: one may perform the data analy‑
sis twice, once with all data points and in addition once after 
exclusion of the respective data points. In prospective exper‑
imental studies, however, it is common and also accepted 
[94, 212, 249] that exclusion criteria are reported in advance, 
excluded experiments are reported, but the analysis as such 
is performed only on per‑protocol experiments.
Effect size and sample size
Most often, the investigator has an approximate idea of the 
expected infarct size in the control/placebo group from prior 
data. Using such data [e.g. infarct size is 50 ± 15% of area 
at risk (mean ± standard deviation)], the sample size can be 
calculated when specifying the effect size. At an expected 
infarct size reduction from 50 to 35 and an expected standard 
deviation of 15, the effect size is (50 – 35)/15 = 1. In a two‑
sided t test (with a significance level α = 0.05), 23 animals/
group are necessary for a power of 90%. With 17 animals/
group, the power is 80%.
A study should only be started if the required sample size 
is in fact achievable. When the required sample size is unat‑
tainably high, other endpoints with less variability or changes 
in study design must be considered. For instance, if a paired 
design is possible, a pre‑specified power can be achieved 
with fewer observations. However, the power should be at 
least 80% (see ICH E9 guideline [168]), and we recommend 
a larger power of 90% or even more. There are various soft‑
ware tools for sample size calculation, for example, the free 
software R has several functions for sample size calculation.
Randomization
Online and free‑of‑charge tools for randomization such 
as the R package randomize R, the Research Randomizer 
available at www.rando mizer .org, or the Random Alloca‑
tion Software proposed by Saghaei [361] should be used to 
randomize to treatment groups. For preparation of the rand‑
omization, the total sample size is needed when generating 
the random list for the entire study. In clinical trials, a block 
randomization is commonly used to reduce bias and achieve 
balance in the allocation of participants to treatment arms, 
especially when the sample size is small [120]. Whenever 
possible, blinding is recommended. When blinding is not 
possible or can be compromised by the effects of the inter‑
vention (e.g. when a cardioprotective intervention is appar‑
ently performed or induces clearly visible responses), this 
fact must be reported. Unblinding of the analyzing investi‑
gators and other staff should be avoided until all data of all 
experiments are obtained. Any interim analysis is only per‑
mitted if planned in advance. However, such interim analysis 
is an additional analysis, which again results in a multiplic‑
ity of statistical tests. When the analysis of the experiment 
results in no or only a borderline significance, it is not per‑
mitted to change the sample size post hoc, to add a new 
randomized group, or to supplement additional experiments.
When, for whatever reason, the required sample size can‑
not be achieved and the study has to be terminated, data 
can be analyzed, but the statistical power is obviously low. 
The premature study termination and reasons for it must be 
reported.
Data analysis
All endpoints must be evaluated in a blinded fashion and/or 
by investigators not involved in the actual experiment. End‑
points should be assessed as objectively as possible and, if 
possible, automatically using a predefined algorithm, espe‑
cially when blinding is not possible. Quantification of infarct 
size by histology and/or software‑assisted planimetry must 
follow standardized protocols in demarcation of infarcted 
areas from non‑infarcted areas, camera/microscope settings 
and image processing.
Parametric vs. non‑parametric statistics
The statistical test(s) for the primary endpoint(s) must be 
selected before the experiment is conducted. Additional 
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statistical analyses can be performed as sensitivity analyses 
to investigate the robustness of the results. Non‑parametric 
tests are “distribution‑free” and, as such, can also be used 
for non‑normally distributed variables. In contrast, para‑
metric tests are those that make assumptions such as that 
obtained data are normally distributed. If data are a priori 
expected to deviate from normality, nonparametric tests can 
be used. Examples are the Wilcoxon–Mann–Whitney and 
the Kruskal–Wallis tests which are analogs to the Student 
t‑ and analysis of variance (ANOVA) F tests.
In some applications, pretests are performed to test data 
for normality or to test for homogeneity of variances. Those 
pretests cannot be recommended, since the failure to reject 
the null hypothesis does not imply that the null hypothesis 
holds, in particular since the power of the pretests is often low. 
Furthermore, preliminary tests have their own assumptions 
and it would be inconsistent not to check these assumptions.
A transformation, such as the logarithmic transformation, 
can be useful to, e.g. normalize the data. However, transfor‑
mations should be determined in advance based on previous 
experimental or scientific evidence.
Missing values and outliers
Missing values can bias the results. In the presence of many 
missing values, the ability to draw valid conclusions is seri‑
ously compromised. Unfortunately, there is “no methodolog‑
ical approach for handling missing values that is universally 
accepted in all situations” [1]. There are imputation methods 
to replace missing values. When the primary endpoint is 
repeatedly measured (e.g. infarct size calculated from release 
of biomarkers during the experiment), the last observation 
carried forward (LOCF) method can be used, i.e. missing 
values of subsequent time points are replaced by previous 
measurements. The LOCF method is considered a conserva‑
tive method when the difference between groups increases 
with time in placebo‑controlled studies. Statistical programs 
such as SAS or R provide easy access to the LOCF method. 
If no imputation method is applied, missing values in the pri‑
mary endpoint result in the exclusion of the patient/animal/
preparation from further analysis of the primary endpoint.
A variety of tests may identify outliers (e.g. the Dean and 
Dixon test). Graphical methods for the identification of outliers 
are recommended. Box plots (Fig. 1) are useful for quantitative 
data whether normally distributed or not, and the identification 
of outliers is easy. The “whiskers” of the full box plot accord‑
ing to Tukey’s [428] original definition extend to the most 
extreme data within the inner fences, that is, first quartile—1.5 
inter‑quartile range and third quartile + 1.5 inter‑quartile range. 
Data outside the inner fences, i.e. data points outside of the 
range depicted by the box and whiskers, are considered outli‑
ers. Except for the intention‑to‑treat analysis of clinical trials, 
outliers can be deleted before statistical analysis if there is a 
rational, context‑related reason or if the observed value is theo‑
retically not possible. However, when outliers are identified, 
one analysis each with and without outliers is recommended, 
and the procedure of outlier identification must be reported. 
There are also statistical methods which are robust with regard 
to outliers such as nonparametric methods based on ranks.
Data presentation and statistical analysis
Data presentation and statistical analysis must be specified 
[54, 176, 249]. For normally distributed data, it is appro‑
priate to present means and standard deviations. However, 
presentation of all single values and a box plot with means, 
medians and quartiles visualizes the data in more detail 
(Fig. 1) [428].
For each statistical test, the value of the test statistic, the 
degree(s) of freedom if appropriate, the estimates of effect 
sizes with their standard deviation or standard error, and the 
accurate P value (when the P value is lower than 0.001 just 
mention P < 0.001) must be reported. Whenever a P value 
is given, in particular for important comparisons, the 95% 
confidence intervals are provided, if available. Caveat—differ‑
ent statistical software packages work with slightly different 
assumptions and can come to different outcomes, as demon‑
strated for the Wilcoxon–Mann–Whitney [38]. An example 
for infarct size data presentation is given in Fig. 1. Infarct 
size of a placebo and a verum group is presented: data are 
presented as box plot and single data points, and a two‑sided 
Fig. 1  Virtually created data on infarct size as percent of area at risk. 
For two groups, placebo vs. verum, data are presented as minimum 
and maximum (crosses), interquartile range from 25 to 75% (box), 
mean (square), and median (line) in a box plot. The maximum value 
of the verum group is identified as outlier. All single values (squares) 
are depicted. P value as the result of a two‑sided Student t test
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Student t test was used for comparison, there is one outlier in 
the verum group. When the analysis is performed with all data 
including the outlier, the test statistic is t = 4.82 (36 degrees of 
freedom) and the P value is given as P < 0.001. As an effect 
size we can consider the difference between the group means. 
This difference is 38.89–20.79 = 18.11 with a standard devia‑
tion of 11.58. The 95% confidence interval for this difference 
ranges from 10.48 to 25.73. When the analysis is performed 
without the outlier, the test statistic is t = 6.08 (35 degrees of 
freedom), the P value is given as P < 0.001, and the differ‑
ence between the group means is 38.89–18.83 = 20.06 with a 
standard deviation of 10.03. The 95% confidence interval for 
this difference ranges from 13.36 to 26.76.
When more than two groups are compared (e.g. placebo, 
verum ± blocking agents), a one‑way ANOVA is appropri‑
ate to compare the different groups. When a significant dif‑
ference is detected in the ANOVA analysis, pairwise com‑
parisons of the individual groups can follow. Again, the 
multiplicity of tests must be considered, and the Bonferroni 
adjustment or another more sophisticated method can be 
applied. Statistical software such as R or SAS offers various 
methods to adjust for multiple comparisons; in any case, the 
respective P values must be given.
Use of statistical analyses in experimental 
and clinical cardioprotection studies
When comparing just a single endpoint at one single time 
point, a Student t test is appropriate for comparison of two 
groups; for more than two groups, a one‑way ANOVA with 
subsequent tests for pairwise comparisons of mean values 
is appropriate. This statistical analysis is appropriate for 
viability assessments at the end of a hypoxia/reoxygenation 
protocol in isolated cardiomyocytes or for infarct size assess‑
ments in isolated perfused heart and in vivo experiments.
When sequential data points are analyzed throughout the 
time course of the experiment, such as viability from base‑
line to reoxygenation in isolated cardiomyocytes or hemody‑
namics in vitro or in vivo or the results of multiple Western 
blots, a two‑way repeated‑measures ANOVA (group, time) 
is appropriate (Figs. 2, 3). Again, the Bonferroni or another 
adjustment must be made for multiple testing. However, to 
reduce the risk of false positive results, sample size and vari‑
ance homogeneity must be taken into account [286].
To assess the outcome of infarction and cardioprotection 
interventions, survival analyses are used in animal experi‑
ments and in clinical trials. For such survival time and other 
time‑to‑event endpoints [as combined endpoints, e.g. major 
adverse cardiac events or major adverse cardiac and cerebral 
events (MACCE)], statistical methods such as the logrank 
test or Cox’s proportional hazards regression are used. Sam‑
ple size and power calculations are then based on an assumed 
hazard ratio, which is based on the expected difference 
between groups. For example, the hazard ratio is 0.2 when 
90% of the animals in one group and 59% of animals in the 
other group are still alive at the same time (assuming a con‑
stant hazard rate). Then, for the logrank test, 47 individuals/
group are needed for a power of 90% (α = 0.05, two‑sided).
Specific guidance for power calculations 
and statistics in clinical myocardial infarction trials
Appropriate power calculation depends on the choice of end‑
point, which is myocardial salvage in proof‑of‑concept trials 
Fig. 2  Virtually created data on cellular viability. Sequential data are 
analyzed throughout the time course (baseline and after incubation) 
of the different experimental groups (time control and hypoxia/reoxy‑
genation (H/R) with buffer, placebo, and verum, respectively). Data 
are presented as mean ± standard deviation. P values as the result of 
two‑way repeated‑measures ANOVA (group, time) with subsequent 
post hoc tests are reported
Fig. 3  Virtually created data on left ventricular developed pressure 
during ischemia (Isch) and reperfusion (Rep). For two groups, pla‑
cebo vs. verum, data are presented as mean ± standard deviation. P 
values as the result of two‑way repeated‑measures ANOVA (group, 
time) with subsequent post hoc tests are reported
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or a combination of cardiac death and hospitalization for heart 
failure in clinical outcome trials. Using imaging modalities for 
the quantification of myocardial salvage, previous studies of 
primary percutaneous coronary intervention (PPCI) with stent‑
ing have demonstrated an area at risk within the magnitude of 
30% of the left ventricle and a salvage index of 0.50 [243, 370]. 
A final infarct size of ≤ 12% of left ventricle is a rational target, 
because an infarct size of this magnitude is associated with 
very low mortality [63, 306]. A 20% reduction in final infarct 
size from 15% to 12% corresponds to an increase in salvage 
index from 0.5 [(30 − 15)/30] to 0.6 [(30 − 12)/30]. Assuming 
a standard deviation of the salvage index of 0.23 [370] and that 
data conform with a parametric distribution, a demonstration 
of an increase in salvage index of 0.1 requires a sample size of 
83 patients in each group with a power of 80% and a two‑sided 
α value of 0.05. With a 5% drop‑out rate, a cohort size of 176 is 
required. For a power of 90%, 113 patients/group are required, 
resulting in a total of 238 patients after adjusting for a drop‑out 
rate of 5%. From a review of means and standard deviations 
of infarct size in CMR studies on cardioprotection in ST seg‑
ment elevation myocardial infarction (STEMI) patients, Bul‑
luck et al. here provided a table to estimate sample size, based 
on patient selection criteria and expected effect size [62].
Using a primary combined endpoint of cardiac death 
and heart failure hospitalization at 12 months for clinical 
outcome, studies will require a number of patients in the 
order of magnitude of 5200 patients, when using a χ2 test. 
Current cardioprotection studies in patients undergoing 
reperfusion for STEMI are challenged by the excellent 
outcome with modern standard therapy. Cardiac mor‑
tality at 12 months has decreased continuously over the 
last 25 years [368] and is now below 6% [126], while 
rehospitalisation for heart failure is 8% [126]. Our most 
recent observations in patients included in the CONDI‑2/
ERIC‑PPCI study (CONDI‑2: effect of remote ischemic 
conditioning on clinical outcomes in STEMI patients 
undergoing pPCI; ERIC‑PPCI: Effect of Remote Ischemic 
Conditioning on clinical outcomes in ST‑segment eleva‑
tion myocardial infarction patients undergoing Primary 
Percutaneous Coronary Intervention) [185] have dem‑
onstrated a further decrease with a cardiac mortality of 
2.1%, rehospitalization for heart failure at 12 months of 
6.4% and a composite endpoint incidence of 8.0%. An 
effect size of 25% relative reduction in the event rate is 
rationalized by proof‑of‑concept clinical studies, in which 
remote ischemic conditioning was reported to induce 30% 
reductions in infarct size [185]. To demonstrate a 25% 
reduction in the primary composite endpoint in the inter‑
vention group (from 8.0 to 6.0%), with 80% power and at 
the 5% significance level, will require 2554 patients/treat‑
ment arm which equates to 5108 patients in total. With 
2% drop‑out rate at 12 months, recruitment of approxi‑
mately 5200 patients is required.
In further analyses, stratification according to infarct 
location, TIMI (Thrombolysis In Myocardial Infarction) 
flow on admission and collateral flow using analysis of 
covariance is recommended, and stratification according 
to duration of chest pain, presence of preinfarction angina 
and presence of comorbidities (predominantly diabetes 
mellitus) is encouraged. Power calculations must be pro‑
vided to ensure the validity of the stratified analyses.
Specific guidance for power calculations 
and statistics in clinical cardiac surgery trials
For proof‑of‑concept studies using biochemical ischemic 
markers of myocardial injury, the geometric mean (95% CI) 
of the area under the curve for the biomarker concentration in 
serum, calculated according to the trapezoidal rule, is com‑
pared between standard treatment and the cardioprotective 
intervention group. The reduction of biochemical marker 
release by a cardioprotective intervention has varied from no 
effect to up to 43% reduction by remote ischemic conditioning 
in previous studies [202]. Although not powered for clinical 
outcome, a previous study demonstrated that a 17.3% reduc‑
tion in the troponin‑I (TnI) area under the curve by remote 
ischemic conditioning translated into a clinical benefit in 
terms of increased survival and lower numbers of MACCE 
[421]. Sample size also depends on the requirement of study 
power. Because outcome following cardiac surgery is favora‑
ble, a high power is desirable. In the study by Thielmann 
et al., a power (1‑beta) of 95% was used, and with reduction 
of 20% in the area under the curve TnI release over 72 h, a 
total of 162 patients was required in each group. With a power 
of 80%, the number decreases to 98 patients in each group.
For clinical outcome analysis, the event rate of the composite 
endpoint after 12 months varies between 14 and 28% [182, 
302]. Earlier data indicate that 20% of participants undergo‑
ing cardiac surgery have MACCE within 12 months [274]. 
A reduction of an event rate of 25% has been assumed to be 
associated with improved short‑ and long‑term outcome. With 
a power of 80% and a P value < 0.05, 905 patients are required 
in each group.
For two‑group studies, t tests are appropriate for pro‑
tocols. Stratification according to presence of comorbidi‑
ties (predominantly diabetes mellitus) and medications is 
encouraged. Power calculations must be provided to ensure 
the validity of the stratified analyses.
Isolated cardiomyocytes
Adult cardiomyocytes are terminally differentiated non‑
replicative cells. They have unique rod‑shaped morphology 
and are one of the largest cells of the body (around 150 µm 
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length). For their continuous contraction–relaxation activity, 
cardiomyocytes experience cyclic increases and decreases 
in intracellular calcium concentration, initiated and termi‑
nated by the sequential activation of the sarcolemma (mem‑
brane depolarization), sarcoplasmic reticulum (calcium 
release and reuptake mechanisms) and mitochondria [energy 
demand–supply matching through adenosine triphosphate 
(ATP) generation].
Cardiomyocytes are the cells with the highest aerobic 
requirement of the body, a feature that makes them particu‑
larly dependent on mitochondrial bioenergetics. Moreover, 
changes in energy demand occur instantly and experience 
continuous fluctuations due to variations in contractile activ‑
ity. To guarantee the supply of ATP and to ensure dynamic 
energy demand/supply matching, mitochondria occupy as 
much as 40% of cardiomyocyte volume and are functionally 
interconnected with other mitochondria and with the sarco‑
plasmic reticulum. Both electrochemical coupling and energy 
demand–supply matching rely on an adequate coordination 
between mitochondria and the sarcoplasmic reticulum, sup‑
ported by a tight interorganelle connection that facilitates 
calcium exchange on a beat‑to‑beat basis [411]. Calcium 
transferred from sarcoplasmic reticulum through ryanodine 
receptors drives the activity of the low‑affinity calcium uni‑
porter in mitochondria [350]. Indeed, mitochondrial calcium 
uptake is more dependent on the amount of calcium released 
by ryanodine receptors than on bulk cytosolic calcium con‑
centration [411]. Mitochondrial calcium uptake modulates 
the activity of several enzymes of the Krebs cycle and pro‑
vides the reducing substrates necessary for the regeneration 
of the antioxidant glutathione [289]. Some conditions, such 
as aging, impair mitochondrial respiratory efficiency and bio‑
energetic matching by a mechanism related to a defective sar‑
coplasmic reticulum–mitochondria calcium exchange [135]. 
This impairment may underlie the transition from healthy 
towards failing cardiomyocytes [70, 257].
Moreover, cardiomyocytes in vivo work as a functional 
syncytium, anatomically sustained by tight cell‑to‑cell 
contacts among them. Contact points contain thousands of 
highly specialized intercellular structures, called gap junc‑
tions, which directly connect the cytoplasm of two adjacent 
cells, allowing direct passage of different molecules and ions 
through a regulated gate system [430]. This communication 
system is essential for cardiomyocyte function (it allows the 
transmission of electrical impulses and the passage of some 
signaling molecules between neighboring cells) but it may 
also amplify cell damage under certain conditions, such as 
ischemia/reperfusion, in which necrosis has been shown 
to propagate from cell‑to‑cell by a gap junction‑mediated 
mechanism, increasing infarct size [149].
Altogether, the specific morphological traits (big size, rec‑
tangular shape) and functional properties (powerful contrac‑
tile system, huge aerobic metabolism, cell‑to‑cell connections) 
of adult cardiomyocytes make these cells particularly vulner‑
able to the conventional chemical and mechanical dissocia‑
tion procedures used for cell isolation. Indeed, to disrupt cell‑
to‑cell contacts, hearts must be perfused with calcium‑free 
buffer for no less than 20–25 min. However, cardiomyocytes 
do not tolerate the restoration of physiological calcium levels 
once they have been depleted of calcium for more than 2 min 
without experiencing a pathological response consisting of an 
abrupt cell shortening and massive myofibrillar hypercontrac‑
tion (“calcium paradox”). Adhesion to the culture dish surface 
allowing superfusion and rapid extracellular media change 
was another important step towards the consolidation of the 
use of isolated cardiomyocytes in basic and translational car‑
diac research [399]. Nowadays, most protocols for the isola‑
tion and cultivation of adult cardiomyocytes are based on this 
approach and use collagenase for the enzymatic digestion of 
the extracellular matrix [321]. Restoration of calcium after 
calcium‑free perfusion is one of the main critical aspects of 
cardiomyocyte isolation and must be performed gradually, fol‑
lowing a step‑by‑step protocol that inevitably results in some 
degree of cell damage.
Protocol for the isolation and culture of adult rat 
or mouse ventricular cardiomyocytes
General aspects
Freshly isolated adult ventricular cardiomyocytes are 
obtained from retrograde perfusion of the heart after aor‑
tic cannulation using a Langendorff system. Usually, hearts 
from rats aged 3–4  months, with an average weight of 
250–350 g, are used for such a protocol. One rat heart is 
sufficient for 20 culture dishes (1 mL/dish; inner diameter of 
the culture dish: 35 mm) with an approximate cell density of 
1.5 × 104 cells/1000 mm2. In principle, this method is based 
on dissociation of cell–cell contacts between cardiomyocytes 
by nominal calcium‑free perfusion of the hearts and subse‑
quent isolation of the cells with collagenase to disrupt cell 
contacts with the extracellular matrix. The protocol given 
here has to be adapted to each individual rat strain. Moreo‑
ver, we strictly recommend the use of rats of either female 
or male sex for standardization of collagen content and, 
therefore, of the collagenase concentration. As the isolation 
procedure requires at least in part calcium‑free perfusion, 
this will cause a calcium paradox and damage during re‑
administration of physiological amounts of calcium. This is 
normally achieved by repeated steps of increasing calcium 
concentrations. Although in principle the following protocol 
is valid for the isolation of mouse cardiomyocytes, too, the 
smaller size of mouse hearts makes the cannulation of the 
aorta more difficult. This is generally performed under a bin‑
ocular loupe or magnifying glasses. The final cardiomyocyte 
yield obtained from mouse hearts is substantially lower than 
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that from rat hearts. Also, because mouse cardiomyocytes 
are more prone to develop hypercontraction, Powell medium 
should contain either a contractile blocker (i.e. 10 mmol/L 
of 2,3‑butanedione monoxime), or alternatively re‑adminis‑
tration of calcium to mouse cells should contain more steps. 
Within this part, the protocol will be described for rat hearts.
Preparation of media and reagents for the isolation
Powell medium (1 L) 6.43 g NaCl (110 mmol/L)
0.19 g KCl (2.5 mmol/L)
0.16 g  KH2PO4 (1.2 mmol/L)
0.3 g  MgSO4·7H2O (1.2 mmol/L)
5.96 g 4‑(2‑hydroxyethyl)‑1‑piperazineethanesulfonic acid 
(HEPES) (25 mmol)
1.98 g d(+)‑glucose monohydrate (10 mmol/L)
1 L sterile distilled water
Adjust pH with NaOH (2 mol/L) to 7.4 and filter (0.7 μm) 
the medium under sterile conditions. Store Powell medium 
at 4 °C.
Calcium chloride stock  (CaCl2) Prepare a 100 mmol/L  CaCl2 
solution (50  mL) and make aliquots containing 500  μL 
 CaCl2. Freeze aliquots at − 20 °C.
Media Three different media are required for the isolation 
and cultivation of myocytes. A pre‑plating medium prepares 
culture dishes for attachment of cells. A plating medium is 
used to resuspend the cells after isolation from the heart and 
to plate them on the culture dishes. A washing medium is 
used to wash culture dishes after attachment of calcium‑toler‑
ant rod‑shaped cardiomyocytes. The basis of all three media 
is called CCT medium, which is a modified Medium 199.
CCT medium
1 L of medium 199
3.6 g HEPES
(mix for 1 h)
655.5 mg creatine (5 mmol/L)
395.4 mg carnitine (2 mmol/L)
625.5 mg taurine (5 mmol/L)
Cytosine β‑d‑arabinofuranoside (10 μmol/L)
Penicillin/streptomycin (2% vol/vol)
Adjust the pH with NaOH (2 mmol/L) to 7.4
Filter the medium under sterile conditions
Store the CCT medium at 4 °C
Pre‑plating medium Use 20 mL CCT medium, as described 
above, and add 4% (vol/vol) fetal calf serum (FCS). Note: 
FCS is batch dependent. Ask manufacturers for free samples 
of FCS and test different batches for attachment. Order the 
best one. Dependent on the FCS batch you use, the amount 
of FCS has to be increased or slightly decreased. However, 
in most cases, 4% (vol/vol) FCS will work. Put 1 mL of the 
pre‑plating medium 2–12 h prior to the cell isolation on 
culture dishes (inner diameter: 35 mm) and incubate over 
night in a cell culture apparatus. If you want to use mouse 
myocytes, replace FCS by laminin (0.5 µg/cm2). If you also 
discover problems with FCS for rat myocytes, laminin can 
also be used for rat myocytes. For confocal microscopy stud‑
ies, coat glass‑bottom dishes for 2 h with laminin (50 µL 
of laminin at 50 µg/mL for a 12‑mm‑inner‑diameter dish).
Plating medium Use CCT medium, as described above.
Washing medium Use CCT medium, as described above. 
If cells are cultivated for longer time periods (> 48 h) add 
20% (vol/vol) FCS to the medium. Please note again, that 
the bioactivity of FCS is batch dependent.
Culture dishes Use preferentially culture dishes with an 
inner diameter of 35 mm (Falcon 3004). Avoid using any 
plastic dishes specifically prepared for primary cells that use 
collagen I or poly‑d‑lysine as attachment substrate because 
cardiomyocytes require either a mix of attachment gradients 
from FCS or laminin, but will not properly attach to collagen 
I or poly‑d‑lysin.
Materials For the isolation of the myocytes you need a Lan‑
gendorff aparatus, standard laboratory centrifuges, water 
baths and a motor‑driven chopper (McIlwain Tissue Chop‑
per, Campden Instruments, UK). The volumes given in this 
protocol may differ depending on the size of the Langen‑
dorff apparatus and might need adjustment according to the 
specific apparatus.
Cell isolation
Warm the plating medium and washing medium to 37 °C. 
Defreeze a tube of 500 μL  CaCl2 and weigh in 25 mg of 
collagenase. Flush the Langendorff perfusion system with 
sterile distilled water, and afterwards let the Powell medium 
circulate through the system for 5 min. Fill the Langendorff 
perfusion system with 80 mL Powell medium, ensuring that 
it does not contain any air bubble, and gas the medium with 
carbogen (95%  O2/5%  CO2). Prepare a tube (50 mL) with 
40 mL Powell medium, warm it to 37 °C, and gas it with 
carbogen. Prepare a thread of about 25 cm in length for 
fixing the heart to the cannula. Degrease a razor blade with 
alcohol (70% by volume) and fasten it to the motor‑driven 
chopper. Clamp a plastic disk into the chopper.
Anesthetize the rat with 4–5% isoflurane and sacrifice it 
with cervical dislocation. Alternatively use 150 mg/kg of 
sodium pentobarbital because isoflurane may induce car‑
dioprotective effects on its own. However, whether or not 
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isoflurane affects cardioprotection in the isolated cell model 
is not clear. Note, the procedure on how to sacrifice the rat 
depends on the requirements of local authorities. Open the 
abdomen below the costal arch with an abdominal inci‑
sion and, with the same pair of scissors, cut through the 
diaphragm to open the thoracic cavity. Remove the heart, 
together with the lungs and thymus, by cutting above the 
thymus. Transfer the material to ice‑cold saline solution 
immediately. Remove the lung and thymus from the heart 
with dissecting scissors (large) and transfer the latter to a 
new saline solution. Remove excess tissue, such as resi‑
dues of thymus, trachea, fat, and connective tissue from the 
heart using capsule forceps and dissecting scissors (large or 
small). Uncover the aorta and sever it with dissecting scis‑
sors (large or small) between the first and second brachial 
arch. Before cannulation, open the tap of the Langendorff 
system and allow the buffer to start dripping.
To initiate perfusion, insert the cannula of the Langendorff 
system through the aorta and fix it first with a crocodile clamp, 
and then by tying with the prepared thread tightly around the 
aorta where it covers the cannula. To ensure a high‑quality 
preparation of cardiomyocytes, the time between extracting 
the heart from the body and the onset of perfusion should be 
as short as possible. A more prolonged time causes damage to 
the heart and results in a higher number of non‑viable cardio‑
myocytes. Rinse the heart until it is free of blood. Immediately, 
dissolve 25 mg collagenase in 5 mL warm Powell medium 
and add 12.5 μL  CaCl2 (end concentration of  CaCl2 in 50 mL 
perfusion buffer: 25 μmol/L). Several commercially available 
batches of collagenase are available, each of them with a dif‑
ferent quality and activity. It is recommended to test different 
samples and to adapt the time of digestion and the amount of 
collagenase for each new batch. Accordingly, the concentra‑
tion and time of digestion described in this protocol can dif‑
fer slightly from other protocols. To start the digestion of the 
heart, add the dissolved collagenase to the perfusion system. 
Start the perfusion for 25 min with a drop velocity of 1 drop/s. 
During perfusion, the heart should swell and develop a waxy 
appearance. Stop the perfusion after 25 min and remove the 
heart from the Langendorff perfusion system. A detailed 
video describing the initial steps is available [321]. Recently, 
an alternative method of isolation of cardiomyocytes using 
direct needle perfusion of the LV ex vivo and without the need 
for Langendorff perfusion has been reported [4].
For progressive calcium restoration, remove and discard 
the aorta, atria, and connective tissue from the heart, then 
open the right and left ventricles. Chop the heart twice at 
an angle of 90° (cutting width 0.7 mm; velocity 0.15 cm/s). 
Note, if no chopper is available, this step might be per‑
formed by quick cutting of the tissue with scalpels. Repeat 
this process manually with two scalpels for 10 s each side. 
Transfer 12 mL of the perfusion medium into a new tube 
(50 mL). Pour the cell slurry into this medium and digest 
cells for another 5 min at 37 °C. Mix the solution by pipet‑
ting up and down every minute. Filter the solution with the 
digested heart through a nylon mesh (200 μm) into a new 
tube (50 mL). Centrifuge the filtered solution at 29×g for 
3 min. Discard the supernatant and add 6 mL warm Powell 
medium with 12.5 µL  CaCl2 (210 μmol/L) to the cell pellet. 
Resuspend the pellet through smooth shaking movements. 
Centrifuge again at 29×g for 2 min. Discard the supernatant 
and add 6 mL warm Powell medium enriched with 25 μL 
 CaCl2 (420 μmol/L). Resuspend the cell pellet through gen‑
tle shaking movements and add 12 mL warm Powell medium 
including 120 μL  CaCl2 (1 mmol/L). Centrifuge for a third 
time at 16×g for 1 min. Again, discard the supernatant. All 
these steps can be seen on [321].
For plating, mix the cell pellet with the pre‑warmed 
plating medium. Remove pre‑plating medium from culture 
plates. Transfer 1 mL plating medium, including the isolated 
cardiomyocytes, to each culture plate. Incubate freshly iso‑
lated cardiomyocytes at 37 °C for 1 h. Thereafter, a quality 
control should be performed. This includes a simple micro‑
scopic view (Fig. 4) and quantification of the number of 
rod‑shaped cells (normally 60–80%; cultures should not be 
used with less than 70% rod‑shaped cells).
Fig. 4  Representative figure of a good cell preparation (left) and a bad preparation (right). Please note the difference in the number of rod‑
shaped cells
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Freshly isolated healthy cardiomyocytes are quiescent 
cells unless they are electrically stimulated. However, they 
can exhibit spontaneous contractions, calcium transients and 
calcium sparks. The more mechanical activity they have, 
the less stable they are in long‑term experiments. Sponta‑
neous contractile activity may induce slow calcium over‑
load in cells not fully energized, as calcium reuptake is an 
ATP‑dependent process. In isolated adult cardiomyocytes, 
cell damage may induce specific morphological changes. 
Thus, when the intracellular ATP level falls below a critical 
threshold (50–100 µmol/L), cardiomyocytes develop rigor 
contracture. In the intact myocardium, rigor contracture is a 
calcium‑independent increase in the mechanical force of the 
tissue secondary to the formation of cross‑bridges between 
actin and myosin promoted by low ATP conditions [13]. 
However, in isolated unrestricted cardiomyocytes, devel‑
opment of rigor contracture induces a partial shortening 
of cell length (square‑shaped morphology). The rate and 
time course of rigor contracture development as well as the 
final cell shortening can be used to characterize the kinetics 
of energy depletion in experiments of ischemia, anoxia or 
metabolic inhibition, and to investigate the effect of some 
pharmacological interventions [356] or pathophysiological 
conditions, such as aging [134] on the mechanical fragility 
of the cells. Although cardiomyocytes with rigor contracture 
are viable and keep their normal cross‑striation pattern, they 
are rather vulnerable to damage.
Rigor‑shortened cells can develop hypercontraction upon 
reperfusion or reoxygenation. During cardiomyocyte isola‑
tion, excessively long procedures or inadequate oxygen bub‑
bling during manipulation may result in a significant propor‑
tion of cells with square morphology as a consequence of 
rigor development.
Cardiomyocytes may undergo a specific form of dam‑
age consisting of an abrupt shortening associated with an 
irreversible distortion of cell architecture, usually known 
as hypercontraction. Hypercontraction is facilitated by the 
powerful contractile machinery of the adult cells that tends 
to overreact in the presence of abnormally elevated calcium 
level. Whereas in intact myocardium, hypercontraction 
induces sarcolemmal disruption and cell death, and isolated 
cardiomyocytes can freely shorten, undergoing irreversible 
rounding‑up and preserving sarcolemmal integrity, due to 
the absence of the mechanical restriction imposed by the 
interaction with other cells. Rounded cells can be metaboli‑
cally competent when the sarcolemma has not been damaged 
[383]; nevertheless they lose their normal morphology, do 
not adequately attach to the culture dish and are discarded 
during washing steps.
The quantification of the number of rounded cells rel‑
ative to the number of rod‑shaped cardiomyocytes is the 
index used to establish the quality of the cell preparation. 
In general, a good preparation of freshly isolated adult 
cardiomyocytes should contain ≥ 70% of rod‑shaped cal‑
cium‑tolerant cells. Nevertheless, even after an optimal 
isolation procedure, a significant proportion of cardiomyo‑
cytes develop calcium paradox‑induced hypercontraction. 
It is important to take into account that the susceptibility 
of cardiomyocytes to isolation protocols may vary between 
animal species and depend on their age.
Cultivation of cardiomyocytes
Remove the plating medium from culture plates. Add 
1 mL washing medium to each culture plate and store 
the plates at 37 °C for up to 6 days without changing 
the medium. For investigating the influence of different 
chemicals and treatments on cardiomyocytes, first refresh 
plating medium by washing medium and thereafter add 
different chemicals. Under these conditions, cardiomyo‑
cytes survive as rod‑shaped cells for 48 h and can be used 
for further analysis such as growth control or function. 
Measuring the cell size enables growth control. Measure 
the long axis of the cells (l), and the diameter of the cell 
(d) at the middle of the long axis. Calculate cell volume 
according to the equation Volume = l × (d/2)2 × π, based 
on the assumption that myocytes display a cylindrical cell 
shape. The function of the cell can be analyzed by load‑
free cell shortening placing two silver electrodes into the 
cell culture medium and stimulating the cells between 0.5 
and 2.0 Hz at room temperature [321].
Long‑term cultures of cardiomyocytes can be per‑
formed by replacing serum‑free media by media con‑
taining 20% (vol/vol) FCS. Under these conditions, cells 
rapidly (within 24 h) round up and reorganize their con‑
tractile apparatus. To perform an evaluation of the cul‑
tured cardiomyocytes throughout time with light micros‑
copy, monitor 150–300 cardiomyocytes/day by light 
microscopy. Subdivide all counted cardiomyocytes into 
groups according to their appearance (e.g. “rod‑shaped”, 
“round down”, “spreading”, and “unusual appearance”). 
The category “spreading” includes all cardiomyocytes 
with pseudopodia‑like structures. “Unusual appearance” 
includes those cardiomyocytes that have an irregular sur‑
face and no detectable intact cell membrane. Please note 
that transfer of this rat cell protocol to mouse cardiomyo‑
cytes does not work.
Some specific experimental cardiomyocyte models
Membrane‑permeabilized cardiomyocytes
For sarcolemmal permeabilization, plated cardiomyocytes are 
washed with an “intracellular‑like buffer” at 37 °C containing 
5 mmol/L  MgCl2, 10 mmol/L HEPES, 250 mmol/L sucrose, 
25 mmol/L Tris, 0.5 mmol/L ethylene glycol tetra‑acetic acid 
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(EGTA), 5 mmol/L succinate, and 4 mmol/L ATP, at pH 7.2. 
100 µmol/L digitonin is added for 1 min, cells are washed 
twice with intracellular‑like buffer to remove digitonin and 
kept at 37 °C with intracellular‑like buffer until the onset 
of the experiment. Alternatively, saponin 0.005% for ~ 30 s 
can be used for membrane permeabilization. Triton X‑100 is 
discouraged in living cells because it can induce cytoskel‑
etal damage. Membrane‑permeabilized cells are extremely 
sensitive to the presence of calcium in the buffer. Therefore, 
they should always be kept in intracellular‑like buffer in the 
presence of a calcium chelator, usually 1–2 mmol EGTA. 
The presence of calcium chelators requires the use of specific 
calcium titration programs to calculate the real free calcium 
concentration present in the medium. When membrane lysis 
is carried out, a concentration of 4 mmol/L (or higher) of 
ATP should always be present in the buffer to guarantee that 
cells retain the rod‑cell morphology [14]. Cardiomyocytes 
with an accurate membrane permeabilization are capable of 
maintaining intact organelles and subcellular microdomains 
(i.e. sarcoplasmic reticulum–mitochondria communication), 
and are a good model for studies in which sarcolemmal bar‑
rier and membrane transport systems can interfere with the 
interpretation of the data.
End‑to‑end connected cardiomyocytes
To increase the proportion of end‑to‑end connected pairs of 
cardiomyocytes in the final cell preparation, the amount of 
calcium during collagenase perfusion is slightly increased 
(i.e. end concentration of  CaCl2 in 50 mL perfusion buffer: 
45–50 μmol/L instead of 25 µmol/L). Pairs of end‑to‑end 
connected cardiomyocytes may be used for electrical propa‑
gation and cell‑to‑cell communication studies.
Use of isolated cardiomyocytes
Isolated cardiomyocytes can be used in a vast array of exper‑
iments measuring different aspects of their biology or patho‑
physiology. The most important applications are: (1) studies 
on tolerance to real or simulated ischemia/reperfusion or 
anoxia reoxygenation and the effect of interventions on cell 
damage/protection. This is a classical model in cardiopro‑
tection studies, and may involve fluorometric monitoring of 
ionic concentrations in the cytosol and other cell compart‑
ments (mitochondria, sarcoplasmic reticulum), immuno‑
fluorescence (protein interaction and trafficking), and bio‑
chemical analyses (signaling pathways, protein expression, 
enzyme release); (2) studies on contractile function in differ‑
ent conditions and response to interventions. This approach 
requires field stimulation of cardiomyocytes [190]; (3) elec‑
trophysiological studies, involving recording of electrical 
activity and impulse propagation. This requires introduction 
of micropipettes into the cytosol of cardiomyocytes for patch 
clamp studies and may be combined with cell imaging‑based 
monitoring of intracellular ionic movement.
Isolated cardiomyocytes for pathophysiological studies
Mitochondrial de‑ and  re‑energization during  ischemia/
reperfusion For ischemia/reperfusion experiments in iso‑
lated cardiomyocytes, two different approaches can be 
used: anoxic work‑station under controlled atmosphere of 
0%  O2–95%  N2–5%  CO2 at 37  °C or microscope‑adapted 
microperfusion chamber. In the first approach, an unlimited 
number of plated cardiomyocytes can be simultaneously 
incubated in a glucose‑free acidic ischemic buffer and reox‑
ygenated. The microscope‑adapted microperfusion chamber 
is used for confocal microscopy studies, in which the kinet‑
ics of intracellular ionic changes or mitochondrial integrity 
and energy status, among other variables, can be investi‑
gated throughout time at the single‑cell level from high‑res‑
olution images. For the anoxic work‑station, cardiomyocytes 
are placed within the anoxic atmosphere and incubated for 
the desired time. When working with absolute anoxia (not 
hypoxia), the duration of incubation in  O2‑free atmosphere 
should not exceed 40–50 min, to get a significant propor‑
tion of surviving cells upon reperfusion (different times of 
anoxia must be tried out in each specific setting). To better 
simulate in vivo ischemia, use glucose‑free acidic ischemic 
buffer previously deoxygenated in an autoclave and bubbled 
with  N2 for 20 min to ensure that it will not introduce  O2 to 
the chamber. Ischemic buffer contains 140 mmol/L NaCl, 
3.6 mmol/L KCl, 1.2 mmol/L  MgSO4, 1 mmol/L  CaCl2, and 
20 mmol/L HEPES at pH 6.4, and it is supplemented with 
4 μmol/L resazurin, 100 μmol/L ascorbic acid, 0.5 mmol/L 
dithionite and 100 U/mL superoxide dismutase. For reper‑
fusion, ischemic buffer has to be gently washed out (to avoid 
detachment of rigor‑contractured cardiomyocytes) and the 
chamber oxygenated with glucose‑containing control buffer 
at pH 7.4.
To simulate ischemia/reperfusion at the single‑cell level, 
a glass‑bottom dish with laminin‑attached cardiomyocytes 
is placed on the stage of an inverted microscope. Cells are 
superfused with the aid of a peristaltic pump within a closed 
microperfusion chamber (airtight chamber adapted to the 
specific microscope setting) with the ischemic buffer at 
pH 6.4, continuously bubbled with  N2. Reoxygenation is 
induced by switching to oxygenated, glucose‑containing 
control superfusion, at pH 7.4. The effect of ischemia/rep‑
erfusion on cell morphology can be simultaneously assessed 
by quantification of the number of cells developing rigor 
shortening during oxygen deprivation (defined as a 25–40% 
reduction of cell length with preserved squared‑shape mor‑
phology) and hypercontraction (defined as > 70% reduction 
of cell length with concomitant disruption of cytoarchitec‑
ture) upon reoxygenation.
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Pelleted freshly isolated cardiomyocytes Isolated cardiomyo‑
cytes obtained immediately after the isolation procedure may 
be plated in culture dishes (as indicated above) or pelleted after 
a low speed centrifugation step. Pelleted cardiomyocytes have 
many of the advantages of plated cardiomyocytes (no contri‑
bution of other cell types, absence of cell‑to‑cell interaction, 
intact and fresh preparations) but may offer additional advan‑
tages in some specific contexts, mainly for in vitro ischemia/
reperfusion and preconditioning experiments [21, 431]. For 
the in vitro ischemic model, excess supernatant is removed (so 
that the fluid over the cells is extremely thin) and the pellet 
containing the viable cardiomyocytes is covered with a min‑
eral oil layer and incubated at 37 °C for 30–120 min. Degree of 
ischemic damage can be determined with a viability staining 
method in cells obtained from the ischemic pellet at different 
time points. Reperfusion is simulated by replacing the oil layer 
with a glucose‑containing oxygenated buffer and gentle resus‑
pension of the cells. This model also allows to precondition the 
cells using brief periods of ischemic pelleting before the index 
ischemia [109] or by application of drugs [22] and has been 
widely used for the quantification of cell death, sarcolemmal 
osmotic fragility and ultrastructural changes associated with 
ischemia/reperfusion injury [191, 406]. Pelleting model with 
an oil layer exposes the cells to low‑oxygen environment while 
reducing the extracellular space. These conditions induce the 
progressive exhaustion of metabolites and favor the accumula‑
tion of lactate and the simulation of the acidosis present in the 
in vivo ischemia with great fidelity.
Modes of cell death and cellular viability assessment
Although detection of cell death may appear a simple task, 
several factors complicate it. The definition of cell death may 
be difficult when it occurs through a complex process during 
which cells may be still living, i.e. may retain metabolic activ‑
ity and trans‑membrane ionic gradients, although they have 
reached a no‑return point in the process of cell death [442].
Cardiomyocyte cell death is particularly important 
in determining the clinical consequences of myocardial 
ischemia and reperfusion. Cardiomyocytes perform cardiac 
work and, in the adult heart, have little or no proliferative 
capacity [37]. In addition, their elevated energy requirements 
and dependence on aerobic metabolism, and their power‑
ful contractile machinery coupled to ample and precise 
mitochondrial–sarcoplasmic reticulum calcium movements 
render cardiomyocytes more susceptible to ischemia/reper‑
fusion than other cell types present in myocardium such as 
endothelial cells, smooth muscle cells or fibroblasts [235].
Cardiomyocyte necrosis
Necrotic cell death is characterized by the loss of cell mem‑
brane integrity and acute loss of cellular ATP [442]. In the 
context of ischemia/reperfusion, cardiomyocyte necrosis 
is generally associated with gross morphological changes 
as a consequence of the associated hypercontracture [150, 
151]. There are two main types of experiments in which cell 
necrosis can be studied: cell preparations and myocardial 
tissue.
In isolated cardiomyocytes, necrosis can be demonstrated 
by a variety of methods based on the detection of membrane 
impermeable dyes within the cell. The two most widely used 
dyes are trypan blue and propidium iodide. In both cases, 
the marker is added to the extracellular media, the cells are 
washed and the presence of the marker within the cell is 
investigated. For the trypan blue test, a 0.4% solution of the 
dye is prepared in isotonic phosphate‑buffered saline at pH 
7.4 and added to the cell suspension or to the cells plated 
in a culture dish in a 1:1 volume for 2–3 min. Cell death is 
calculated as the number of blue stained (non‑viable) cells 
divided by the total number of cells. Trypan blue‑positive 
cells as well as the total number of cells may be detected and 
counted by microscopy. The results are in general clear, but 
the wash‑out protocol and the timing of the readout as estab‑
lished in the protocol should be carefully followed. Longer 
incubations (> 10 min) may decrease cell viability and dis‑
tort the results due to dye toxicity. Propidium iodide binds to 
nucleic acids in cells with permeabilized plasma membrane 
and emits red light, between 600 and 700 nm, when excited 
with 400–600 nm light. Usually, a volume of 5 µL of pro‑
pidium iodide is added to 100 µL of the buffer containing the 
cells for 5–10 min. Counting of propidium iodide‑positive 
cells can be performed by microscopy or flow cytometry, the 
latter having the advantage of allowing an automatic analysis 
of larger numbers of cells. Importantly, total cell count must 
be determined. Other tests, such as cell‑permeable calcein 
acetoxymethyl labeling, are based on the ability of the AM 
esters to cross the plasma membrane of living cells. Once the 
non‑fluorescent dye reaches the cytosol, it is hydrolyzed by 
intracellular esterases to green‑fluorescent calcein. A stand‑
ard protocol for cell loading includes 30 min of cell incuba‑
tion in the presence of 1 µmol/L calcein acetoxymethyl ester 
at 37 °C followed by a washing step. Fluorescent‑positive 
cells (viable) can be automatically measured using a fluo‑
rescent plate reader (excitation: 490 nm/emission: 520 nm).
Isolated adult cardiomyocytes, which undergo necrosis 
upon reoxygenation or reperfusion, invariably show hyper‑
contracture. Unlike rigor contracture, hypercontraction is an 
energy‑dependent response and can be considered the his‑
tological hallmark of reperfused myocardial infarcts [150].
However, hypercontracted cardiomyocytes may retain 
sarcolemmal integrity and metabolic activity if shortening 
is not restrained by firm physical interactions with other cells 
or surfaces [383]. Although these cells are alive, it may be 
reasonable to assume that they would have experienced sar‑
colemmal rupture and death if hypercontracture would have 
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happened within intact myocardial tissue [30, 148]. Thus, 
to have a more informative picture of the effects of inter‑
ventions on reperfusion injury in isolated adult ventricular 
cardiomyocytes, it is important to report the number of cells 
undergoing hypercontracture. Hypercontracted cardiomyo‑
cytes are clearly identifiable by visual inspection in micro‑
scopic fields and can be also automatically detected by flow 
cytometry [284].
Under certain conditions (i.e. osmotic stress) or in the 
presence of sarcolemmal fragility (induced by aggressive 
collagenase digestion) hypercontraction of isolated cardio‑
myocytes may be associated with sarcolemmal rupture and 
death [355].
Viability tests may provide information, which 
goes beyond the concept of sarcolemmal rupture. The 
[3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium 
bromide] tetrazolium (MTT) reduction assay is a high 
throughput viability screening suitable for a 96‑well format, 
although in small‑well formats variability of readouts tends 
to be high between replicates. For the reaction, 0.2–0.5 mg/
mL MTT substrate is dissolved in physiological buffer 
and added to the cells for 1–4 h at 37 °C. Viable metaboli‑
cally competent cells convert MTT into a purple‑colored 
formazan product that can be measured as a proportional 
increase in absorbance at 570 nm using a spectrophotometer. 
The particularity of this assay is that reduction of MTT into 
formazan seems to involve mitochondrial enzymes which 
transfer electrons to MTT. Therefore, it may be useful for 
measuring the lack of mitochondrial activity [41].
Cardiomyocyte necrosis can be indirectly assessed by 
measuring enzyme release. Lactate dehydrogenase (LDH) 
is the most widely used enzyme for this purpose and can be 
accurately measured in cell culture media or in the efflu‑
ent of perfused hearts or myocardium using both a NADH‑
linked ultraviolet–visible spectrophotometric method or a 
NADH‑linked LDH fluorescent assay.
In experiments using cardiomyocyte preparations, LDH 
should be normalized with respect to total LDH content of 
the preparation, as measured after inducing sarcolemmal 
rupture or permeabilization by osmotic or chemical methods.
Other forms of cell death
The possible contribution of cardiomyocyte apoptosis to 
reperfusion injury has been investigated in many studies 
[77]. However, recent data strongly support the notion that 
apoptosis has little or no role in reperfusion‑induced cell 
death of adult cardiomyocytes. First, these cells do not 
express anymore the caspases necessary to execute the 
apoptotic program [364]. Moreover, genetic deletion of 
caspase 3 and 7 has no effect on infarct size or postinfarc‑
tion remodeling in mice [222]. It is clear that embryonic 
or neonatal cardiomyocytes and modified myocyte lines 
such as HL1 or H9c2 cells can undergo apoptosis, but it is 
doubtful whether studying apoptotic pathways and targets 
in these cells can be relevant to cardioprotective interven‑
tions in adult patients.
Recently, another form of programmed cell necrosis has 
been described, known as necroptosis, in which the execution 
of a complex chain of events leads to cell swelling, rupture 
of the plasma membrane, release of cytosolic contents and 
activation of the innate immune response [5]. Activation of 
the receptor interacting kinase 3 (RIP3) by receptor interact‑
ing kinase 1 through the formation of a receptor interacting 
kinase 1/3 complex is an essential part of this chain of events 
[78] and requires blockade of caspase activation. A number 
of methods have been devised to detect necroptosis in isolated 
cells, histological preparations and even in vivo. As necrop‑
tosis leads to disruption of cell membranes, conventional 
methods to assess loss of sarcolemmal integrity, such as cell‑
impermeant dyes that bind to deoxyribonucleic acid (DNA) 
or enter the cytosol (propidium iodide, 4′,6‑diamidino‑
2‑phenylindole (DAPI), trypan blue), followed by imaging 
techniques or flow cytometry, can be used for its detection. 
Nevertheless, identification of necroptosis is challenged by 
the fact that cells readily shift from apoptosis to necroptosis 
and necrosis. Therefore, assessment of necroptosis should 
be complemented with time‑dependent analysis of morpho‑
logical changes and other technical approaches specifically 
targeted to the involved signaling pathways. In this respect, 
assessment of mitochondrial membrane potential with fluo‑
rescent probes which accumulate in healthy mitochondria, 
such as tetraethyl‑benzimidazolyl‑carbocyanine iodide(JC‑1), 
methyl ester of tetramethylrhodamine (TMRM), and ethyl 
ester of tetramethylrhodamine (TMRE), may be a useful tool 
to discriminate between necroptosis and necrosis, as hyper‑
polarization of mitochondrial membrane potential (resulting 
in a transient increase in fluorescence) has been described in 
the early stages of necroptosis. Although it has been shown 
to occur during ischemia in different cell types, there is not 
sufficient evidence for necroptosis of cardiomyocytes during 
reperfusion.
Limitations of the cardiomyocyte cell model
The main limitation of the isolated cardiomyocyte model 
is that it does not consider interactions with other myo‑
cardial cells, in particular endothelial cells, fibroblasts and 
macrophages. While this simplification may be useful in 
mechanistic studies, it can be misleading. This limitation is 
partially overcome by different co‑culture methods in which 
other cells types, for example fibroblasts, endothelial cells 
and pericytes, are added to the preparation either in the same 
chamber or in separate chambers communicating through 
filters or diffusible membranes [66]. This technical solution 
may be useful for specific purposes, such as for studying 
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cardiomyocyte–fibroblast interaction through connexin 43 
gap junctions. Isolated cardiomyocytes are quiescent cells. 
This feature eliminates the main energy expenditure of adult 
cells. Field stimulation simulates in vivo contractile activity; 
however, continuous pacing is not practical (nor stable) in 
prolonged studies. The fact that isolated cardiomyocytes are 
physically unrestrained, except for their adherence to the well, 
makes them prone to develop exaggerated rigor contracture 
and hypercontraction. Moreover, hypercontraction does not 
necessarily induce sarcolemmal rupture and cell death, in 
contrast to in situ myocardial hypercontraction. Although 
they can be maintained in culture, cardiomyocytes are post‑
mitotic cells that rapidly lose their adult elongated phenotype. 
This makes it very difficult to use them for genetic modi‑
fication approaches. Importantly, high‑quality preparations 
of adult isolated cardiomyocytes are difficult to obtain and 
require well trained and experienced technicians. When prep‑
arations are not good enough, studies can still be conducted 
with the remaining few rod‑shaped cardiomyocytes; never‑
theless, this may introduce a selection bias. All laboratories 
experience problems from time to time with cardiomyocyte 
quality that may be very difficult to tackle and correct; occa‑
sionally, these problems persist for several weeks.
Future perspectives of isolated cardiomyocyte 
models
The technology for cell physiology studies keeps evolving. 
The development of powerful confocal microscopy plat‑
forms, with increasingly sophisticated imaging acquisition 
software, runs in parallel with the development of novel fluo‑
rescent probes and methods to selectively target subcellular 
compartments. This technological development will bring a 
long and fruitful future to the cardiomyocyte model that may 
have further potential by co‑culturing with other cell lines.
Involvement of mitochondria 
in cardiomyocyte injury
Mitochondria are involved in the major functional and 
structural derangements characterizing the transition from 
reversible to irreversible injury during cardiac ischemia and 
reperfusion [108]. As outlined in the chapter "Isolated car‑
diomyocytes", during the early phase of ischemia, the fail‑
ure of contraction and the rigor contracture, which are the 
most relevant changes in myocardial function, are caused 
by intracellular acidosis and severe reduction in ATP con‑
tent, respectively. Then, the sudden changes produced by 
reperfusion on myocardial viability are concomitant with 
massive accumulation of calcium within the mitochondrial 
matrix. This seminal finding that highlighted the role of 
intracellular  Ca2+ overload in myocardial pathology [380] 
indicates that the rapid transition towards cell death requires 
a coupled mitochondrial respiration. In fact, pre‑ischemic 
respiratory chain inhibition or uncoupling of oxidative 
phosphorylation blunts enzyme release occurring at the 
onset of post‑ischemic reperfusion [123, 145] and preserves 
mitochondrial function [226, 405]. Therefore, oxidative 
phosphorylation is essential for cell recovery, but can also 
contribute to the processes resulting in cell necrosis.
Upon reperfusion, mitochondria are exposed to high 
levels of  Ca2+ that is increased in the cytosol due to both 
the failure of  Ca2+ ATPases and uptake through the sar‑
colemmal  Na+/Ca2+ exchanger. Since mitochondrial  Ca2+ 
uptake and ATP synthesis utilize the same driving force, 
namely the mitochondrial membrane potential ΔΨm, mito‑
chondrial  Ca2+ accumulation results inevitably in a signifi‑
cant decrease in ATP formation. In addition and impor‑
tantly, the rise in intramitochondrial  [Ca2+]  ([Ca2+]m) 
promotes opening of the mitochondrial permeability 
transition pore (mPTP) and is associated with increased 
formation of reactive oxygen species (ROS). Eventually, 
a vicious cycle is generated whereby high  [Ca2+]m, mPTP 
opening and ROS formation hamper mitochondrial func‑
tion and jeopardize the maintenance of cell viability.
Isolation of subsarcolemmal and interfibrillar 
mitochondria from cardiac tissue
To investigate mitochondrial function in detail, they must 
be purified in sufficient quantity and retain their functional 
capacity. The following protocols describe the isolation of 
two different mitochondrial subpopulations, subsarcolem‑
mal (SSM) and interfibrillar (IFM) mitochondria, which are 
used to study mitochondrial function in terms of oxygen 
consumption, ROS formation, or calcium retention capac‑
ity. To date, there is no protocol available to purify perinu‑
clear mitochondria which are clustered around the nucleus. 
Depending on the subpopulation(s), two different protocols 
can be followed. All steps of the isolation procedure are 
performed at 4 °C. In the following, focus is on isolation 
from mouse heart tissue. However, all processes can be 
translated to heart tissue of rats and pigs with appropriate 
adjustment of buffer volumes to tissue mass.
Isolation of subsarcolemmal mitochondria (SSM) only
Isolation buffer (prepared at the day of the isolation or filter‑
sterilized before use):
250 mmol/L sucrose
10 mmol/L HEPES
1 mmol/L EGTA 
pH 7.4
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Fatty acid‑free bovine serum albumin (BSA, 0.5%) is added 
to the isolation buffer during the homogenization steps to 
protect the organelles from damage during the isolation pro‑
cess and to remove free fatty acids. After homogenization, 
mitochondria are kept in isolation buffer without BSA, sup‑
plemented with proteinase and/or phosphatase inhibitors.
Mice are sacrificed according to the recommendations 
of local authorities, e.g. by cervical dislocation without or 
with prior anesthesia with 5% isoflurane. Hearts are rapidly 
removed and placed immediately in a small volume (10 mL) 
of isolation buffer with BSA. Tissue is minced with a small 
scissor, and the buffer is changed several times to remove as 
much blood as possible. If mitochondria are isolated from 
Langendorff‑perfused hearts, there is no need to wash the 
tissue. The tissue is further homogenized using an UtraTur‑
rax (IKA, Staufen, Germany; two steps of 10 s, rotation rate 
6500 rpm; samples are put on ice during homogenization, 
with 1 min intervals between homogenization steps to avoid 
warm‑up of the mitochondria) or with a Teflon pestle in a 
glass potter (five strokes, pre‑cooled glassware and pestle).
After homogenization, samples are transferred to fresh 
tubes and centrifuged at 700g for 10 min to remove intact cells 
and nuclei. The supernatants containing the SSM are trans‑
ferred to fresh tubes and centrifuged at 14,000g for 10 min. 
The SSM, which are now sedimented, are resuspended in 
1–2 mL isolation buffer (without BSA) and washed by cen‑
trifugation at 10,000g for 5 min. After this centrifugation, the 
mitochondria are resuspended in a small volume (150–500 µL) 
of isolation buffer, depending on the initial amount of tissue.
Isolation of both subsarcolemmal (SSM) and interfibrillar 
(IFM) mitochondria
The distinction between SSM and IFM has first been made 
by Palmer and colleagues [327]. The protocol presented here 
follows that reported by Judge and colleagues [231] with slight 
modifications. SSM and IFM differ in their respiratory capacity 
and in their calcium retention capacity, in that IFM consume 
more oxygen than SSM and take up more calcium ions until 
mPTP opening occurs [52, 327]. The use of the present protocol 
yields mitochondrial subpopulations with these characteristics. 
Morphologically, the cristae structure of SSM and IFM differs, 
in that SSM have mostly lamelliform cristae, whereas IFM have 
tubular or a mixture of tubular and lamelliform cristae [349]. 
The isolation of IFM requires the use of a protease to release 
IFM from the myofibrils. Nagarse is the most used protease 
(and the present protocol focusses on this enzyme); however, 
trypsin [92] or proteinase K [359] are also used to isolate IFM.
Homogenization buffer (prepared at the day of the isola‑
tion or filter‑sterilized before use):
100 mmol/L KCl
50 mmol/L 3‑(N‑morpholino) propane sulfonic acid (MOPS)
5 mmol/L  MgSO4
1 mmol/L EGTA 
pH 7.4
Homogenization buffer with ATP (prepared at the day of 
the isolation):
The homogenization buffer is supplemented with 
1 mmol/L ATP.
Myocardial tissue is removed and washed, as described 
above. The myocardial tissue is weighed before placing it in 
homogenization buffer with ATP or in isolation buffer [156, 
388]. Tissue homogenization and the first centrifugation step 
are performed, as described above. Subsequently, SSM and 
IFM are processed individually. The supernatant of the first 
centrifugation step contains the SSM, which are further puri‑
fied as indicated. IFM—together with intact cells, nuclei and 
debris—are present in the sediment of the first centrifugation 
step. This sediment is resuspended in homogenization buffer 
with ATP (10 mL/g myocardial tissue) and transferred to a glass 
potter. Nagarse (proteinase type XXIV) is added (2–8 U/g), and 
after incubation for 1 min on ice the sample is homogenized by 
2–6 strokes of the pestle [156, 259, 388, 400]. Homogenization 
buffer with ATP is added to a total volume of 12 mL, samples 
are then centrifuged at 1000g for 10 min, supernatants are col‑
lected and centrifuged at 8000g for 10 min. The IFM, which 
are now sedimented, are resuspended in isolation buffer and 
washed by centrifugation at 8000g for 10 min. Finally, IFM are 
resuspended in a small volume (200–500 µL) of isolation buffer.
The incubation of samples with nagarse is the critical step 
during the isolation of IFM. If the concentration/activity of 
the enzyme is too low, IFM are not released; if it is too high, 
mitochondrial proteins are digested. In fact, immunoreactiv‑
ity for mitofusin 2 is detected predominantly in SSM. How‑
ever, after inhibition of nagarse by 1 mmol/L phenyl methyl 
sulfonyl fluoride, mitofusin 2 is also seen in IFM, indicating 
an underestimation of mitofusin 2 in IFM using the above 
protocol [259]. Therefore, protease sensitivity must be con‑
sidered when assessing the presence and distribution of 
mitochondrial proteins using nagarse‑based isolation.
Using an aliquot of the resuspended mitochondria, the 
protein concentration of the mitochondrial isolation is deter‑
mined. For this quantification, a standard assay is used, e.g. 
the Lowry assay with BSA as external standard.
The above protocols yield mitochondria, which are suit‑
able to study their function. However, these preparations are 
still contaminated with proteins of other cellular compart‑
ments. In case that an investigation of mitochondrial proteins 
is planned by western blot analysis, a further purification 
step should be included. The SSM and IFM are then lay‑
ered on top of a 30% Percoll solution in isolation buffer, 
and a subsequent ultracentrifugation is performed at 35,000g 
for 30 min. The ultracentrifugation results in two bands, of 
which the lower one contains the intact mitochondria. The 
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mitochondria are collected, washed twice in isolation buffer 
by centrifugation at 10,000g for 10 min, and the purified 
mitochondria can be stored at − 80 °C.
Mitochondrial parameters and experimental models
The evaluation of mitochondrial function depends largely 
on the model tested (Table 1). The number of parameters 
that can be assessed in isolated mitochondria is significantly 
reduced in isolated cardiomyocytes, while only indirect 
information can be obtained in whole hearts. A relevant 
exception to the latter is represented by the elegant technique 
using arylboronic acid conjugated to triphenylphosphonium 
for the direct detection of mitochondrial ROS formation 
in vivo [80, 84]. Until now, this method has only been used 
for detecting the large burst in ROS formation occurring at 
the onset of reperfusion. The assessment of mitochondrial 
function in intact organs, including beating hearts, should 
become feasible by combining the targeted expression of 
fluorescent proteins with intravital microscopy [437].
The limitations imposed by the increasing complex‑
ity of the experimental models (i.e. isolated organelle vs 
whole heart) apply also to the assessment of mPTP open‑
ing (Table 2). Differences among the various methods are 
detailed in the following sections.
Major methods for evaluating mitochondrial 
function in vivo
Oxygen consumption
Oxygen consumption can be assessed in intact cells, however, 
without testing the response to adenosine diphosphate (ADP) 
and specific respiratory substrates. More recently, the Seahorse 
extracellular flux analyzer (Agilent) has been introduced for the 
evaluation of oxygen consumption in intact cells. In this device, 
accurate measurements require the analyzed cells to be grown 
in a uniform monolayer configuration that cannot be obtained 
with adult cardiac myocytes. This technique can be adapted to 
the study of neonatal rat ventricular cardiomyocytes. Neonatal 
rat ventricular cardiomyocytes (60,000/well) are seeded onto 
Seahorse 24‑well microplates 24 h prior to the analysis. Oxy‑
gen consumption rate data consist of mean rates during each 
measurement cycle consisting of a mixing time of 30 s and a 
waiting time of 3 min followed by a data acquisition period of 
3 min. Rates displayed are basal respiration and rates follow‑
ing addition of 1 μg/mL oligomycin, 250–750 nM carbonyl 
cyanide‑4‑(trifluoromethoxy)phenylhydrazone (FCCP), 1 μM 
rotenone and 1 μM antimycin A. The addition of oligomycin 
mimics state 4 respiration, while the maximal values obtained 
with FCCP provide a reliable estimate of the total activity of 
respiratory chain complexes. The difference between FCCP or 
baseline and oligomycin values reflects the total respiratory 
capacity and the coupling efficiency, respectively. Of note, the 
FCCP concentration must be titrated to determine the optimal 
concentration necessary to maximize respiration (please note 
that at high doses FCCP inhibits respiration).
This approach is undermined by two major shortcomings: 
(1) variations in the number of seeded cells are paralleled 
by changes in respiration independently of mitochondrial 
function; (2) during the assay it is not possible to assess the 
occurrence of cell death that would obviously decrease the 
rate of oxygen consumption, thus flawing the evaluation of 
mitochondrial function.
Table 1  Detectable parameters of mitochondrial function
ATP adenosine triphosphate, NAD nicotinamide adenine dinucleotide, 
FAD flavin adenine dinucleotide, ROS reactive oxygen species
Preparation Parameter
Isolated mitochondria Oxygen consumption
ATP synthesis
Redox changes (NAD and FAD)
ROS formation
ΔΨm (quantitative)
Matrix volume
Ion movements
Isolated cells Oxygen consumption
Redox changes (NAD and FAD)
ROS formation
ΔΨm (semiquantitative)
Matrix volume
Ion movements (reliable only with 
genetically encoded probes)
Whole Hearts Oxygen consumption
(severe) mitochondrial ROS formation
ATP content
Table 2  Methods for detecting the opening of the mitochondrial per‑
meability transition pore (mPTP)
CsA: cyclosporine A
Preparation Parameter
Isolated mitochondria (or permeabi-
lized cells)
Swelling
Ca2+ retention capacity (CRC)
Permeability to solutes
CsA inhibitable changes
Isolated cells Calcein redistribution
Swelling
CsA inhibitable changes
Whole hearts Mitochondrial NAD depletion
Mitochondrial accumulation 
of tritiated deoxyglucose
CsA inhibitable changes
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Mitochondrial membrane potential
Although mitochondrial membrane potential (ΔΨm) can 
be measured also in isolated mitochondria, its assessment 
represents the most common approach for the evaluation of 
mitochondrial function in intact cells [40].
The aim of cell respiration is to build an  H+ gradient 
(ΔΨm) in the intermembrane space of mitochondria that 
provides the energy necessary for ATP generation. Mito‑
chondrial ATP synthase is the molecular machine that trans‑
forms the electrical power accumulated in the  H+ gradient 
into ATP‑containing chemical energy, following the che‑
miosmotic principle that governs the life of all organisms: 
the energy dissipated when  H+ flows back to the matrix 
through the  H+‑conducting channel of the ATP synthase is 
used by the enzyme to catalyze the conversion of ADP into 
ATP. Therefore, the mitochondrial electrochemical gradi‑
ent or membrane potential (ΔΨm) results from the balance 
between  H+ extrusion and  H+ dissipation and may be used as 
an index of the efficiency of mitochondrial respiration and/
or degree of respiratory (un)coupling. Several factors, such 
as high energy expenditure, the presence of pharmacological 
uncouplers (such as dinitrophenol or FCCP) or the expres‑
sion of uncoupling proteins may contribute to the dissipation 
of ΔΨm which, in turn, reduces ROS production [72]. Under 
ischemic conditions, lack of  O2 stops the activity of the elec‑
tron transport chain through the respiratory complexes, and 
mitochondria progressively depolarize mainly because  H+ 
extrusion to the intermembrane space is interrupted and  H+ 
flows back into the mitochondrial matrix through ATP syn‑
thase and other uncoupling proteins [360].
Here, one potential and frequent source of misinterpreta‑
tion is that in isolated cells ΔΨm can be maintained by the 
inverse operation of the FoF1 ATPase. In this process, ATP 
produced by glycolysis is hydrolyzed to maintain the pro‑
ton gradient across the inner mitochondrial membrane. The 
addition of the FoF1 ATPase inhibitor oligomycin allows 
one to discriminate whether ΔΨm is maintained by the res‑
piratory chain or ATP hydrolysis. This latter possibility is 
the direct consequence of alterations in respiratory com‑
plexes and/or mPTP opening.
The assay is based on the use of lipophilic cations with 
fluorescence emission that can be monitored by means of 
fluorescence microscopy. These fluorescent probes are good 
substrates for the multi‑drug resistance (MDR) pump [40]. 
Thus, different levels of fluorescence can result from vari‑
ations in MDR expression independently of mitochondrial 
function. To avoid this problem MDR activity should be 
inhibited. We suggest use of cyclosporine H, an analog of 
cyclosporine A (CsA) that inhibits the MDR without affect‑
ing mPTP opening.
To measure the ΔΨm, cells are pre‑incubated with 25 nM 
tetramethylrhodamine (TMRM, Thermo Fisher Scientific) in 
the presence of 1.6 µmol/L cyclosporine H. TMRM (exci‑
tation 535 nm and emission 600 nm) is a lipophilic rhoda‑
mine dye that accumulates in the mitochondria of live cells 
depending on their ΔΨm. Fluorescence microscopy is used 
to generate images that are collected before and after the 
addition of 2.5 µmol/L FCCP to completely abolish ΔΨm. 
TMRM fluorescence intensity is expressed as ΔF according 
to the following formula: ΔF = F0/FFCCP, where F0 = TMRM 
fluorescence intensity at baseline and FFCCP = fluorescence 
intensity after addition of FCCP.
Mitochondrial calcium homeostasis
Rhod‑2 is a high‑affinity calcium indicator with a Kd 
of ~ 570 nmol/L that tends to accumulate in the mitochon‑
drial matrix following the negative electrochemical gradi‑
ent; however, part of the dye may diffuse (or be retained) in 
the cytosol. Permeabilization of the sarcolemma reduces the 
cytosolic rhod‑2 fluorescence contribution, increasing the 
specificity of the signal, and allows a precise manipulation 
of the organelle environment (including the use of phar‑
macological inhibitors that otherwise would not cross the 
membrane barrier).
Before permeabilization, cardiomyocytes are loaded with 
4 μmol/L rhod‑2 acetoxymethyl ester (previously prepared 
and aliquoted following manufacturer’s indications) using 
a cold–warm protocol, consisting of 60 min incubation at 
4 °C followed by 30 min incubation at 37 °C. This double 
incubation enhances the retention of the dye within mito‑
chondria. Alternatively, a simple warm protocol consisting of 
50–60 min incubation with 4 µmol/L rhod‑AM at 37 °C can 
be used when working with permeabilized cardiomyocytes, 
in which the cytosolic fluorescent contribution is negligi‑
ble. Subsequently, cardiomyocytes are permeabilized and 
maintained in an intracellular‑like buffer, as indicated above. 
When studying mitochondrial function, it is critical to work 
with healthy energized cells, because mitochondrial depo‑
larization interferes with mitochondrial calcium uptake and 
retention of the fluorescent indicators. Changes in cytosolic 
calcium are induced by release of calcium from the sarco‑
plasmic reticulum through a caffeine pulse (10–20 mmol/L) 
while simultaneously monitoring changes in rhod‑2 fluores‑
cence throughout time with respect to the initial value (F/F0, 
excitation 561 nm/emission 605 nm). Permeabilized cells 
are more vulnerable to photobleaching and phototoxicity; 
therefore, it is important to quantify the contribution of pho‑
tobleaching in control‑permeabilized cells not submitted to 
any treatment and exposed to the same laser power (energy 
and speed of acquisition) as the treatment group (sham cells). 
When mitochondrial calcium is investigated, it is necessary 
to rule out the possibility that total sarcoplasmic reticulum 
calcium content is altered. To quantify total calcium load, 
intact (not permeabilized) cardiomyocytes are loaded with 
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the cytosolic calcium indicator fluo‑4 acetoxymethyl ester 
(5 μmol/L, 30 min at 37 °C), washed and post‑incubated for 
15 min at 37 °C. Cells are then placed on the stage of the 
microscope and submitted to a brief period of electrical pac‑
ing using field stimulation (0.5–1 Hz for 30 s) to allow cal‑
cium transient stabilization and appropriate replenishment of 
sarcoplasmic reticulum. During pacing, record calcium tran‑
sients from fluo‑4 fluorescence changes (excitation 488 nm/
emission 520 nm). After a few transients, a single pulse of 
caffeine (10–20 mmol/L) is applied directly to the cells. The 
maximal amplitude of caffeine‑induced fluo‑4 fluorescence is 
normalized by the initial fluorescent value (F/F0); this value 
can be considered an index of total sarcoplasmic reticulum 
calcium load. Figure 5 shows an example of cytosolic cal‑
cium transients and maximal sarcoplasmic reticulum calcium 
release in intact cardiomyocytes (A) and the kinetics of mito‑
chondrial calcium uptake in response to sarcoplasmic reticu‑
lum calcium release in permeabilized cardiomyocytes (B).
Permeability transition
Mitochondrial permeability transition has attracted much 
attention in the past decades as one of the critical determi‑
nants of cell death during ischemia/reperfusion [167, 174]. 
Sustained mPTP opening results in mitochondrial matrix 
swelling and energetic collapse that is incompatible with cell 
life. Its contribution to necrotic death during reperfusion has 
been unambiguously demonstrated in multiple studies [82, 
174, 183, 224]. Moreover, several lines of evidence suggest 
that the infarct sparing effect of ischemic pre‑ and postcon‑
ditioning is at least in part mediated by the prevention of 
mPTP opening [179, 324]. Although the exact molecular 
entity of mPTP remains debated, its opening is triggered 
by well‑characterized factors, among which increased mito‑
chondrial calcium, ROS and normalization of intracellular 
pH are of main importance [31].
Various methods are available for the direct evaluation of 
mitochondrial permeability transition in different experimental 
models, including primary cells (see above). Whatever method 
is used or consequence is detected, mPTP involvement is usu‑
ally confirmed by the inhibitory effect of CsA. However, this 
approach can easily generate both false‑positive and ‑nega‑
tive results. First, mPTP‑independent effects could be elicited, 
since CsA binds all the cyclophilins in addition to the mito‑
chondrial cyclophilin‑D. This is the case with calcineurin inhi‑
bition followed by a decreased occurrence of mitochondrial 
fission [68]. Second, cyclophilin‑D is only a mPTP modulator; 
thus mPTP opening could still occur also in the presence of 
CsA. Thus, the absence of a CsA effect is not sufficient to rule 
out the involvement of mPTP opening in a given process [39].
Calcein release The calcium retention capacity assay can 
be used in isolated cells following permeabilization with 
saponin. Nevertheless, it cannot be used in intact cells and 
monitoring mitochondrial swelling requires a complex pro‑
cedure of confocal microscopy [232]. The reference method 
for detecting mPTP opening in intact cells is based upon 
the intracellular redistribution of calcein coupled with  Co2+ 
quenching of cytosolic calcein fluorescence [338]. In par‑
ticular, cells are loaded for 15 min with 1 mmol/L calcein 
acetoxymethyl and 1 mmol/L  CoCl2 at 37 °C. Cells are then 
washed free of calcein and  CoCl2, and the experiment begins 
by controlling the attainment of quenching of the cytosolic 
fluorescence signal resulting in the visualization of bright 
mitochondria glowing against a dark background.
Opening of mPTP is detected as a decrease in calcein 
fluorescence using a confocal or epifluorescent microscope 
(excitation 488 nm/emission 525 nm). To semi‑quantitatively 
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Fig. 5  a Calcium transient recording in a fluo‑4 loaded rat cardio‑
myocyte submitted to field stimulation (1  Hz, acquisition set at 40 
images/s). After a period of stabilization, the cardiomyocyte is sub‑
jected to a single pulse of 10 mmol/L caffeine (red arrow) to induce 
maximal SR calcium release. The sequence of images shows diastolic 
and systolic calcium levels during pacing and after caffeine pulse. b 
Mitochondrial  Ca2+ uptake throughout time in response to sarcoplas‑
mic reticulum  Ca2+ release (induced by a single pulse of 10 mmol/L 
caffeine, red arrow) in digitonin‑permeabilized rhod‑2 loaded 
mouse cardiomyocytes, under control conditions (black circles) or 
in the presence of 10 µmol/L of the mitochondrial calcium uniporter 
blocker Ru360 (white circles). Data correspond to mean ± standard 
error of the mean of n = 8 cardiomyocytes per group. Images corre‑
spond to a sarcolemmal‑permeabilized cardiomyocyte loaded with 
rhod‑2, before and after caffeine addition
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calibrate the signal, maximal calcein release can be pharma‑
cologically induced at the end of the experiment by addition 
of 30 µmol/L alamethicin. Calcein release kinetics may be 
automatically quantified with the aid of imaging software 
and expressed as percent of calcein fluorescence decrease 
with respect to maximal calcein release after atractyloside 
treatment. Alternatively, calcein release can be normalized 
with respect to the initial fluorescent value (F/F0), although 
in this case, it is recommended to quantify the contribution 
of photobleaching to the total fluorescence decay. Also, to 
avoid the occurrence of reperfusion‑induced hypercontrac‑
tion that interferes with calcein quantification, a concentra‑
tion of 5 mmol/L 2,3‑butanedione monoxime can be added to 
the reperfusion buffer. Monitoring of mitochondrial calcein 
release reflects mPTP opening in cardiomyocytes submit‑
ted to ischemia/reperfusion (or other pathological condi‑
tions) and its occurrence usually correlates with the severity 
of cell damage, although the mechanisms of damage may 
vary among the specific experimental context and conditions 
(degree of calcium overload, kinetics of pH normalization, 
severity of mitochondrial dysfunction). Figure 6 shows an 
example of mitochondrial calcein release and quantification 
in cardiomyocytes subjected to ischemia/reperfusion.
Mitochondrial reactive oxygen species
In the past decade, several probes have been developed to 
measure intracellular and compartmentalized ROS forma‑
tion inside the cell [110, 237, 457]. Small molecule fluores‑
cent dyes, such as MitoSOX and reduced MitoTracker dyes, 
are commonly used for the detection of mitochondrial ROS 
formation in intact cells.
MitoSOX Red is a derivative of hydroethidine and is 
widely used for the measurement of  O2− formation in active 
mitochondria. This dye is specifically targeted to mitochon‑
dria because it contains the lipophilic cation triphenyl phos‑
phonium substituent [88, 237]. MitoSOX Red is oxidized by 
 O2− to form a red fluorescent product 2‑hydroxyethidium, 
which is excited at 510 nm and emits at 580 nm [88]. Even 
though MitoSOX is used to specifically detect  O2− forma‑
tion, this probe can also be oxidized by other oxidants to 
form ethidium, which overlaps with the fluorescence peak of 
2‑hydroxyethidium [238, 463]. Moreover, at high concentra‑
tions, MitoSOX displays some non‑mitochondrial staining, 
for instance, in the nucleus [351].
MitoTracker Orange CM‑H2TMRos and MitoTracker 
Red CM‑H2XRos are derivatives of dihydrotetramethyl 
Fig. 6  a Sequence of a calcein‑
loaded mouse cardiomyocyte 
with rigor contracture during 
the first 5 min of reperfusion 
(60 × magnification). Because 
calcein is entrapped in mito‑
chondria, the decay of green 
fluorescence reflects mitochon‑
drial permeabilization. b Quan‑
tification of total mitochondrial 
calcein release at 15 min reper‑
fusion, with respect to maximal 
mitochondrial calcein release 
achieved after the addition of 
atractyloside (ATR), in isolated 
cardiomyocytes from wild‑
type (WT) and cyclophilin‑D 
knock‑out (CyD‑KO) mouse 
hearts, previously submitted to 
either 15 or 25 min ischemia. 
The inset shows mitochondrial 
calcein kinetics [changes in 
fluorescence with respect to the 
initial value, F/F0)] through‑
out reperfusion, indicating 
mitochondrial permeability 
transition pore (mPTP) opening 
in the different groups of cells. 
Maximal mitochondrial calcein 
release was induced in WT 
cardiomyocytes treated with 
20 µmol/L atractyloside. Data 
are expressed as mean ± SEM of 
5–6 cardiomyocytes per group. 
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rosamine and dihydro‑X‑rosamine, respectively [237]. 
Reduced MitoTracker dyes do not fluoresce until entering 
viable cells, where they get oxidized and become positively 
charged. The cationic fluorescent compound then accumu‑
lates in the mitochondria depending on ROS levels and 
mitochondrial membrane potential, and forms fluorescent 
conjugates with thiol groups [215]. The excitation/emis‑
sion wavelengths for MitoTracker Orange CM‑H2TM‑
Ros and MitoTracker Red CM‑H2XRos are 554/576 and 
579/599 nm, respectively [237]. Unlike MitoSOX, these 
reduced MitoTracker dyes are not specific for single oxidant 
species and thus detect general mitochondrial ROS [237]. 
Moreover, the fact that their mitochondrial localization 
and accumulation depend on the mitochondrial membrane 
potential is a crucial aspect to bear in mind for the cor‑
rect interpretation of the fluorescence intensity levels [351, 
463]. Indeed, it is necessary to measure mitochondrial 
membrane potential to avoid erroneous interpretations.
Use of genetically encoded fluorescent probes, exemplified 
by  HyPer As described above, fluorescent redox probes 
such as MitoSOX and MitoTracker dyes present limitations 
in terms of selectivity, sensitivity and localization. There‑
fore, genetically encoded biosensors have been developed 
to measure  H2O2 or other species fluctuations in different 
compartments of living cells, such as reduction–oxidation‑
sensitive green fluorescent protein [114], Orp1, [11] and 
HyPer (Hydrogen Peroxide sensor) [114].
HyPer contains a  H2O2‑sensitive regulatory domain of 
E. coli transcription factor OxyR [36, 79], bound to a circu‑
larly permuted yellow fluorescent protein (cpYFP). OxyR can 
be oxidized by  H2O2, leading to the formation of a disulfide 
bond between Cys‑199 and Cys‑208; this oxidative modifica‑
tion can be reversed by the activity of endogenous glutaredox‑
ins. Oxidation‑induced conformational change is transmitted 
to cpYFP that is integrated into the conformation‑changing 
region in OxyR between residues 205 and 206 [79]. There‑
fore,  H2O2‑induced oxidation of OxyR is reflected by changes 
in fluorescence properties of cpYFP. In particular, a decrease 
in the 420‑nm peak is coupled with a proportional increase in 
the 500‑nm peak, making the sensor ratiometric [287].
The major advantages of this genetically encoded redox 
sensor are that it is ratiometric, reversible and can be tar‑
geted to specific compartments of the cell. Several variants 
of HyPer are commercially available, such as cytosolic 
(pHyPer‑cyto), mitochondrial (pHyPer‑dMito) and nuclear 
(pHyPer‑nuc) constructs. In addition, other versions of the 
plasmid targeted to endoplasmic reticulum, lysosomes and 
different compartments within the mitochondria have been 
reported. Thus, HyPer is a useful tool to measure compart‑
mentalized  H2O2 formation [293].
HyPer has two excitation maxima (420/500 nm) and a 
single emission peak maximum (516 nm). Upon oxidation, 
the intensity of the 420‑nm peak decreases proportionally to 
the increase of the intensity of the 500‑nm peak, thus mak‑
ing HyPer a ratiometric sensor. An increase in  H2O2 levels 
is directly proportional to the increase in fluorescence ratio 
F500/F420 [44].
Even though HyPer is widely used to detect  H2O2, its flu‑
orescence levels can be influenced by pH, potentially lead‑
ing to erroneous result interpretation. Hence, it is important 
to monitor pH in the same compartment and experimental 
conditions in which HyPer is being used. This can be accom‑
plished using SypHer, a form of HyPer bearing a mutation in 
one of the two  H2O2‑sensing cysteines of the OxyR domain, 
making it a  H2O2 insensitive but pH‑sensitive sensor [237].
Major methods for evaluating mitochondrial 
function in vitro
Oxygen consumption
Oxygen consumption is usually measured by means of an 
oxygen electrode put at the bottom of glass chambers with 
sizes ranging from few microliters to 2 mL. The measure‑
ment of respiration states along with the specific evaluation 
of the activity of respiratory complexes can be obtained only 
in isolated mitochondria or permeabilized cells. Mitochon‑
dria are isolated by means of enzymatic and/or mechani‑
cal cell disruption followed by conventional procedures of 
differential centrifugation [106, 141, 278]. Permeabiliza‑
tion, i.e. loss of sarcolemmal integrity, can be obtained by 
adding 10 µmol/L saponin to cells incubated in the same 
buffer used for assessing respiration (125 mmol/L sucrose, 
65–125 mmol/L KCl, 20 mmol/L HEPES, 1 mmol/L  MgCl2, 
100–200 µmol/L EGTA, 2.5 mmol/L  KH2PO4, pH 7.4). 
Isolated mitochondria or permeabilized cells are added to 
the respiration chamber to achieve a final concentration of 
0.1–0.2 mg protein/mL in the case of cardiac samples. Basal 
(state 4) respiration is monitored following addition of res‑
piration substrates, 5/2.5–5 mmol/L glutamate/malate (com‑
plex I) or 5 mmol/L succinate (complex II) in the presence of 
2 µmol/L rotenone. After 3 min, 0.6 mmol/L ADP is added 
to induce state 3 respiration. The ratio between state 3 and 
state 4 respiration, termed respiratory control index, is a reli‑
able marker of the quality of the mitochondrial preparation. 
Values should be > 6 and > 3 with NAD‑dependent and fla‑
vin adenine dinucleotide‑dependent substrates, respectively. 
In a separate assay, or after the return to state 4 respiration, 
mitochondrial uncoupling can be obtained by adding (sub)
micromolar amounts of FCCP, determined upon titration. 
This procedure is necessary to assess the maximal rate of 
respiration independently of its coupling with ATP synthe‑
sis. Indeed, a reduced state 3 rate could be affected by altera‑
tions in the activity of FoF1 ATPase and/or adenine nucleo‑
tide translocase, while uncoupled respiration depends only 
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on respiratory chain complexes. Data are expressed as the 
rate of oxygen consumption normalized to mg of mitochon‑
drial proteins in the case of isolated organelles or number of 
cells in the case of cell permeabilization.
Mitochondrial swelling
Mitochondrial swelling is monitored as the changes in 
absorbance at 540 nm. Incubations are carried out with 
0.25 mg of mitochondrial protein/mL in a respiration buffer 
containing 0.25  mol/L sucrose, 10  mmol/L Tris‑Mops, 
0.05 mmol/L EGTA, pH 7.4, 5 mmol/L pyruvate, 5 mmol/L 
malate, and 1 mmol/L Pi‑Tris, pH 7.4. Alternatively, a KCl‑
based buffer can be used containing 137 mmol/L KCl, 
2 mmol/L  KH2PO4, 20 mmol/L HEPES, and 20 μM EGTA, 
pH7.4, with pyruvate/malate or glutamate/malate as the res‑
piratory substrates. mPTP opening is induced by the addition 
of 0.25 mmol/L  CaCl2 [107]. Please note that variations of 
this general protocol can be used for the study of mPTP 
opening in de‑energized mitochondria [19].
Calcium retention capacity
The assay measures the amount of  Ca2+ that mitochondria 
can accumulate and retain before the precipitous release 
that marks mPTP opening [140]. Extra‑mitochondrial  Ca2+ 
fluxes are measured fluorometrically using Calcium Green‑
5N that increases its fluorescence emission upon  Ca2+ 
binding. Mitochondria (0.1–0.25 mg/mL) are suspended in 
200 μL of respiration buffer that also contains 1 μM Cal‑
cium Green‑5N but no EGTA. The suspension is subjected 
to a train of  Ca2+ pulses or spikes (typically 10 μM each). 
Each spike represents the increase in fluorescence (due to 
extra‑mitochondrial  Ca2+ binding to Calcium Green‑ 5N) 
followed by a decrease in fluorescence due to the accumula‑
tion of added  Ca2+ into mitochondria. Mitochondrial accu‑
mulation of  Ca2+ continues upon addition of subsequent 
pulses until the “threshold” for mPTP activation is reached 
and all the  Ca2+ is released from mitochondria (represented 
by the dramatic terminal fluorescence increase) due to the 
opening of the mPTP. Dose–response curves are calculated 
by comparing the total  Ca2+ added for mPTP activation in 
the presence of a test compound with respect to the calcium 
retention capacity in the absence of test compound.
Measurement of reactive oxygen species by Amplex Red
The Amplex Red assay is a widely used procedure for 
assessing  H2O2 formation in cell‑free extracts, including 
mitochondria [237]. This technique is devoid of limitations 
affecting other assays that are frequently used. Among 
these, the fluorescence of 2′,7′‑dichlorofluorescein is 
hampered by its low specificity for  H2O2 [65] and suscep‑
tibility to oxidation by iron or cytochrome c [238]. Amplex 
Red is a substrate of horseradish peroxidase, which is oxi‑
dized in the presence of  H2O2 resulting in the production 
of a red fluorescent compound resorufin (excitation/emis‑
sion: 540 or 571/580 or 585 nm) [402]. Amplex Red reacts 
with  H2O2 in a 1:1 stoichiometry to produce resorufin. 
The major shortcoming is the significant light sensitivity 
of Amplex Red that can lead to the formation of resorufin 
even in the absence of horseradish peroxidase and  H2O2 
[459]. Thus, necessary precautions should be taken to 
prevent photooxidation of this probe. Moreover, the fact 
that Amplex Red is cell impermeable limits its use to the 
permeabilized cells [402].
Amplex Red assay is commonly used to measure ROS 
produced by the mitochondrial respiratory chain in the 
presence of substrates, such as succinate or glutamate/
malate. Moreover, it is also possible to measure the activ‑
ity of several enzymes that produce  H2O2, including 
monoamine oxidases. These mitochondrial flavoenzymes 
catalyze the oxidative deamination of catecholamines and 
biogenic amines, resulting in the production of  H2O2, alde‑
hydes and ammonia [236].
Measurement of mPTP opening in whole hearts
In the procedure devised in Halestrap’s laboratory, 
perfused hearts are first loaded with  [3H] 2‑deoxyglucose, 
which accumulates within the cytosol as  [3H]‑deoxyglucose‑ 
6‑phosphate, but can only enter the mitochondria when the 
mPTP opens. Using this approach, it has been shown that mPTP 
remains closed during ischemia but opens upon reperfusion 
[80]. A similar conclusion has also been obtained using a pro‑
cedure based on the release of mitochondrial  NAD+ upon mPTP 
opening [82]. Besides representing a useful analytical tool, the 
loss of mitochondrial  NAD+ provides additional pathways link‑
ing mPTP opening to cell death [83].
Issues and limitations in evaluating mitochondrial 
parameters
Besides limitations associated with experimental models, 
one cannot be too cautious in interpreting results of mito‑
chondrial dysfunction as evidence of cardiac injury or pro‑
tection. The following list summarizes the major issues, as 
well as common misinterpretations.
1. Mitochondrial dysfunction is not necessarily related to 
cell death, since it is involved in many forms of cardio‑
protection.
2. The assessment of functional parameters in mitochon‑
dria isolated from a given cell or tissue exposed to injury 
does not provide reliable information on the function 
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of mitochondria in situ and their contribution to loss or 
maintenance of viability. Indeed, the quality of the mito‑
chondrial preparation is determined by the quality of the 
starting material. Invariably, a damaged heart yields a 
mitochondrial fraction with decreased function without 
indicating whether mitochondrial dysfunction is causally 
related to heart/cardiomyocyte derangements in situ.
3. Mitochondrial function or structure should not be evalu‑
ated as a single endpoint at the end of a given protocol. 
For instance, mitochondrial derangements are expected to 
occur at the end of reperfusion, but this kind of observa‑
tion does not determine whether mitochondrial abnormal‑
ities are a cause or a consequence of reperfusion injury.
4. The observation that a given mitochondrial compo‑
nent is up‑ or down‑regulated is hardly informative on 
mechanisms causing cardiomyocyte injury or protec‑
tion. Mechanistic information should be obtained by 
demonstrating that the absence of that mitochondrial 
component or process modifies the extent of injury (or 
protection).
5. The qualitative assessment of mitochondrial changes is 
hardly predictive of cellular outcome and does not allow 
the elucidation of detrimental or beneficial pathways. 
This is especially the case with changes in levels of  Ca2+ 
and ROS that appear to be involved in both injury and 
protection. What is lacking is the knowledge of a precise 
threshold separating protective from deleterious levels.
6. Mitochondrial changes associated with protection 
against acute injury, such as the classic ischemia/rep‑
erfusion model, are frequently detrimental in chronic 
settings. Besides the extreme (and seminal) examples 
of cardioprotection elicited by cyanide or mitochondrial 
uncouplers [123, 145], cardiac alterations have been 
reported to result from long to lasting mPTP inhibi‑
tion [122]. Furthermore, cardiac function is inevitably 
hampered by respiratory chain inhibition that protects 
against acute ischemia/reperfusion protocols [69, 80].
Cell types other than cardiomyocytes
HL‑1 cardiomyocytes
Immortalized cardiomyocytes, which proliferate in culture 
conditions and maintain their fully differentiated phenotype, 
do not exist. In the last decades, different attempts to cre‑
ate such cell models have been made with little success. 
Technical approaches have been based on the generation of 
transgenic mice that contained an oncogene, the expression 
of which was targeted to the myocardium using different car‑
diac‑specific promoters [100, 245]. In 1998, Claycomb et al. 
developed the commercially available HL‑1 cell line [83], 
which was established from an atrial subcutaneous tumor 
excised from an adult female C57BL/6J mouse. HL‑1 cells 
can grow in culture for long‑time and display a myofibrillar 
organization similar to the mitotic cardiomyocytes of the 
developing heart. They form cell‑to‑cell contacts through 
gap junction‑containing intercalated disks and, after some 
days in the appropriate culture conditions, they exhibit spon‑
taneous contractile activity that tends to synchronize in the 
form of clusters of contracting cells. Culturing of HL‑1 
cells is relatively easy. With the usual caution and sterility 
required for the management of cells, HL‑1 cells can be effi‑
ciently passaged and expanded. They can also be frozen and 
recovered from frozen stocks. Nevertheless, long‑term culti‑
vation of HL‑1 cells is expensive, because it requires the use 
of a very specific medium (Claycomb medium), the com‑
position of which is protected under patent. Despite some 
limitations, i.e. progressive loss of contractile activity after 
several passages by not well‑controlled mechanisms, the 
HL‑1 cell line is a widely accepted model for basic research 
studies on cardiac pathophysiology [137], cell signaling 
[453], cardioprotection [357], electrophysiology [379] and 
pharmacology [159]. Indeed, HL‑1 cells express important 
proteins of the adult heart (e.g. connexin 43, ANT, alpha iso‑
form of the myosin heavy chain), preserve an adult pattern 
of sarcomeric genes, maintain several voltage‑dependent 
electrical currents and exhibit cyclic calcium movements 
[83]. In addition, HL‑1 cells are a suitable model for stud‑
ies with gene transfection and protein overexpression [50]. 
However, of note, they do not represent true adult cardio‑
myocytes but rather a hybrid stage between embryonic and 
postmitotic cells. In contrast to adult cardiomyocytes, the 
energy metabolism of HL‑1 cells relies on glycolytic activ‑
ity [308]. Because HL‑1 are atrial‑derived cells, they may 
not share the functional traits of ventricular cardiomyocytes.
H9c2 cells
H9c2 cells are a subclone of the original cell line derived 
from embryonic BD1X rat heart tissue [251], which pro‑
liferates in culture for a limited number of passages on a 
Dulbecco’s modified Eagle’s medium. H9c2 myoblasts have 
ventricular origin but share some properties with skeletal 
muscle. Indeed, they have the ability to transdifferentiate 
into multinucleated skeletal myotubes with very low prolif‑
erative capacity when serum is reduced to 1% concentration. 
In addition, when subjected to chronic treatment (5–6 days) 
with all‑trans‑retinoic acid (100 nmol/L–1 µmol/L), H9c2 
may undergo an additional differentiation step into a car‑
diac‑like phenotype [298]. Depending on their differen‑
tiation stage, H9c2 cells predominantly exhibit cardiac‑
specific voltage‑dependent calcium channels, skeletal 
voltage‑dependent calcium channels or a mixture of both 
[194, 298]. It is, therefore, of critical importance to establish 
the appropriate differentiation phenotype before planning 
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experiments. In the fully cardiac differentiated stage, H9c2 
cells display an elongated morphology and express sarcom‑
eric proteins as well as proteins involved in calcium handling 
which are typical of the adult cardiomyocyte, including sar‑
coplasmic reticulum calcium ATPase 2, ryanodine receptor 
and phospholamban [59]. They also adopt a more oxida‑
tive metabolism, characterized by good coupling between 
glycolysis and mitochondrial respiration and indicative of 
higher energetic efficiency [336]. Different reports agree that 
cardiac‑like H9c2 cells resemble more closely adult cardio‑
myocytes than HL‑1 cells in terms of their metabolic signa‑
ture, mitochondrial respiratory function and vulnerability to 
ischemia/reperfusion injury [2, 265, 314].
Stem cells
Physiological experiments requiring cardiomyocytes are still 
limited by the fact that adult, terminally differentiated cardio‑
myocytes are mostly isolated from rodents which may differ 
from human cardiomyocytes, by the need of fresh isolation, 
and by their limited cell number. The use of stem cells may 
be regarded as an alternative strategy. The use of stem cells 
from various origins has become popular in regenerative 
medicine. The advantages and limitations of such protocols 
have recently been discussed in detail [291]. With respect 
to experimental studies, the most successful strategy is the 
use of human pluripotent stem cells (PSC) which routinely 
differentiate into cardiomyocytes by more than 80% [45]. 
However, the remaining cultures are still a mixture of atrial, 
ventricular, and nodal cells with different phenotypes and 
they represent a spontaneously beating culture which differs 
from native differentiated cardiomyocytes. Such cell culture 
models may be of specific advantage to identify the paracrine 
potential in myocardial infarction [290]. Similarly, embryonic 
stem cells have been used to study potential cytoprotective 
effects. The longevity of these cells under culture conditions 
can be prolonged by administration of NO [162, 163, 328].
Endothelial cells
Cardiac endothelial cells are less susceptible than cardiomy‑
ocytes to oxygen deprivation but may develop hypercontrac‑
ture, necrosis and apoptosis during reperfusion. In contrast 
to cardiomyocytes, endothelial injury may affect cardiac 
function by mechanisms other than the death of endothe‑
lial cells, including increased permeability and edema, and 
recruitment of platelets and inflammatory cells [407].
Endothelial cell necrosis can be detected in cell cultures 
with the same techniques used in cardiomyocytes, except for 
the absence of gross morphological changes, as hypercon‑
tracture of endothelial cells is much more subtle than that 
of cardiomyocytes.
There is strong evidence that endothelial cells may 
develop apoptosis during initial reperfusion. In cell cultures, 
apoptosis can be detected by a large variety of methods, 
including the quantification of cell membrane proteins, in 
particular those which are externalized early during the 
apoptosis process, detection of DNA fragmentation, or anal‑
ysis of morphological changes in cell nuclei (for detailed 
protocols see [91]).
Apoptosis‑induced translocation of the phospholipid 
phosphatidyl serine is easily detected with fluorescein‑
labeled annexin V (FICT‑Fluorescein V). Annexin V labe‑
ling occurs before DNA fragmentation and persists until the 
end of the apoptotic process, but also occurs during necrosis, 
as permeabilization of the plasma membrane allows annexin 
V to reach intracellular phosphatidyl serine. To distinguish 
apoptotic from necrotic cells, a double labeling with annexin 
and propidium iodide is usually performed. Cells labeled 
with annexin V but not with propidium iodide are considered 
apoptotic, while those labeled with both are classified as 
necrotic. Detection and quantification of fluorescence can be 
performed by conventional or confocal fluorescence micros‑
copy or by flow cytometry analysis.
Detection of apoptosis‑induced DNA fragmentation may 
be carried out by different forms of electrophoresis and by 
sophisticated labeling methods in cell preparations but is 
less sensitive and less practical that Annexin V‑based meth‑
ods [18].
In tissue, detection of DNA fragmentation through elec‑
trophoresis does not allow identification of which types of 
cells are undergoing apoptosis. Histologic analysis of fixed 
tissue after staining with hematoxylin–eosin or other meth‑
ods allows morphological identification of apoptotic cells, 
but the sensitivity, reproducibility and quantitative informa‑
tion provided by this method is limited.
Quantitation of infarct size by morphology, 
biomarkers and imaging
Measuring the size of the infarct is essential for all cardio‑
protection studies. Quantification can be achieved by differ‑
ent techniques but they all carry specific concerns. Conse‑
quently, it is important to be aware of conceptual limitations 
of the measurement of infarct size that are common to all 
techniques.
Common key issues for infarct size measurement
Why measure infarct size?
The measurement of infarct size is a crucial issue of car‑
dioprotection, since the amount of irreversible myocardial 
damage influences left ventricular remodeling, recovery 
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of contractile function, and patient’s prognosis. It has then 
naturally become the common way to evaluate and com‑
pare the beneficial effects of potential protective therapies, 
and is currently the endpoint of most experimental studies 
as well as phase II clinical studies in the field of ischemia/
reperfusion [184]. This consensus should, however, not 
mask difficulties. Assessing the size of an infarct is not lim‑
ited to technical questions, but first and foremost requires a 
good knowledge of some conceptual limitations and pitfalls 
of interpretation.
Infarct size according to models
Animal models Progress in understanding the pathophysi‑
ology of ischemia/reperfusion comes largely from seminal 
studies using transient coronary occlusion in large ani‑
mal models, particularly anesthetized dogs [348]. Infarcts 
were often large, transmural, corresponding to what was 
observed clinically at the time due to absent or late rep‑
erfusion. As it should be, these authors expressed the size 
of the infarct in grams of myocardial tissue irreversibly 
injured. Global ischemia in the rat isolated perfused heart 
has also been a very useful model for understanding the 
pathophysiology of ischemia/reperfusion especially with 
respect to its metabolic aspects. Nevertheless, the patho‑
physiology of cell death is different from that in in vivo 
models, and extrapolation from one model to the other of 
data regarding the beneficial effects of given treatment 
should be made with caution.
Cell death after  hypoxia reoxygenation Cell cultures 
and isolated cells are widely used for pathophysiological 
studies but also for testing pharmacological agents [326]. 
These experimental conditions are obviously very dif‑
ferent from those of in  vivo models, because of lack of 
contractile activity and the absence of neighboring cells 
such as fibroblasts, vascular cells and nerves. Importantly, 
quantitation of the number (or percentage) of dying cells 
after hypoxia and re‑oxygenation is not the equivalent of 
measurement of infarct size. Consequently, observing a 
decrease in viability following any treatment does not pre‑
sume an equivalent reduction in infarct size after the same 
therapeutic intervention in an in vivo model.
Clinical settings The average infarct size observed now‑
adays in STEMI patients has been considerably reduced 
by shortened delay to PPCI and the development of inter‑
ventional cardiology techniques. While smaller infarcts 
are much more frequent, their impact on left ventricular 
remodeling, recovery of contractile function, heart failure 
and mortality is less clear than for a large STEMI. Unfor‑
tunately, the size of the infarct is not even measured in 
many interventional cardiology centers even though rou‑
tine biomarkers for that measurement are easily available 
and inexpensive. Although infarct size is recognized as a 
major predictor of prognosis, all patients with acute myo‑
cardial infarction patients usually receive the same treat‑
ment at discharge regardless of the amount of irreversible 
damage to the heart.
In contrast, peri‑operative and peri‑procedural myocar‑
dial damage is assessed in clinical settings such as cardiac 
surgery or endovascular procedures for chronic coronary or 
even valvular diseases [74, 193, 234, 330, 422]. Here, how‑
ever, tissue destruction is fortunately quite minimal and 
its impact on ventricular function and clinical outcomes 
remains less clearly defined and in any case not compa‑
rable to that in STEMI. As a matter of fact, reducing by 
40% a troponin release peak of 6 μg/L does not have the 
same meaning as reducing by 40% a troponin release peak 
of 150 μg/L [74, 340]. This identical use of the measure‑
ment of infarct size in STEMI and experimental conditions 
where infarction is very small deserves significant caution. 
As for cardioprotection, this use of infarct size measure‑
ment may have been misleading and in part explains some 
of the “failures” of the transfer to the clinic of certain car‑
dioprotective interventions [182, 302].
Measuring reperfusion infarction: a critical unsolved issue
Most of the cardioprotection studies aim to reduce infarct 
size through new therapies administered at the time of PPCI, 
i.e. mainly targeting reperfusion injury. Unfortunately, we do 
not know how to specifically measure reperfusion lesions, 
i.e. to distinguish them from ischemic lesions: we measure a 
final infarct size which encompasses ischemic plus reperfu‑
sion injuries. The size of the reperfusion injury cannot be 
measured in a given individual but may only be averaged 
by comparing the mean infarct size in a treated group com‑
pared to that in a control group. Imaging of the infarct size 
before PPCI and following its extension after reflow would 
be the only way to address this question. For the moment, 
this poses unresolved technical problems and risks delaying 
reperfusion by having to image before coronary recanaliza‑
tion. Such developments, including new imaging methodolo‑
gies such as computed tomography and cardiac magnetic 
resonance imaging (CMR) in the catheterization laboratory, 
are currently being studied.
Infarct size as a function of area at risk
The experimental studies have clearly shown that the final 
size of the infarct is determined mainly by the duration of 
ischemia, the size of the area at risk and the amount of resid‑
ual myocardial flow in the ischemic bed [184]. Any meas‑
urement of infarct size should, therefore, be accompanied 
by a concomitant measurement of these determinants. All 
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experimental models use a fixed duration of ischemia. Col‑
lateral flow may be measured using labeled microspheres; 
alternatively, one may choose an experimental model with 
little or no collateral circulation (e.g. rat, rabbit, pig).
While the measurement of the area at risk is well defined 
in experimental models (see below), it is much more diffi‑
cult in clinical conditions. IV administration of 99Technetium 
sestamibi while the artery is still occluded allows a reliable 
assessment of the hypo‑perfused area if single‑photon emis‑
sion computed tomography (SPECT) is completed within 6 h 
after injection. Unfortunately, it is often not compatible with 
emergency care because 99Technetium sestamibi must be pre‑
pared within a few hours preceding the SPECT imaging [20].
CMR is the most commonly used technique to measure 
both the area at risk and infarct size. T2‑weighted CMR 
(T2w‑CMR) allows the evaluation of the size of the area 
at risk. It does not measure tissue perfusion during the 
ischemic period but detects myocardial edema which devel‑
ops particularly after reflow [301]. Experimental evidence 
suggests that the post‑ischemic edematous zone matches the 
area at risk [12]. This well‑standardized method nevertheless 
poses several major problems [210]. First, the edema area 
is indeed wider than the area of hypoperfusion during the 
ischemic phase. Second, the dynamics of the myocardial 
edema are unpredictable in a given patient and there seems 
to exist significant variation in tissue water content between 
day 1 and day 7 after reflow [131, 132]. Third, treatments 
that reduce infarct size also attenuate myocardial edema 
[423]. Then, the size of the area at risk measured in patients 
who received a cardioprotective therapy will appear smaller 
than the “real” area at risk, which is obviously a bias when 
compared with an untreated group. Altogether, T2w‑CMR 
should not be used to assess the size of the area at risk in 
cardioprotection studies [89]. In contrast, CMR evaluation 
of infarct size by late gadolinium enhancement (LGE–CMR) 
(see below) is reliable and relatively simple, and is currently 
considered as the standard technique for measuring infarct 
size (expressed in grams of myocardium) in patients. Unfor‑
tunately, only a minority of interventional cardiology centers 
are capable of performing quality CMR evaluation of infarct 
size 24 h every day. Other modes of CMR imaging analysis 
are under development that might improve its performance.
Reference techniques
Histology
For in vivo models, the recommended technique is the blue 
dye coloration for delineating the area at risk and the iden‑
tification of viable myocardium by 2,3,5‑triphenyl tetrazo‑
lium chloride (TTC) staining. At the end of the reperfu‑
sion period, the coronary artery is briefly re‑occluded and 
0.5 mg/kg Evans blue is injected intravenously to delineate 
the left ventricular area at risk [439]. The left ventricle is 
then excised and cut into five or six transverse slices. Each 
slice is then incubated in TTC at 37 °C to differentiate 
infarcted (pale) from viable (brick red) myocardial area. 
Slices are weighed and photographs of the proximal side of 
each slice are taken. Online software (e.g. Image J) allows 
measurement of surface areas of the whole slice, the risk 
region, and the necrotic area. For each slice, multiplication 
of the fraction of the slice’s surface area that is TTC negative 
by the slice weight results in the amount of infarcted tissue 
in grams. Addition of infarct sizes of each slice results in the 
total amount of infarcted tissue in grams for a given heart. 
Identification of necrotic vs. viable myocardium by TTC is 
not always easy due to failure of well‑contrasted coloration. 
Therefore, analysis must be blinded and consistent (by the 
same investigator). In case of poor staining, the heart should 
be discarded.
Imaging
CMR assessment of infarct size should be performed 
3–5 days after PPCI; for consistency, it is recommended 
to perform the examination always at the same time delay 
(e.g. 2 days) after PPCI. However, if the decision is made 
not to measure the edema‑based area at risk, another strat‑
egy would be to measure infarct size (only), for example, at 
1 month after PPCI, when most of the acute edema has dis‑
appeared. The inconvenience is that the patient must come 
back.
When eventually measured (but not recommended, as 
indicated above), T2w‑CMR imaging is based on breath‑
hold T2w‑short tau inversion recovery sequences cover‑
ing the whole left ventricle [300]. The T2w‑CMR hyper‑
intense area is quantified on the T2w‑CMR images using 
semi‑automatic detection with the full width at half‑max‑
imum approach. The myocardial edema area is quantified 
in each short‑axis slice. The extent of myocardial edema is 
expressed as the indexed mass of the myocardial edema (in 
grams of tissue) according to the following formula: [hyper‑
enhanced area (in  cm2)] × slice thickness (in cm) × myocar‑
dial specific density (1.05 g/cm3)/body surface area  (m2).
Infarct size is assessed as the area of hyper‑enhance‑
ment on the LGE–CMR images. Delayed hyper‑enhance‑
ment is evaluated 10 min after the injection of gadolinium 
(0.2 mmol/kg at 3 mL/s) with the use of a three‑dimensional 
inversion‑recovery gradient‑echo sequence. The area of 
hyper‑enhancement is expressed as the indexed mass of the 
infarcted myocardium.
Biomarkers
The release of ischemic biomarkers, mainly serum cre‑
atine kinase (CK) and troponins, has long been used for 
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confirming the diagnosis of acute myocardial infarction. The 
amount of enzymes released into the blood circulation may 
be evaluated either at a single time point (usually the esti‑
mated peak of the release kinetics) or by the area under the 
curve of several measurement points [417]. In both cases, 
the value obtained is often considered as measuring the size 
of the infarct.
For example, in several phase two studies, blood sam‑
ples were taken at admission, every 6 h after opening of 
the coronary artery during day 1, and every 6 h on days 
2 and 3. The area under the curve (arbitrary units) of CK 
release (Beckman Kit, expressed in IU/L) was measured in 
each patient by computerized planimetry (Image J 1.29x) 
and used as a surrogate marker of infarct size [401, 419]. A 
similar approach can be used for TnI, although care should 
be taken that different assay kits yield discordant values. 
On the other hand, the CK assay is robust and in particular 
correlates well with the measurement of CMR infarction. 
However, whereas the CK kinetics are clear in patients with 
TIMI flow grade 0–1 on admission with an early peak near 
6–8 h post‑PPCI and return to near baseline values in about 
72 h, the release profile may be significantly altered (e.g. no 
identifiable peak) in patients with TIMI flow > 1, in patients 
with cardiopulmonary arrest who underwent defibrillation, 
or in patients revascularized by thrombolysis. Above all, the 
interpretation of the infarct size and the effect on it by a 
therapeutic intervention must be made cautiously. One does 
not know the equivalence in grams of necrotic myocardial 
tissue of a given quantity of cardiac enzymes released into 
the blood. In other words, the CK or TnI value is not an 
infarct size. A percentage reduction in the CK/troponin peak 
or area under the curve following administration of a sup‑
posedly protective treatment should not be interpreted as 
a percentage reduction in infarct size. For example, in the 
study by Piot et al. CsA reduced peak CK release by 36% 
which corresponded to a reduction of 20% in infarct size 
as measured by LGE–CMR [340]. Hence, cardiac enzyme 
release is a robust method, the interpretation of which must 
be made with caution, in particular by assessment of the 
potential benefit of an infarct‑size reducing drug.
Practical summary: your best way to measure infarct 
size
Several reliable techniques are available to measure infarct 
size in various experimental models and in patients. Recom‑
mendations are: (1) to make sure that what is measured is 
really an infarct size, (2) to be aware of the technical limita‑
tions and difficulties of interpretation of the results, (3) to 
choose a largely available and well‑validated method with 
respect to the experimental model, (4) to use largely acces‑
sible techniques in patients.
Isolated perfused hearts
The method of retrograde mammalian heart perfusion was 
developed by Oscar Langendorff in 1895 [269]. It provides 
the ability to study the function of the heart in isolation from 
the rest of the body and nervous system, while retaining the 
advantage of studying cardiac cells in their native myocar‑
dial structure and environment. More detailed discussions 
of the rationale behind the model as described below can be 
found in reviews [35].
Species and strain
Any mammalian heart can be perfused using the Langen‑
dorff technique, and hearts from mice, rats, guinea pigs, 
rabbits, dogs, primates and even humans have been stud‑
ied [233], although their sensitivity to ischemic injury and 
responsiveness to myocardial protection varies [144]. These 
days, however, most experimentalists use rats or mice. Rat 
hearts have the advantage of being slightly larger, rendering 
the left anterior descending coronary artery (LAD) more 
accessible and hence easier to tie off, and infarct size deter‑
mination is somewhat more accurate. The main advantage of 
mouse hearts is that it allows the use of genetically modified 
strains. Animals are usually 10–12 weeks old and 200–300 g 
(rats) or 8–12 weeks and ~ 20 g (mice). Older animals may 
have additional fat around the heart which may complicate 
harvesting.
The most commonly used rat strains are Sprague–Daw‑
ley, Lewis, and Wistar, generally for reasons of practicality 
or convenience. These strains are all outbred (i.e. a closed 
population of genetically variable animals that is bred to 
maintain maximum heterozygosity), which means that 
strains bred in different places may be slightly different due 
to genetic drift. Other strains of rats can also be used—in 
fact Fischer inbred rats may be advantageous as they have 
been reported as having a less variable coronary architecture 
[282]. Resistance to myocardial ischemia differs between 
different inbred strains of rats [28].
The most commonly used mouse strain for routine experi‑
ments is C57Bl/6. These are inbred and, therefore, geneti‑
cally nearly identical. However, there are several different 
sub‑strains of C57Bl/6, notably C57Bl/6J and C57Bl/6N 
which have significant phenotypic differences including their 
response to ischemia [320]. Therefore, the precise strain and 
its origin should be reported for all studies. There is wide 
inter‑strain variability in sensitivity to ischemia/reperfusion 
[171]. Importantly, however, a reduction of infarct size by 
direct and remote ischemic preconditioning has been reli‑
ably demonstrated in all strains of mice tested [61]. Some 
transgenic or knockout strains may be on other backgrounds, 
in which case it is essential to use the same precise strain 
 Basic Research in Cardiology  (2018) 113:39 
1 3
39  Page 28 of 73
as the mutated mice for the WT controls, and preferably 
littermates [164].
Historically, most experiments have been performed 
using only male animals, as this is believed to reduce poten‑
tial variability due to hormonal influences. However, the 
importance of studying the response of both male and female 
hearts is becoming clear, as sex can clearly influence sensi‑
tivity to ischemia [47, 323].
The Langendorff apparatus
Several companies market fully functioning equipment for 
construction of a Langendorff apparatus. Alternatively, the 
necessary glassware can be acquired and assembled one‑
self. One key difference is that kits typically require a peri‑
staltic pump (in either constant pressure or constant flow 
mode—see below), whereas a self‑assembled apparatus is 
usually simpler and uses gravity to deliver the buffer at the 
required pressure. The essential components of the apparatus 
are shown in Fig. 7. The standard technique for infarction 
studies is retrograde aortic perfusion. In this configura‑
tion, the aorta is cannulated and perfused, which causes the 
aortic valves to shut and the perfusate to flow through the 
coronary arteries and then through the myocardium (Fig. 7). 
The apparatus may be designed so as to provide either a 
constant pressure or constant flow of buffer to the heart. 
Constant flow requires the use of a peristaltic pump and has 
the advantage of minimizing the total size of the apparatus 
and the total volume contained within the tubing. However, 
it is less suitable when performing regional ischemia, since 
it will cause an undesirable increase in perfusion pressure. 
When using constant flow, the perfusion pressure should 
always be measured and the flow adjusted to maintain a 
physiological pressure. Constant pressure can be delivered 
either by placing the buffer reservoir at sufficient height to 
obtain the desired pressure at the cannula, or using a peri‑
staltic pump with the capability of adjusting to the pres‑
sure measured. When using a pump, an inline “Windkes‑
sel” device (compliance chamber) is required to minimize 
oscillations in the flow. This is also useful in either case for 
eliminating air bubbles.
A cannula may be purchased or made, e.g. from a 
21‑gauge stainless steel luer‑lock needle (for mice), or 
3‑mm‑diameter metal tube (for rats). The end should be 
filed flat, and machined grooves on the tip can aid in pre‑
venting the heart from slipping off. The perfusion pressure, 
Fig. 7  Diagram of a gravita‑
tional Langendorff perfused 
heart rig with an isolated rat 
heart
funnel for filling system
with distilled water and
releasing bubbles
jacketed heated reservoir
filled to generate ~100 mmHg 
perfusion pressure
connecting tubing (minimal
length to prevent loss of heat)
jacketed heated cylinders
intraventricular balloon (IVB) inserted into the 
left ventricle via the left atrium, connected to a
pressure transducer
ECG electrode inserted into the
apex of the left ventricular wall,
connected to a Powerlab module
jacketed heated cannula
(delivering Krebs at 37 °C
metal cannula
isolated rat heart
cannulated via the aorta
metal cannula
ECG
electrode 
IVB in
the LV
heater circulator
inlet
outlet
isolated rat 
heart
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measured at the cannula, should be 70–80 mmHg for rats 
and mice. In a gravity‑fed apparatus this may require adjust‑
ment of the height of the buffer reservoir.
It is of vital importance to maintain the cleanliness of the 
apparatus as even minor contamination can drastically affect 
results. The apparatus should be flushed through with several 
liters of boiling water (e.g.: from a kettle) before and after 
every use. If it has not been used for more than 2–3 weeks, 
or if cardiac function is unexpectedly poor, the apparatus 
can be filled with 0.1 mol/L HCl, commercially available 
detergent or Decon 90, and left to decontaminate for several 
hours before rinsing thoroughly with distilled, de‑ionized 
water. Note that detergent is advised in place of acid in the 
case of some commercial apparatus to protect the plastic 
from crazing. Worn or damaged tubing, particularly in the 
peristaltic pump, should be replaced.
Harvesting and cannulation of the heart
Prepare a weight‑boat by filling with ice‑cold buffer. If 
necessary, add some crushed ice to keep it cold. The heart 
must be removed while still beating, and the animal must be 
deeply anaesthetized or dead when doing so. The animal can 
be anaesthetized using any standard technique in accordance 
with regulations, but deep anesthesia (loss of pedal reflex) 
must be verified before beginning surgery. The use of subcu‑
taneous unfractionated heparin before harvesting the heart is 
advised. The chest is opened, and the heart is removed with 
scissors. The aorta should be cut leaving as long a stump on 
the heart as possible and cannulated as soon as possible to 
avoid prolonged ischemia. The cannula should be verified as 
being positioned such that the end is visible 1–2 mm above 
the aorta’s entry to the heart, and is, therefore, not inserted 
past the aortic valve.
To cannulate a mouse heart, a dissection microscope or 
jeweler’s lens is needed. The cannula can be removed from 
the apparatus. Use a syringe to prefill the cannula with buffer 
(excluding air bubbles) and place it in a Petri dish containing 
buffer and a small amount of ice. The cleaned heart can be 
held with fine forceps by the aortic root, slid over the end of 
the cannula and secured in place using a suture.
The entire process from cutting the aorta to starting per‑
fusion must be < 3 min. It is absolutely essential to avoid 
any bubbles entering the aorta either during mounting or 
subsequent perfusion as this will cause air embolism and 
infarction. Once mounted and perfused, any remaining non‑
cardiac tissue can be removed with scissors.
Perfusate buffer
Krebs–Henseleit buffer (KHB) is considered the most appro‑
priate buffer for Langendorff perfusion and infarct stud‑
ies. The standard recipe is: NaCl 118.5 mmol/L,  NaHCO3 
25.0  mmol/L, KCl 4.7  mmol/L,  MgSO4 1.2  mmol/L, 
 KH2PO4,1.2  mmol/L, glucose 11  mmol/L and  CaCl2 
1.2 mmol/L. High quality, ultrapure water (Milli‑Q) should 
be used. It is recommended to filter the perfusate (< 0.45 µm) 
as precipitates can otherwise degrade cardiac function [187]. 
There is some variation in the precise concentration of  CaCl2 
used. A higher concentration was used in the original recipe 
based on the concentration in blood, but was later adjusted 
downwards to account for the fact that much of this is bound 
to albumin [409]. Note that the 11 mmol/L glucose is well 
above the normal plasma level in rats (5–6 mmol/L) with 
the aim being to maintain sufficient glucose entry in the 
absence of insulin [413]. It is also important to be aware that 
although the heart demonstrates high metabolic flexibility, 
in situ it typically metabolizes more fatty acids and lactate 
than glucose [412]. It is possible to add fatty acids to the 
perfusate but they must be conjugated to albumin, which 
can cause substantial practical difficulties due to frothing and 
bubbles, unless care is taken using a non‑bubbling aerator to 
gas solutions. The addition of pyruvate is not generally rec‑
ommended as it has been shown to be cardioprotective [139, 
366]. When using pyruvate 2.0 mmol/L, glucose is reduced 
to 5.6 mmol/L [388]. A further limitation of KHB is its low 
oncotic pressure due to the absence of proteins, which is 
partly responsible for causing edema in the myocardium. It 
is possible to use blood to perfuse the heart but this requires 
a donor animal and anticoagulation, and is usually out‑
weighed by the technical complications and disadvantages 
[35]. Rather, it would usually be preferable to progress to 
the in vivo model if a more physiological system is required.
The buffers are pre‑gassed with 95%  O2/5%  CO2 (“Carbo‑
gen”) by gentle bubbling through sintered glass, and gassing 
of the reservoirs is maintained throughout the protocol. The 
pH of this bicarbonate‑based buffer should be 7.4 when bub‑
bled with 5%  CO2 at 37 °C (without requiring adjustment), 
and should be verified as such.
Instrumentation
The heart must be instrumented to monitor perfusion condi‑
tions and heart function.
The contractile function of rat hearts is routinely meas‑
ured so as to verify that the heart is functioning sufficiently 
well at the beginning of the experiment, as well as to moni‑
tor its condition during and after ischemia. Although many 
cardioprotective agents will result in an improved recovery 
of contractile function during reperfusion, this may be due 
to attenuated stunning and/or reduced infarction and, there‑
fore, an additional, more direct measurement of infarction is 
required to confirm cardioprotection (see below). It is impor‑
tant to note that even under the most optimal conditions of 
Langendorff perfusion, left ventricular function will dete‑
riorate naturally during the course of the experiment due to 
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edema and gradual tissue damage. A 5–10% loss of contrac‑
tile and chronotropic function per hour is to be expected [35].
In Langendorff’s original studies, left ventricular contrac‑
tile function was measured by passing a tie through the apex 
and connecting it to an isometric force transducer. A more 
accurate measurement can be obtained by cutting off the 
left atrial appendage and passing a small, water‑filled bal‑
loon through the mitral valve into the left ventricle [187]. 
The left ventricular contractions are isovolumic, but oxy‑
gen consumption is determined primarily by developed 
pressure with little contribution from muscle shortening. 
Therefore, function more closely resembles left ventricular 
work in vivo. The balloon pressure can also be increased 
step‑wise to obtain Frank–Starling curves. However, the use 
of a balloon is particularly challenging with small hearts, 
and the quality of the data thereby obtained from mouse 
hearts may not be very reliable. Formation of the balloon is 
somewhat of an art. It needs to be made of a material that 
is highly compliant and thin, (e.g.: Saran wrap, cling film, 
or condom latex is ideal), so as to provide rapid feedback of 
pressure changes without any dampening. It should be filled 
with water, mounted on a length of non‑compliant tubing (a 
21‑gauge flat needle can be used for mouse hearts) and tied 
off with a suture. The volume of the balloon is crucial—its 
unstressed volume must be greater than that of the ventricle 
so that the balloon fills the left ventricular cavity without 
stretching the balloon’s wall which would give an artificially 
high pressure reading. The balloon is inflated to give an end‑
diastolic pressure of 5–15 mmHg at baseline. The tubing, 
filled with water, is connected to a calibrated pressure trans‑
ducer. This is attached to a recorder. There must be no leaks 
or air present within the circuit.
The left ventricular balloon can be used to measure a vari‑
ety of contractile function data, including heart rate, systolic 
pressure, end‑diastolic pressure, and maxima and minima of 
left ventricular pressure derivative. Left ventricular devel‑
oped pressure is calculated as the difference between maxi‑
mal systolic and end‑diastolic pressures.
Rate‑pressure product is sometimes used as an index of 
cardiac work and correlates with myocardial oxygen con‑
sumption (MV ̇O2) in larger animals. However, since iso‑
lated rodent hearts demonstrate a negative force–frequency 
relationship (left ventricular developed pressure decrease 
with increasing heart rate) [409], rate‑pressure product is 
not correlated with oxygen consumption in the Langendorff‑
perfused isolated rat heart [10].
Coronary perfusion
Perfusion can be performed either at constant pressure or 
at constant coronary flow rate. In either case, coronary flow 
and perfusion pressure are continuously monitored to assess 
the conditions of the preparation and coronary vascular 
resistance. Excess perfusion pressure may damage the aor‑
tic valve and increase the rate of edema formation during 
ischemia/reperfusion protocols. Since coronary vascular 
resistance is equal to perfusion pressure divided by coronary 
flow, it may seem that there is theoretically no difference 
between performing experiments at constant perfusion pres‑
sure or at constant coronary flow. However, from a physi‑
ological point of view some differences exist between the 
two perfusion modalities. In models of regional ischemia, 
constant pressure may be preferable; since a constant flow 
system delivers more coronary buffer per unit of myocardial 
mass in the territory of non‑occluded arteries, which can lead 
to a damaging shear stress. This issue is less important in the 
case of a global ischemia model although care must still be 
taken to avoid an aortic pressure of greater than 80 mmHg 
which may damage the leaflets of the aortic valve. A constant 
flow model allows for the presence of an ischemia/reperfu‑
sion injury independent of changes in global myocardial per‑
fusion and oxygen consumption due to a Gregg effect (see 
also below regional and global ischemia) [334].
The coronary flow rate with perfusion of a crystalloid 
buffer should be around 10 mL/min/g of tissue. In a rat heart, 
therefore, it should be about 10–20 mL/min for the whole 
heart. With these flows, the expected perfusion pressure is 
in the range of 60–80 mmHg. If there is no correspondence 
between perfusion pressure and coronary flow, problems 
with the preparation exist and the heart should be discarded 
if the problem cannot be solved in a couple of minutes. 
For mouse hearts and for rabbit hearts, the coronary flow 
is about 2–3 mL/min and 35–40 mL/min, respectively, and 
pressure is between 60 and 80 mmHg.
Constant perfusion pressure model
In the constant perfusion pressure model, the perfusion pres‑
sure is usually set between 60 and 70 mmHg (815–950 mm 
 H2O), although up to 80 mmHg can also be used (1090 mm 
 H2O). The perfusion pressure must be maintained through‑
out the experiment. This is simply set using gravity by posi‑
tioning a reservoir and its fluid meniscus at a set distance 
above the tip of the perfusion cannula (1 mm Hg = 13.6 mm 
 H2O). Constant perfusion pressure can also be achieved via 
a peristaltic roller pump connected with a sealed pressur‑
ized chamber. In this modality, pressure can be monitored 
with a manometer and used to control perfusion pressure in 
a servo‑controlled fashion [409]. Servo‑controlled systems 
can be bought and offer the advantage of using either con‑
stant perfusion pressure or constant coronary flow, switching 
from one to another modality easily.
Retrograde flow in the aorta closes the aortic valve, thus 
preventing the crystalloid fluid from entering the left ven‑
tricle chamber. If the cannula erroneously passes the valve, 
the heart will not be well perfused and will perform poorly.
Basic Research in Cardiology  (2018) 113:39  
1 3
Page 31 of 73  39 
In a constant pressure model, coronary flow can be meas‑
ured by a flowmeter placed within the perfusion line. Also, 
sequential collection of the heart’s effluent can be used to 
measure coronary flow, and, if required, the buffer can be 
recirculated to the reservoir via a micro‑filter. However, this 
procedure can lead to inaccuracy and a flowmeter placed 
within the perfusion line is preferable; moreover, the non‑
recirculating procedure is preferable.
A constant pressure model is preferable when auto‑reg‑
ulation of coronary tone is of interest. However, a gravity‑
driven apparatus requires a large dead space, which may 
be a problem when expensive agents/drugs are to be used. 
Moreover, in a constant pressure model, changes in coronary 
resistance will alter the volume of fluid and the amount of 
drug delivered to the heart. Therefore, for testing drugs it is 
better to use a constant flow model.
Constant coronary flow model
Constant coronary flow can be achieved with a roller pump 
connected to a small compliance chamber. This model offers 
different advantages: (1) constant coronary flow may limit 
the Gregg effect (myocardial oxygen consumption increases 
when coronary perfusion increases); (2) it is easier to moni‑
tor coronary perfusion pressure with a manometer than to 
measure changes in coronary flow with a flowmeter; (3) 
the constant flow model facilitates rapid evaluation of the 
vasoactive properties of drugs by measuring the changes in 
perfusion pressure; (4) constant flow simplifies the infusion 
of drugs in a small volume of fluid, even if the drugs induce 
changes in coronary resistance.
Working heart model
There are some important limitations to the Langendorff 
model of isolated heart perfusion. Most notably, the heart 
performs less work than in vivo, due to the absence of after‑
load in the retrograde configuration. Under standard con‑
ditions, the saline‑perfused Langendorff heart preparation 
is energy deprived and relies on its stores of glycogen to 
obtain ~ 1/3 of the glucose needed for oxidative phospho‑
rylation [352], resulting in a lower level of high‑energy 
phosphates (phosphocreatine and ATP) in glucose‑perfused 
Langendorff than in vivo hearts. This situation is slightly 
improved by the provision of 11 rather than 5 mmol/L glu‑
cose and can be further improved by the addition of insulin 
to drive glucose uptake and metabolism [352]. However, of 
note, insulin itself is cardioprotective [229].
The hemodynamic limitations of the standard Lan‑
gendorff model can be overcome by reverting the flow of 
the buffer through the heart to the antegrade direction, so 
that the left ventricle is filled via the left atrium and ejec‑
tion occurs in the normal direction into the aorta (Fig. 8). 
Consequently, the heart performs physiological mechani‑
cal work against a resistance (afterload). In this “working 
heart” model, as first developed by Neely et al. in 1967 
[105, 316, 409], atrial filling pressure is increased and the 
left ventricle pumps against a hydrostatic pressure head. 
This model also allows the coronary sinus effluent to be 
sampled.
Additional equipment is required for the “working mode” 
configuration but it is commonly used to assess ventricular 
performance with full control of preload and afterload, oxy‑
gen tension and heart rate. It also allows metabolic measure‑
ments to be made under more physiological conditions. It 
has been used for the investigation of myocardial responses 
to ischemia and reperfusion, particularly in relation to the 
recovery of ventricular contractile function [240, 307], but 
it can also be used to evaluate cardioprotection in terms of 
infarct size reduction [283]. The performance of the working 
rat heart is stable for up to 3 h [316], but after 1 h cardiac 
function may decrease [130], and time‑matched controls are 
mandatory.
The following method describes the establishment of a 
working heart model using rat hearts, but protocols have 
also been developed for mouse [97, 169, 271], rabbit [23] 
and pig hearts [76].
The apparatus for the working heart model is similar to 
the standard Langendorff apparatus but with the addition of 
a second cannula that is attached to the left atrium (Fig. 8). 
This line must be capable of delivering at least 150 mL/
min for a 1 g heart to ensure that the flow rate supports the 
maximum cardiac output of a working heart at any particular 
preload.
aortic cannula atrial cannula
Langendorff configuration working heart configuration
aortic cannula
LV
Fig. 8  In the Langendorff configuration, buffer from the aortic can‑
nula is prevented by the aortic valve from entering the heart, and 
passes instead through the coronary arteries (not shown), which origi‑
nate from the base of the aorta. In the working heart configuration, 
buffer enters the left atrium via the atrial cannula, passes through the 
mitral valve to the left ventricle (LV), then is ejected during systole 
through the aortic valve into the aortic cannula
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Initially, the heart is removed and the stump of the aorta 
cannulated for retrograde perfusion in precisely the same 
manner as described for the Langendorff perfusion method. 
The heart is then retrogradely perfused for at least 10 min to 
remove all blood and stabilize the heart. Differently from the 
Langendorff procedure, the pulmonary arteries and veins are 
then ligated, the left atrium incised and cannulated using a 
separate venous cannula, the left heart loaded and retrograde 
perfusion stopped, creating the working heart model.
The Langendorff‑perfused heart is positioned to provide 
access to the posterior of the heart. The right pulmonary 
artery and veins are occluded using either a surgical clip or 
suture, followed by occlusion of the left pulmonary artery 
and pulmonary veins. The pulmonary vessels must be com‑
pletely occluded to ensure adequate preload. The right ven‑
tricle will then increase its pressure, the right atrium will 
distend, and the heart may become bradycardic. If this does 
not occur, a further tie or clip may be necessary to eliminate 
potential leakage. However, as soon as it is established that 
there are no leaks, the pulmonary artery should be cut to 
depressurize the coronary veins. Viewing the heart from the 
anterior side, a transverse incision in the pulmonary artery 
approximately 3 mm above the pulmonary valve is made 
with a small scissor, relieving the pressure in the right heart.
Next, the left atrium is cannulated. The upper body of the 
left atrium is incised a few mm above the atrioventricular 
groove. Flow of buffer is started so that it drips through the 
left atrial cannula. The cannula is carefully inserted into the 
left atrium, such that there is no pressure on the atrial wall. 
A suture is then tied around the tissue of the left atrium to 
provide a tight seal around the cannula. The atrial cannula is 
positioned to ensure that there is free flow, then fully opened 
to impose preload on the left atrium.
The drips from the heart now come solely from coro‑
nary effluent, and its rate should not change, unless there 
are leaks. Optionally, the coronary sinus effluent can be col‑
lected by inserting a piece of 0.8 mm flexible tubing into the 
incision made previously in the pulmonary artery.
Transition to working heart mode is made by turning off 
the retrograde aortic pump. Preload (left ventricular end‑dias‑
tolic volume) is now being delivered from the left atrial can‑
nula. It can be adjusted by changing the pressure of the fluid 
entering the left atrium. Afterload is delivered via the aortic 
cannula. A pressure–volume catheter may be inserted into the 
left ventricle either via the aortic valve or via apical puncture. 
As with the standard Langendorff configuration, the heart may 
be electrically paced with wires sutured to the right atrial wall.
Filling pressures for rat hearts are usually in the range of 
7–15 mmHg and afterloads in the range 45–75 mmHg. Under 
these conditions, the coronary flow from the heart from a 
250 g rat is up to 25 mL/min and aortic flow is 50–80 mL/
min. The end‑diastolic pressure is set to about 3–5 mmHg, 
and the peak systolic pressure will be ~ 100 mmHg.
Because of the large volumes of perfusion fluid pumped 
by the heart, the working preparation is often operated in 
the recirculating mode, in which case an in‑line 5‑µm filter 
must be included in the circuit to remove any particulate 
contaminants which may originate from the hearts.
Temperature monitoring and control
In an isolated heart preparation, it is crucial to continually 
monitor and regulate the temperature of the heart. This is 
particularly important in infarction experiments, since infarct 
size is proportional to the temperature of the heart during 
the ischemic period [305]. To help maintain the appropriate 
temperature, a water‑jacketed reservoir and heat exchang‑
ers along the perfusion line are used. A temperature sensor 
(micro‑thermistor) can be placed on the heart surface or into 
the right ventricle. Good temperature control can be achieved 
using a thermocouple. Usually, the selected temperature is 
the same as the core temperature of the animal species stud‑
ied (temperature (e.g.: 37.0–37.5 °C. for rat hearts). If tem‑
perature tends to decrease as it passes through the tubing to 
the heart, it is tempting to set a slightly higher temperature 
for the fluid in the reservoir. However, setting a temperature 
in the water jacket of the reservoir at more than 0.5–1.0 °C 
above the required temperature should be avoided to pre‑
vent significant overheating in case of an increase in flow. 
The hearts tolerate a decrease in temperature better than an 
increase in temperature. A small incision can be made in the 
right ventricular outflow tract or in the pulmonary artery to 
retrogradely pass a thin thermocouple into the right ventricle, 
which is connected to a thermometer. A digital and servo‑
controlled system can be used to fine‑tune the temperature 
of the fluid in the heated chambers. Although less precise, 
the temperature can be manually adjusted during the stabi‑
lization period by modifying the sources of exogenous heat, 
e.g.: by immersion in a temperature‑controlled organ bath 
or exposure to a radiant external heat source such as a lamp.
Since the extent of ischemia/reperfusion injury is highly 
temperature dependent, in such studies temperature moni‑
toring is particularly important and particularly challeng‑
ing. Usually, with ischemia the heart temperature will drop. 
Furthermore, reperfusion exposes the heart to rapid vari‑
ations in temperature. The thin thermocouple placed into 
the right ventricle during all phases of perfusion provides 
information about temperature variations during the experi‑
ment and can help to avoid these potential variations during 
the ischemia/reperfusion protocol. Immersion of the heart in 
buffer warmed to the preferred temperature is the best way 
to control heart temperature during ischemia/reperfusion. 
A heart suspended in room air is not a good solution for 
ischemia studies. Indeed, in this condition heart temperature 
decreases during ischemia and ischemic injury is affected in 
an uncontrolled manner.
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Electrocardiogram (ECG)
The ECG provides a convenient and simple measurement for 
routine assessment of electrical heart function. ST segment 
elevation provides a simple confirmation of ischemia. One 
lead of the ECG can be clipped to the (metal) cannula, and 
the other inserted into the apex of the left ventricle.
Pacing
The extracorporeal heart is bradycardic due to the absence of 
neuro‑hormonal regulation, and because the sinoatrial node 
is not supplied by the coronary vasculature, but from extra‑
cardiac vessels [35, 409]. The isolated perfused mouse heart 
contracts at 380–420 vs. 580–600 beats/min in vivo, and a 
rat heart at 250–320 beats/min compared to 350–400 beats/
min in vivo. Some investigators prefer to add pacing wires 
to maintain heart rate and equalize it between hearts, as 
heart rate can influence cardiac function [409] and influence 
recovery from ischemia [187]. Pacing may not greatly affect 
infarct size in hearts from healthy animals, but can be benefi‑
cial for diabetic or aged hearts with reduced or variable heart 
rates. Pacing can be achieved relatively simply using the 
cannula as one electrode, and a silver wire or stainless steel 
needle as the other, inserted into the epicardium of the right 
atrium. Mouse heart pacing can be set at 500–600 beats/
min, using a square form wave of 4‑ms duration and voltage 
amplitude of 1.5 × the minimum threshold for stimulating 
contraction. Rat heart pacing should be set to 300–400 beats/
min. Pacing should be paused during ischemia and restarted 
several minutes after reperfusion has commenced.
Ischemia/reperfusion
The experimental protocol of ischemia/reperfusion studies 
consists of three fundamental phases: an initial stabilization 
period, a relatively long period of test/index ischemia and 
the phase of reperfusion during which the effect of ischemia 
and/or the effect of protective stimuli are assessed. Cardio‑
protective interventions can be performed before, during 
or after ischemia in the isolated heart model. When using 
global ischemia, cardioprotective interventions can only be 
performed prior to ischemia or at the onset of reperfusion.
Stabilization
After the cannulation and the beginning of the buffer per‑
fusion, regular heart function is restored within a few sec‑
onds. However, more than 10–15 min may elapse before the 
heart function is stabilized. Therefore, after instrumentation, 
the experimental protocol should be preceded by at least 
20–30 min of stabilisation to be sure that only very little, if 
any, changes in cardiac function (heart rate, coronary flow, 
perfusion pressure and left ventricular pressure) are present 
during this period. 40‑min stabilization is recommended if 
western blot analyses of kinase phosphorylation are included 
in the study [403].
Ischemia
Short periods of ischemia, which may induce only myo‑
cardial stunning (a reversible attenuation of myocardial 
contractile function) under in vivo conditions may already 
result in myocardial necrosis in Langendorff hearts [96, 
335]. Therefore, caution should be used with this model 
in studying myocardial stunning. In cardioprotection stud‑
ies, 25–35 min of zero‑flow normothermic (37.0–37.5 °C) 
ischemia is considered optimal for rodents, which results 
in approximately 50% infarction of the risk area. This 
infarct size leaves room for an appreciable reduction in 
its extension following a cardioprotective protocol. In 
experiments designed to investigate protection using two 
different drugs or protective modalities, in which > 50% 
infarct size reduction is anticipated, it may be necessary 
to use a longer period of ischemia to reveal such additive 
protection. However, this must be carefully tested, as too 
long an ischemic period may prevent proper reflow and 
reperfusion.
The isolated heart preparation can be used for studying 
global or regional ischemia at either zero or reduced inflow 
rates. Indeed, the whole heart (global ischemia) or just a 
part of the myocardium (regional ischemia) can be subjected 
to flow reduction in the Langendorff preparation. In both 
cases, ischemia can be achieved at various levels of flow. 
However, global ischemia allows easier and more precise 
approaches and more possibilities of different degrees of 
ischemia (through controlling flow). Regional ischemia 
in the isolated mouse heart should be avoided because the 
risk zone becomes so small that the ambiguity in discern‑
ing the infarct borders due to a blurry image becomes very 
significant.
Global ischemia Global zero‑flow ischemia is easily 
induced in the isolated heart model by stopping the perfu‑
sion pump, in the case of constant flow model, or occluding 
the perfusion inflow lines, in the case of constant pressure.
In the constant flow model, restriction of flow can be 
precisely obtained by adjusting the output of the perfusion 
pump. In the constant pressure model, a partial and gradual 
occlusion of the perfusion line can also be applied using, 
for example, a micromanipulator and a Starling resistance to 
create a stenosis along the perfusion line. However, there is 
an advantage to using a pump‑controlled system, which with 
the precise calibration of the pump speed avoids the uncon‑
trolled variation of coronary resistance and coronary flow, 
which, in turn, may influence the level of damage induced 
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by flow restriction in a biased manner in constant pressure 
models.
Regional ischemia Regional ischemia can be induced in 
isolated heart preparations by occluding a coronary artery 
(usually the LAD), and the size of the ischemic zone (risk 
area) can be influenced by the different position of the liga‑
tion point. The ligation is obtained by placing a snare around 
the artery. A snare can be made using a small‑diameter 
polyethylene tube size 50 for a rat heart passing through a 
large‑diameter tube. Regional ischemia can also be induced 
by ligating the artery with a silk thread. To prevent lacera‑
tion of the vessel wall and to facilitate the reperfusion, the 
ligature is usually tied to include a small plastic tube placed 
along the artery.
Since coronary vessels are more easily seen in the pres‑
ence of blood, the snare can be placed around the artery 
(without tightening) while the heart is still in situ. However, 
this procedure introduces additional complications requiring 
anesthesia, intubation, mechanical ventilation and the surgi‑
cal opening of the chest.
As a guide for effective tightening of the suture upon 
induction of regional ischemia, one should expect an instan‑
taneous reduction in coronary flow of at least 30% (of base‑
line coronary flow) in hearts with a large ischemic zone 
(placement of the suture proximal to the tip of the atrial 
appendage), and a reduction in heart rate and left ventricular 
developed pressure, along with an increase in left ventricular 
end‑diastolic pressure. If these changes are not seen, it would 
suggest that the suture has not been tightened effectively to 
induce regional ischemia (zero flow to the ischemic zone), 
resulting in a smaller infarct. Similarly, if there is no increase 
in coronary flow or lactate release upon reperfusion, this too 
is indicative of poor occlusion [443].
In general, it is recommended: (1) to use the heart of rats, 
a species with minimal collateralization and minimal vari‑
ation among individuals; and (2) to ligate the LAD proxi‑
mally, so that if ischemia is accurately induced, the risk zone 
is about 45–50% of the left ventricle mass and coronary 
flow and left ventricular developed pressure should decrease 
by about 30% [35]. This standardized procedure will allow 
consistent application of the same degree of ischemia in 
various experiments. Validation of occlusion can also be 
ascertained by transient infusion of a colored dye or fluo‑
rescent particles.
The coronary circulation of some species, such as guinea 
pigs and hamsters are totally collateralized, thus preventing 
the study of regional ischemia. In rats and mice (the species 
most commonly used in ischemia/reperfusion studies), the 
scarcity of collateral vessels between the various coronary 
vascular beds is not a significant problem for the study of 
regional ischemia. Nevertheless, to completely avoid the 
problem of collateralization, global ischemia can be used. 
The Langendorff preparation is unique in this sense: it is the 
only model that allows global ischemia.
The isolated heart preparation is also suitable for studying 
hypoxia and reoxygenation, again either global or regional. 
Nevertheless, also in this case, global hypoxia is less com‑
plicated for studying the desired level of hypoxygenation by 
changing the oxygenation of the buffer used. A dual‑lumen 
perfusion catheter can be used to perfuse the left and right 
coronary arteries separately. This catheter is a powerful tool 
for studying the regional effects of hypoxia or ischemia [24].
Reperfusion
In the global ischemia model, reperfusion can easily be 
achieved by opening a tap in the constant pressure model, or 
by restarting the roller pump when using constant flow. In the 
regional ischemia model, which is usually performed with con‑
stant pressure, reperfusion is obtained by loosening/removing 
the snare—an increase in coronary flow should occur.
Occasionally, ventricular fibrillation may occur when the 
heart is reperfused. If this does not resolve spontaneously, the 
heart can be gently flicked or squirted with some cold buffer. 
If this does not work, a small amount of cold KHB buffer can 
be injected into the side port of the apparatus. If all else fails 
KCl 0.1% can be injected into the side port. If the heart still 
does not recover the experiment must be abandoned.
Either reperfusion or reoxygenation can be performed at 
various rates and with different modalities (e.g. ischemic 
postconditioning obtained with intermittent reperfusion) for 
assessing several features of ischemia/reperfusion damage. 
Also, reperfusate compositions can be varied, thus providing 
a powerful tool to study cardioprotective agents of interest.
Duration: to assess infarct size, the duration of reperfu‑
sion is dependent upon the animal species used. For the rat 
heart, 60–120 min of reperfusion is mandatory. Frequent 
analysis of biomarkers reveals two distinct phases of rep‑
erfusion injury [342]. With the mouse heart, there is no 
detectable difference in infarct size following 30 or 60 min 
reperfusion [136, 325, 376, 408].
Nevertheless, at least in the mouse heart, infarct size 
measured by TTC staining depends on both the duration 
of ischemia and the length of the reperfusion period [353].
Exclusion criteria
Exclusion criteria (Table 3) must be pre‑defined and adhered 
to without exception, as they indicate problems had occurred 
with cannulation or perfusion, and inclusion of the data from 
these hearts may lead to erroneous results.
For mouse and rat hearts, recommended exclusion criteria 
are: (1) a time between cessation of blood circulation and 
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the start of perfusion in the Langendorff mode of greater 
than 3 min; (2) a temperature outside the 37 ± 0.5 °C range; 
or (3) a perfusate flow rate of < 1 or > 6.5 mL/min during a 
stabilization period of at least 20 min.
For rat hearts, recommended exclusion criteria are dis‑
played in Table 3. The ischemic risk area in regional ischemia 
experiments should be within a range of 40–70% of the heart 
mass. If not, the heart should be excluded from analysis.
Measurement of injury by contractile function
Contractile function (left ventricular developed pressure) 
decreases during ischemia and recovers slowly during reper‑
fusion. The recovery of function corresponds generally with 
the degree of tissue infarction [187], but it is important to 
note that some interventions may reduce infarct size without 
having a beneficial effect on the recovery of cardiac func‑
tion [157], particularly when there is a degree of myocardial 
stunning [256].
Measurement of infarct size by TTC staining
At the end of reperfusion of rat hearts, the balloon should be 
deflated and removed from the heart. In a heart subjected to 
regional ischemia, the suture should be re‑tightened around 
the coronary artery and Evans blue dye injected via the side‑
port. In all cases, the heart is then removed from the appara‑
tus, weighed and placed at − 20 °C for at least 2 h until frozen 
through. Make up 0.05–0.075 g TTC per 5 mL phosphate 
buffered saline and warm to 37 °C in a tube in a water bath. 
Slice the frozen heart into five equi‑width slices from the 
point of the suture to the apex of the ventricle. Place the sliced 
tissue into the tube with the TTC solution for 5–15 min in the 
water bath. Scan immediately, or alternatively drain and place 
the slices into 10% formalin (5 mL/heart) for 24 h—overnight 
at room temperature. Arrange the slices between two glass 
plates, taking care to ensure all the slices are orientated the 
same way. Images of the slices are then digitally imaged, and 
planimetry software (i.e. Image J and/or Scion Image pro‑
grams) used to calculate volume of infarct (which appears 
white), total heart volume, and, if regional ischemia was per‑
formed, risk zone volume (blue). The area at risk and infarct 
size are automatically transformed into volumes. The infarct 
size is calculated as infarct volume/left ventricular volume, or 
for regional ischemia: infarct volume/risk zone volume and 
expressed as percent of the area at risk.
For mouse hearts, it is easier to inject 5 mL of TTC in 
phosphate buffered saline through the aortic cannula and 
incubate the whole heart for 10 min at 37 °C. The heart is 
then weighed and then frozen overnight at − 20 °C. It is then 
sectioned perpendicular to the long axis, the slices trans‑
ferred into 10% neutral formalin buffer for 1 h, then infarct 
measured as above.
For rabbits, the normally perfused area of the myocar‑
dium is determined by injection of either Evans blue dye 
(5 mL, 2.5% in normal saline) or Zn–Cd fluorescent particles 
(0.8 mg/mL in normal saline), which are infused through the 
aortic cannula. After 1–2 min hearts are frozen for 24 h at 
− 4 °C and then sliced in 1–2‑mm sections. Sections are then 
incubated in TTC solution (1% TTC in phosphate buffered 
saline, pH = 7.4) for 25 min at 37 °C. Subsequently slices are 
fixed in 4% neutral buffered formalin at 25 °C for at least 1 h. 
After fixation, slices are pressed between two transparent 
glass surfaces and scanned/digitized using as above, and area 
Table 3  Summary of exclusion criteria for Langendorff perfused hearts
Parameter Mouse heart Rat heart (250–400 g bw)
Baseline (prior to any intervention, e.g. IPC)
 Time to perfusion > 3 min > 3 min
 Coronary flow < 2 or > 5.5 ml/min < 10 or > 28 ml/min
 Arrhythmias > 10 ectopics during 10 min baseline record‑
ings (VT or VF should not occur)
> 10 ectopics during 10 min baseline recordings 
(VT or VF should not occur)
 Heart rate < 300 bpm < 200 or > 400 bpm
 Left ventricular end‑diastolic pressure < 5 or > 10 mmHg < 5 or > 10 mmHg
 Left ventricular developed pressure < 60 or > 140 mmHg < 70 or > 140 mmHg
 Temperature 37 ± 0.5 °C (< 36 °C or > 38 °C for > 1 min) 37 ± 0.5 °C (< 36 °C or > 38 °C for > 1 min)
Reperfusion
 Coronary flow ≤ ischemic flow ≤ ischemic flow
 Arrhythmia duration (ventricular tachycar‑
dia or fibrillation)
> 2 min (intervene immediately—flicking, cold 
buffer or KCl)
> 2 min (intervene immediately—flicking, cold 
buffer or KCl)
 Heart rate < 150 bpm (irrelevant if pacing)
Infarct criteria
 Area at risk n/a for global ischemia n/a for global ischemia; for regional 
ischemia: < 40 or > 70% of ventricular tissue
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at risk, infarct size and total area of the slice are quantified 
in each slice and averaged for each heart.
Measurement of infarct size by necrotic marker 
proteins in perfusate
Similar to isolated cardiomyocytes, LDH is commonly 
used. For this analysis, coronary effluent samples are col‑
lected at 5, 10, and 15 min from the start of reperfusion, 
then every 15 min throughout reperfusion, noting the flow 
rate each time a LDH sample was collected. The samples 
can be stored on ice. LDH activity in the perfusate can then 
be determined by means of a commercially available assay 
kit (e.g.: CytoTox 96 Non‑Radioactive Cytotoxicity Assay; 
Promega, United Kingdom), correcting for coronary flow 
and heart weight as: LDH concentration (pg/mL) × coronary 
flow (mL/min/g). Thus, the final units are pg/min/g.
Harvesting of left ventricular tissue for western blot 
analysis
Myocardial samples and perfusate can be collected at vari‑
ous time points throughout reperfusion according to the 
desired parameters to evaluate. For instance, to evaluate 
phosphorylation of cardioprotective kinases it is recom‑
mended to collect myocardial samples between the 7th 
and 10th min of reperfusion when they are most strongly 
activated [426]. Moreover, care should be taken to analyze 
transmural samples [95].
Hybrid studies using a cross‑species approach
Mediators of cardioprotection by local and remote ischemic 
conditioning are transferable from one individual to another 
[161] and even between species [211, 225, 304, 381, 385]. A 
strategy using components, such as plasma or microvesicles 
from experimental animals, healthy volunteers or patients at 
different time points before and after a remote ischemic con‑
ditioning maneuver and testing their cardioprotective effects 
in a Langendorff‑perfused mouse, rat or rabbit heart used 
as bioassay, represents a proof‑of‑concept way to translate 
the understanding of remote ischemic conditioning’s signal 
transduction to the clinical setting.
Transfer of circulating cardioprotective mediators 
from humans to rabbit hearts
Circulating cardioprotective mediators from healthy volun‑
teers or patients undergoing remote ischemic conditioning 
(four cycles of 5 min of upper arm ischemia achieved by 
inflation of a blood pressure cuff to 25 mmHg above systolic 
blood pressure followed by 5 min reperfusion) can be studied 
by transferring dialysate of blood samples obtained before 
and after the intervention to an isolated animal heart in the 
Langendorff model. Blood samples (150 mL) are collected 
before remote ischemic conditioning and 5 min after the last 
cycle of remote ischemic conditioning. Transfer from pigs 
with remote ischemic conditioning is also successfully per‑
formed to isolated mouse and rat hearts, but the preparation 
of the transferred material is different. For rat hearts, pig 
plasma is filtered (5‑µm pore size, Macherey–Nagel, Düren, 
Germany) and added with a syringe pump to the perfusate 
in a 1:6—10 dilutions before passing the heat exchanger. 
For mouse hearts, pig plasma is placed in 12–14 kDa dialy‑
sis tubing (SpectraPor, Spectrum Europe B.V., Breda, NL) 
and dialyzed at 4 °C against a fivefold volume of modified 
KHB, resulting in a 1:6 dilution of the dialyzed plasma frac‑
tion. The plasma dialysate must be titrated to 2.0 mmol/L 
 CaCl2 and 24.9 mmol/L  NaHCO3, filtered (5‑µm pore size, 
Chromafil Xtra PES‑500/25, Macherey–Nagel, Düren, Ger‑
many), oxygenated and pre‑warmed to 37 °C before use. 
Mouse hearts are perfused with undiluted plasma dialysate 
for 15 min before global zero‑flow ischemia. In humans, the 
blood samples are drawn from the contralateral cubital vein, 
and in pigs arterial blood samples are taken. Samples are 
saved in heparinized vials, immediately centrifuged at 800g 
for 20 min at 4 °C, and the plasma is either immediately 
transferred for dialysate preparation or stored at − 80 °C 
until use. A total of 75 mL plasma is dialyzed for 24 h at 4 °C 
against 20‑fold volume of KHB using a 12–14 kDa Spectra/
Por Dialysis Membrane (Spectra/Por, Rancho Dominguez, 
California). Dialysates are adjusted to 2.5 mmol/L  CaCl2 
and 24.88 mmol/L  NaHCO3, filtered (5 μm Chromafil Xtra 
PES‑500/25, Macherey–Nagel GmbH & Co. KG, Düren, 
Germany), oxygenated and equilibrated to 37 °C before use. 
The resultant yield of 1.5 L dialysate/150 mL human blood 
sample (app. 75 mL of plasma) is used for interventional per‑
fusion of one isolated heart. Primary endpoint is myocardial 
infarct size in a global or regional infarct model [304, 381].
Timing of plasma sample collection is important. Plasma 
taken 5–10 min after the remote ischemic conditioning 
maneuver by three cycles of 5 min ischemia/5 min reperfu‑
sion on one arm is somewhat protective in isolated mouse 
hearts, but protection is more robust when samples are taken 
after 30 min, and protection is seen with samples taken up to 
a week after the conditioning procedure [211].
Transfer of circulating cardioprotective mediators 
from humans to mouse hearts
Similarly, circulating cardioprotective mediators can be 
transferred with human dialysate to an isolated mouse 
(C57Bl6/J; age 8–12 weeks; weight 20–30 g) heart in the 
Langendorff mode. When frozen plasma is used, 4 mL 
is thawed and centrifuged at 4500g for 10 min at 4 °C. 
The supernatant is placed in a 12–14 kDa dialysis tubing 
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(SpectraPor, Spectrum Europe B.V., Breda, the Netherlands) 
and dialyzed for 24 h at 4 °C against a 20‑fold volume of 
modified KHB. Dialysates are adjusted to 2.5 mmol/L  CaCl2 
and 24.88 mmol/L  NaHCO3, filtered (5 μm Chromafil Xtra 
PES‑500/25, Macherey–Nagel GmbH & Co. KG, Düren, 
Germany), oxygenated and equilibrated to 37 °C before 
use. The resultant yield is used for interventional perfu‑
sion of one mouse heart. Primary endpoint is myocardial 
infarct size, but the activation of intracellular kinases is also 
assessed by western blot [211].
Transfer of extracellular vesicles between animals
Extracellular vesicles can be isolated from hearts perfused in 
Langendorff mode during either aerobic perfusion for 30 min 
(control) or after exposure to 3 × 5/5 min global ischemia and 
reperfusion as ischemic preconditioning. Extracellular vesi‑
cles are then isolated from the collected coronary perfusates 
by filtration and differential centrifugation. Perfusates are 
dialyzed against 0.45% saline containing 5 mmol/L EDTA 
for 4 h at room temperature to remove calcium ions, then 
vacuum‑distilled to 40 mL. Concentrated perfusates are fil‑
tered through 800‑nm pore filters and centrifuged at 12,200g 
for 20 min at 4 °C. Pellets are saved as microvesicle fraction. 
Supernatants are filtered through 200‑nm pore filters and cen‑
trifuged at 100,000g for 90 min at 4 °C. Pellets are saved as 
exosome‑rich pellets, and the supernatant is saved as extra‑
cellular vesicle‑depleted perfusate. Pellets and perfusates are 
then reconstituted to their original volume with KHB and can 
be used in isolated heart perfusion experiments.
To confirm their presence, isolated vesicles must be visual‑
ized by transmission electron microscopy. Vesicle pellets are 
fixed with 4% formaldehyde, postfixed in 1%  OsO4. Extracel‑
lular vesicles are block‑stained with 1% uranyl acetate in 50% 
ethanol, then dehydrated in graded ethanol, and embedded in 
Taab 812 (Taab Laboratories, Aldermaston, UK). Ultrathin 
sections are cut and then analyzed with an electron micro‑
scope. Hydrodynamic average particle size of extracellular 
vesicles in perfusates is measured by dynamic light scattering 
apparatus Zetasizer Nano ZS (Malvern Instruments, Malvern 
Hills, UK) or by Nanoparticle Tracking Analysis. The presence 
and amount of extracellular vesicles are assessed by immuno‑
blots from vesicular pellets and extracellular vesicle‑depleted 
perfusates [161]. Extracellular vesicles can then be transferred 
to isolated heart preparations or recipient animals [396].
Small animal hearts in situ
Species (mouse, rat, rabbit)
Small animals (mice, rats and rabbits) are frequently used 
lab animals for cardioprotection research because they have 
small size, are relatively inexpensive, and are easy in han‑
dling and maintenance.
The mouse model of myocardial infarction was published 
first in 1995 by Michael et al. [303] to investigate pathophys‑
iological mechanisms of myocardial ischemia. Since then, 
it has been widely employed in many experimental studies 
of myocardial infarction, mainly because of the high cost of 
larger animals and the ability to modify the murine genome 
which provides a wide variety of knockout or overexpress‑
ing lines [435, 438]. This mouse heart permits reliable and 
reproducible assessment of the area at risk and infarct size 
[347].
The rat model of myocardial infarction was established 
prior to the mouse model by Heimburger in 1946 [189] 
and further modified by other research groups [227, 246, 
378]. Throughout the years, the rat model of myocardial 
infarction has been firmly established since rats are easier 
to handle and house, have a shorter gestation time, can be 
genetically manipulated and have lower maintenance costs 
than larger animals; therefore, they are highly suitable for 
“high‑throughput” studies [64].
The rabbit is frequently used and has distinct advantages 
in experimental studies of myocardial infarction. Rabbits are 
medium‑sized animals, they have a docile and non‑aggres‑
sive character, are handled with ease and have a favorable 
cost‑effectiveness [128]. More importantly, the rabbit heart 
lacks collateral blood flow and has minimal fatal arrhythmia 
and death after coronary occlusion compared with other spe‑
cies [143, 273].
Strain, sex, age, weight
Mouse
C57BL6 is the standard strain of mice used in the majority 
of myocardial ischemia/reperfusion injury in vivo models 
[299]. Among 19 different strains, two strains, namely B6/
ecSODWT and FVB/N mice, have smaller infarct sizes than 
other strains, indicating that these genotypes are inherently 
protected and, therefore, not recommended for ischemia/rep‑
erfusion studies. C57BL6 mice have average infarct sizes 
[171], and their use is recommended, since it is the best 
characterized strain and easily accessible. Since there are 
different sub‑strains of C57BL/6 with different phenotypes 
and responses to ischemia, it is important to report the pre‑
cise sub‑strain (e.g. C57BL/6J and C57BL/6N) [320].
Age must be considered as a decisive factor of myocar‑
dial infarction and cardioprotection [51, 129]. Young mice 
(4–8  months) are usually used in ischemia/reperfusion 
experiments. Advanced age (i.e. over 22 months) is associ‑
ated with increased susceptibility to myocardial ischemia/
reperfusion injury and loss of cardioprotection [25, 49].
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Female mice are less vulnerable to ischemia/reperfu‑
sion. Increased expression of β1‑adrenergic receptors and 
estrogens has been proposed to explain pre‑existing car‑
dioprotection in female mice [312]. Use of mixed gender 
in myocardial infarction experiments can complicate the 
final outcome. For initial experiments, therefore, male mice 
should be used.
Rat
Sprague–Dawley, Lewis and Wistar rats have been used 
for myocardial infarction studies [276]. Lewis and Wistar 
are the most commonly used strains in ischemia/reperfu‑
sion experiments, present an intermediate infarct size com‑
pared to other inbred strains and are adequate for myocardial 
infarction studies [28].
Gender selection of rats is of utmost significance since 
estrogen plays a protective role in myocardial ischemia/rep‑
erfusion injury. Hearts of ovariectomized rats have more 
severe myocardial damage and cardiac dysfunction after 
ischemia/reperfusion than hearts of intact female rats [456]. 
To avoid the interference of estrogens (depending on the 
exact phase of the menstrual cycle), male rats should be used 
in preliminary studies. Rats at the age of 3–4 months weigh‑
ing 200–300 g are recommended for initial experiments of 
ischemia/reperfusion.
Rabbit
So far, mostly New Zealand white rabbits have been used 
in myocardial infarction studies [15, 17, 18, 128, 218, 223, 
244] although Japanese white rabbits have also been occa‑
sionally used [143]. New Zealand white rabbits are less 
aggressive in nature and have less health problems than other 
breeds [296].
Estrogen impact on cardioprotective effects and ovariec‑
tomized females is more susceptible to cardioprotective 
maneuvers [101, 367]. For this reason, male rabbits are usu‑
ally taken for initial studies. Mostly, young adult rabbits are 
used weighing 3.0–5.0 kg [223, 244].
Housing and feeding conditions
Housing and feeding conditions must be standardized for 
reproducibility and conform to the institutional guidelines 
and national and international laws and policies on the use of 
animals (Guide for the Care and Use of Laboratory Animals 
prepared by the National Academy of Sciences and pub‑
lished by the National Institutes of Health; NIH Publication 
No.85‑23, revised 1996).
Mouse
Mouse colonies must be maintained in standard condi‑
tions [125] (maximum 5/cage—including litters—with a 
minimum area of 60 cm2/mouse, 21–24 °C and 40–80% 
humidity) and maintained on a 12/12‑h light/dark cycle. It 
is important that mice are not housed together with rats, as 
they exhibit distress. Standard rodent chow, appropriate for 
mice, and fresh water must be provided ad libitum, unless 
special permission has been obtained from the Animal Eth‑
ics Committee of the institution to alter this practice.
Rat
Rats must be housed in standard conditions [125] (3/cage 
with a minimum area of 250 cm2/rat, 21–24 °C and 55 ± 10% 
humidity) and maintained on a 12/12‑h light/dark cycle with 
the light on from 7:00 a.m. Rats should be fed the standard 
rat chow, with water ad libitum [341].
Rabbit
Rabbits must be housed in separate cages in an environmen‑
tally controlled animal research facility. All rabbits should 
be exposed to a 12/12‑h light/dark cycle; room temperature 
should be maintained at 17–21 °C and humidity between 30 
and 70% [142]. Standard rabbit chow and water should be 
provided ad libitum. Fasting of animals can be incorporated 
in special protocols [244].
Pre‑operative preparation
Preoperative preparation of the animals is mandatory to 
attenuate side‑events that might appear during the surgery or 
postoperatively when a chronic model of ischemia/reperfu‑
sion (24 h of reperfusion) is used. Animals undergoing sur‑
gery for the induction of myocardial infarction must receive 
preoperative analgesia and—for chronic experiments—anti‑
biotics. Opioids are cardioprotective per se, and their use 
before surgery must be considered for their value versus this 
limitation [116, 397].
Mouse
The use of an opioid analgesic, e.g. buprenorphine [0.1 mg/
kg subcutaneously (s.c.) twice daily before surgery] is rec‑
ommended. Non‑steroidal anti‑inflammatory drugs, such as 
caprofen (2–5 mg/kg s.c.), can also be administered pre‑
operatively and postoperatively [258]. A broad‑spectrum 
antibiotic should be used to prevent postoperative infec‑
tions. Cefuroxim [100 mg/kg intraperitoneally(i.p.)] shortly 
prior to and after the procedure provides adequate antibiotic 
prophylaxis [118].
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Rat
Different schemes of analgesics have been employed, such 
as caprofen, buprenorphine and tramadol [81, 446]. How‑
ever, the selection of analgesics should be considered with 
caution. Tramadol reduces infarct size in rats at a dose of 
12.5 mg/kg, i.v. [458] and should, therefore, be avoided. 
Buprenorphine (0.1–2.5 mg/kg s.c.) and caprofen [4 mg/kg 
i.p. or orally 1 tablet] the day before surgery and one dose 
of buprenorphine (0.1–2.5 mg/kg s.c.) prior to surgery can 
be used [446]. Ampicillin 100 mg/kg intramuscularly (i.m.) 
immediately prior to surgery (2 min before) is suggested.
Rabbit
Buprenorphrine (0.08 mg/kg, i.m.) relieves pain both prior 
to and after surgery [128], while lidocaine (20 mg/kg s.c.) 
for local anesthesia can also be used [415]. For chronic 
experiments, broad‑spectrum antibiotics such as cefuroxime 
(25 mg/kg i.m.) should be administered to rabbits before and 
after the surgery [244].
Anesthesia
Deep sedation is mandatory for the well‑being of the animals 
and the decrease of mortality from arrhythmias [416]. Opi‑
oids can trigger cardioprotection through interaction with 
their receptors and reduce infarct size [116, 397]. Cardiopro‑
tection results also from volatile anesthetics, which can last 
for several days [34]. On the other hand, the cardioprotec‑
tive efficacy of remote ischemic preconditioning is lost on a 
background anesthesia of propofol [260], whereas propofol 
per se induces cardioprotection [462].
Mouse
Anesthesia results in deep sedation, analgesia and immobil‑
ity throughout ischemia/reperfusion in in vivo mouse stud‑
ies. The level of anesthesia is evaluated by the loss of a pedal 
reflex in response to a toe‑pinch stimulus as well as by the 
rate and depth of respiration [43].
A combination of xylazine with ketamine is often used, 
but xylazine results in low systolic pressure and bradycardia 
[242]. 100 mg/kg ketamine results in stable left ventricular 
function and is the recommended dose in mice [447]. Keta‑
mine may cause excessive bronchial and salivary secretions 
and xylazine can cause bradycardia, undesired effects which 
may be prevented by atropine at a dose of 0.02–0.05 mg/kg 
body weight [292].
Isoflurane induces a dose‑dependent blood pressure 
decrease [154], and the recommended dose is 4–5% for 
induction and 1–2% for maintenance to produce minimal 
cardiac depression [170]. Caution: isoflurane per se may be 
cardioprotective [34]. Pentobarbital causes significant brady‑
cardia and contractile depression [451]. The recommended 
dose is 90 mg/kg as bolus followed by 15–20 mg/kg when 
required during the experiment [48].
Propofol can be also used for induction of anesthesia and 
administered intravenously at a dose of 12–26 mg/kg with 
repeated doses as needed; however, a high dose of propofol 
(50 or 100 mg/kg) results in significant bradycardia [382].
One of the best anesthetic combinations is keta‑
mine–medetomidine–atropine, which preserves stable blood 
pressure in different genetic mouse strains. Medetomidine 
has a high selectivity for alpha‑2 receptors [465].
Based on the above, the recommendation for anesthesia 
in mice is a combination of ketamine, xylazine, and atropine 
(final doses of ketamine, xylazine, and atropine 100, 20, and 
0.6 mg kg−1, respectively), or pentobarbital 90 mg/kg as 
bolus followed by 15–20 mg/kg when required or isoflurane 
4–5% for induction and 1–2% for maintenance.
Rat
Widely used and generally accepted anesthetics in rats are 
a ketamine/xylazine mixture or pentobarbital [3, 446]. A 
mixture of ketamine (50–75 mg/kg) and xylazine (1–5 mg/
kg) induces anesthesia [464], while a single injection of 
pentobarbital [15–80 mg/kg] is also used [216, 446, 464]. 
However, in a recent study ketamine/xylazine induced brad‑
ycardia and increased serum‑free fatty acids, while both 
ketamine/xylazine and isoflurane induced hyperglycemia. 
Therefore, pentobarbital is currently the best choice at a dose 
of 50 mg/kg [365]. Volatile anesthetics and propofol should 
be used with caution since these agents induce long‑lasting 
cardioprotective effects.
Rabbit
Short‑acting barbiturates are the anesthetics of choice. A sin‑
gle intravenous injection of sodium pentobarbital or sodium 
thiopental (30 mg/kg) injected into a peripheral vein of the 
rabbits is sufficient for the induction and maintenance of 
anesthesia [15, 17].
Surgery
Tracheotomy, intubation and temperature
Orotracheal/endotracheal intubation or tracheotomy is used 
for ventilation, tracheotomy only after anesthesia.
Mouse Surgical procedures for the induction of myocar‑
dial ischemia/reperfusion have been described in detail [55, 
303]. In brief, a midline cervical skin incision is performed 
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using micro‑scissors after a slight lift of the skin with a 
straight forceps. The salivary glands are moved out of the 
way after gentle separation of the tiny muscles overlying the 
trachea and then fixed aside with ligatures (6–0 prolene). 
After the trachea is visible, a small cut between the fourth 
and fifth tracheal cartilage ring is performed and a cannula 
inserted into the trachea, ligated against the tracheal tube 
and connected to a rodent ventilator via a plastic tube. In 
case of experiments with longer reperfusion and recovery 
of the animals, orotracheal or endotracheal intubations are 
preferred. In brief, the end (approximately 5 mm) of a Tef‑
lon intravenous cannula (20 G) is cropped before inserting 
it into the mouse trachea. Mouse forelimbs are immobilized 
using adhesive tape and the upper incisors using a 4–0 silk 
ligature. The anesthetized mouse is secured against a plastic 
surface, which is then placed in a supine‑angled position. 
The tongue is held with a small piece of gauze and a light‑
emitting diode flashlight held against the frontal surface of 
the neck. The intravenous cannula is inserted into the mouth 
and passed through the vocal cords. The proper orotracheal 
intubation is confirmed after connection of the cannula with 
a syringe bearing one drop of saline (drop will move back 
and forth with the animal’s in‑ and exhalation) [329]. If the 
cannula is falsely inserted into the esophagus, the drop will 
not move. Artificial respiration (e.g. 120–150 breaths/min, 
180 μl volume, 0.8 L/min oxygen flow) is provided through‑
out surgery by a ventilator [16, 55].
Body temperature plays a major role for infarct size [75, 
172, 375]. The temperature must be carefully controlled 
throughout the experiment by heating pads and lamps with 
continuous monitoring using a stabilized rectal thermometer. 
The heating pad should heat to 40–42 °C to maintain normal 
body temperature around 37 °C throughout the procedure 
[146].
Rat In brief, a midline cervical skin incision is performed 
with micro‑scissors after a slight lifting of the skin with a 
straight forceps. Subsequently, the salivary glands are dis‑
sociated, and the trachea is prepared by use of a 4–0 silk 
suture. A small incision is performed between the fourth 
and fifth tracheal cartilage ring and the endotracheal tube 
inserted and fixed on the trachea by use of the sutures [446]. 
In chronic experiments, endotracheal intubation is pre‑
ferred. Briefly, an endotracheal polyethylene tube size 90‑ or 
a 18‑gauge scalp vein needle tube, lubed with xylocaine gel, 
is inserted into the trachea after the animal is secured in a 
vertical position [214]. For both acute and chronic ischemia/
reperfusion experiments, mechanical ventilation is set at 
90 breaths/min and a tidal volume of 1.5 mL/100 g room air.
Body temperature can influence infarct size [93]. Body 
temperature must be maintained in the physiological rage, 
namely 37 ± 1 °C, by use of a heating pad and continuously 
monitored by a rectal thermometer.
Rabbit Endotracheal intubation is the technique of choice 
in experiments that include the recovery of the animals 
after surgery. Intubation is performed with a  30° rigid endo‑
scope and an uncuffed (or cuffed) endotracheal tube size 
2.5–4.5 mm, previously lubricated with xylocaine gel [425]. 
In acute models of myocardial infarction, tracheotomy can 
also be used. Briefly, the skin is incised on the middle line 
with a sterilized scalpel, and underlying muscles covering 
the trachea are gently pulled aside. Once the trachea is visu‑
alized, a small incision (preferably using cautery to avoid 
bleeding) is performed. Subsequently, an endotracheal tube 
size 2.5–4.5 mm is inserted into the trachea and fixed by use 
of 2–0 ligatures [15, 17, 43]. Adequate ventilation of the 
animals is afforded by 35–40 breaths/min and a tidal volume 
15 mL/kg [404].
A thermal mattress is used to maintain body temperature 
at values of 38/39 °C. Mild hypothermia is cardioprotective 
and reduces infarct size [172, 424].
Thoracotomy, induction of ischemia and reperfusion
An ECG recording from baseline and throughout the 
ischemia/reperfusion is recommended. Technical details for 
the ECG recordings are available for small animal experi‑
ments with ischemia/reperfusion [377].
Mouse In mice, the anatomy of the coronary arteries is vari‑
able and highly debated [263, 362]. The left coronary artery 
runs to the apex as either one or two major vessels with sev‑
eral smaller branches. It is usually referred to as the LAD 
because the circumflex artery is considered non‑important 
[303]. The variability of both its branching pattern and vas‑
cular territories interferes with reproducibility in the size of 
the area at risk. Therefore, assessment of the area at risk 
after the experiment is mandatory [98, 239, 332].
To perform temporary ligation of the LAD, a left‑sided 
thoracotomy in the third intercostal space is the standard 
and most widely used method. The skin is incised and the 
subcutaneous tissue dissected, the ventral serrated muscle 
of the thorax and the intercostal muscles are transected. The 
opening is broadened with a rib retractor. The lung is gently 
displaced with a cotton swab to visualize the left auricle, 
under which the LAD takes course toward the apex. A silk 
6–0 suture is mostly used to occlude the LAD just proximal 
to the site where the artery divides into two smaller branches 
or alternatively at the level of the tip of the auricle [98]. 
In the majority of studies, the LAD is ligated between the 
conus arteriosus and the left auricle, resulting in large areas 
of myocardial infarction with poor short‑term survival [9]. 
This approach has resulted in great heterogeneity of the final 
infarct size, ranging between 10 and 70% of the left ventricu‑
lar region [33, 147, 332, 363, 414].
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Ischemia is terminated by releasing the knot, and reperfu‑
sion is verified by direct visual inspection.
Rats The animal is placed in its right lateral position and the 
skin incised using sterilized scissors. Underlying muscles 
are dissected using a hemostatic forceps. A small incision is 
made between the fourth and fifth ribs with caution to avoid 
bleeding and lung injury. The thorax is slightly lifted with 
the forceps, and a rib retractor is then positioned within the 
fourth intercostal space, so that the left ventricle is revealed, 
taking maximal care not to damage the lung. Finally, the 
pericardium is dissected and the myocardium exposed [138].
In rats, the anatomy of the myocardium is similar to that 
of mice. However, the circumflex artery is absent. The LAD 
lies beneath the epicardium and is embedded in myocardial 
tissue. Therefore, the LAD is rarely visible to the naked eye, 
creating controversies on the method of its ligation and the 
outcome of the infarction. LAD ligation very close to its 
origin induces infarction and severe arrhythmias, resulting 
in high mortality. On the contrary, LAD ligation at a site 
close to the apex induces small infarction only [322]. The 
optimal site for LAD ligation is 2.0–3.0 mm below the ante‑
rior–inferior edge of the left atrium along a line connecting 
the insertion of the left auricular appendage with the apex or 
4.0 mm from its origin between the left atrial border and the 
pulmonary artery sulcus. The ligation is achieved by use of a 
propylene or silk suture 5.0. The more atraumatic propylene 
sutures are preferred. LAD ligation at this site induces an 
infarct size of approximately 65% of the area at risk [214].
Reperfusion is achieved by release or removal of the knot. 
If animals are required to recover after the surgery, the rib 
retractor is removed and the intercostal space closed by liga‑
ture of the ribs using 2–0 sutures. The negative intrathoracic 
pressure is restored by a Bülau tube (connected to a three‑
way stopcock and a syringe). Finally, muscle layers and skin 
are closed using 4–0 prolene sutures [214, 446].
Rabbit In contrast to smaller rodents (such as mice and 
rats), the coronary arteries are quite prominent in rabbits 
and appear as pale red epicardial vessels originating from 
underneath the left auricle and running down the left ven‑
tricular wall. The LAD is small in rabbits and the apex of the 
heart is supplied by a prominent coronary branch labeled as 
the circumflex in Ref. [444], and this is the recommended 
ligation site. This branch can clearly be seen on the LV’s 
surface anterior to the intraventricular grove where the 
residual LAD resides, and the branch’s occlusion will render 
about a third of the ventricle ischemic. The artery branches 
out along its course to the apex of the heart. These branches 
are evident mainly as bifurcations in young rabbits and as 
bi‑ or trifurcations in aged rabbits [310]. Therefore, ligation 
should be performed above the division of the vessel at a 
site approximately 2 cm below its origin.
Open‑chest procedures best mimic the clinical scenario 
[310]. Briefly, hair is removed and the skin incised using 
a sterilized scalpel and hemostats. Subsequently, underly‑
ing muscular layers are dissected. Major vessels, arteries 
and veins are located superficially under the skin or in the 
thoracic muscles and can be easily injured during surgical 
manipulations, causing severe or even ominous bleeding. 
Therefore, the superficial incisions must be done with cau‑
tion. Once the ribcage of the animals is revealed, the chest is 
opened via a left thoracotomy in the fourth intercostal space 
and maintained open using a chest retractor. After pericar‑
diotomy, the beating heart is exposed. A 3.0–4.0 silk thread 
is passed around a prominent branch of the coronary artery, 
and regional ischemia is induced by pulling the ends of the 
suture through a small polyethylene tube to form a snare. 
Clamping the tube with a hemostat keeps the coronary artery 
occluded. The successful induction of ischemia is verified 
by visual inspection (cyanosis) and by ST segment elevation 
on the ECG [218].
Reperfusion is achieved by unclamping the tube. Main‑
taining the suture loosely around the vessel at the site of 
occlusion facilitates re‑occlusion at different time points and 
for post‑mortem staining. Successfully reperfused myocar‑
dium is distinguished by the recovery of the color on the 
ventricular surface; however, bruising of the myocardium 
can also be observed as a result of hemoglobin degradation 
[220, 427]. In case the protocol requires recovery of the ani‑
mals after surgery for further monitoring, the chest retractor 
is removed, the intercostal space is closed by intermittent 
ligatures using 2.0 sutures and the muscle layers are sutured 
together with 2.0 silk sutures [128]. As in rats, the restora‑
tion of negative intrathoracic pressure by a Bülau drainage is 
preferable for the achievement of successful recovery [445].
Duration of ischemia and reperfusion
Mouse The duration of ischemia must be sufficient to cause 
significant infarction, but not complete death of all cardio‑
myocytes at risk in the control cohort. The most frequent 
periods of ischemia in mice in vivo are 30 min in duration 
[299]. Many studies have shown loss of cardioprotective 
potential after longer periods of ischemia, e.g. 60–90 min 
[295]. Reperfusion is extremely important for quantita‑
tive evaluation of ischemia/reperfusion injury. The time 
course of reperfusion needed differs for different endpoints. 
The duration of reperfusion must be sufficient to allow an 
accurate and unequivocal delineation of necrotic and viable 
myocardium. Reperfusion is the start of the healing process 
in reversibly damaged cells, but may also exaggerate injury 
in irreversibly damaged cells [188]. A minimum duration of 
1–2 h reperfusion is mandatory for adequate TTC staining in 
murine hearts. More prolonged reperfusion, such as 24 h, is 
recommended when the experimental protocol is designed 
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for investigation of inflammatory responses or when more 
long‑term protection from an intervention is studied.
Rat Ischemia duration in rats is quite standardized, and 
30 min of ischemia is the duration of choice. The duration 
of reperfusion in rats is also quite standardized [393]. Rep‑
erfusion for 120  min is sufficient for experiments investi‑
gating acute effects of myocardial infarction. Systolic and 
diastolic left ventricular function deficits can be present 
as early as 3 h after coronary occlusion [346], while after 
3–4 weeks there is hypertrophy which manifests in elevated 
left‑ventricular end‑diastolic pressure and right ventricular 
systolic pressure [339]. Reperfusion for 120 min is the mini‑
mum time for infarct size determination in cardioprotection 
experiments. Keep in mind that shrinkage of the infarcted 
area with scar formation is observed in long‑term experi‑
ments (months) [250].
Rabbit 30‑min regional ischemia is adequate for the induc‑
tion of myocardial injury and commonly used in myocardial 
infarction protocols in rabbits [219, 393].
The reperfusion duration can vary among myocardial 
infarction protocols [46, 393]. Reperfusion for 120 min is 
inadequate to reveal the full extent of myocardial injury 
compared to 3, 4 and 6 h reperfusion. Insufficient NADH 
leakage from irreversibly impaired cardiomyocytes at 
120 min reperfusion might lead to underestimation of the 
actual infarct size (~ 20% of the ischemic area). On the other 
hand, infarct size does not differ between 3 and 6 h rep‑
erfusion (~ 40% of the ischemic area), indicating that 3 h 
reperfusion is sufficient for an acute model of myocardial 
infarction [46, 219, 393].
Endpoints
In studies assessing cardioprotection, the primary endpoint 
must be the quantitative determination of myocardial necro‑
sis. Determination of infarct size and area at risk is funda‑
mental for ischemia/reperfusion studies [435]. The methods 
to assess myocardial infarct size in mice, rats and rabbits is 
TTC staining. Biomarkers have been also used to evaluate 
the extent of myocardial injury, such as cardiac troponins, 
CK, and plasma proteins (i.e. macrophage migration inhibi‑
tory factor) [90]. The infarct size/area at risk ratio decreases 
with interventions that protect myocardium against ischemia/
reperfusion injury [441].
Determination of infarct size
Mouse The area at risk is delineated by injection of micro‑
sphere particles or Evans blue staining after re‑tightening 
of the suture at the same anatomical site of the artery where 
it was occluded. After snare release reperfusion starts, and 
mice are sacrificed at the end of the reperfusion period; the 
heart is rapidly excised, directly cannulated and retrogradely 
washed with 2.5 mL saline–heparin 1% for blood removal. 
After the tightening of the suture, 2.5% Evan’s Blue solu‑
tion is infused through the catheter for the identification 
of the non‑ischemic part of the myocardium. Afterwards, 
hearts are frozen for 24 h and then sliced in 1‑mm sections, 
which are incubated for 20 min in TTC (1% in phosphate 
buffered saline pH = 7.4) for the identification of the infarct 
area [16]. Many investigators use the salvage index which is 
estimated from the formula [(area at risk—infarct size):area 
at risk] [42, 113, 119]. Other methods for the determination 
of infarct size in mice include transthoracic myocardial con‑
trast echocardiography [331].
Rat Infarct size is the primary endpoint of most of studies 
on myocardial infarction in rats. TTC staining is the widely 
accepted method to measure infarct size [214]. Transtho‑
racic echocardiography [71, 436], CMR [124, 166, 288] and 
positron emission tomography [175, 177] have also been 
used in studies of myocardial infarction in rats.
Rabbit Rabbits are euthanized by a high bolus dose of thio‑
pental, and hearts are excised, blood is washed out using hep‑
arinized saline, and the suture is re‑ligated around the coro‑
nary artery. Infarct size is the primary endpoint of most studies 
on myocardial infarction in rabbits. TTC staining is the most 
widely accepted method to measure infarct size [46, 285].
For post‑reperfusion monitoring of infarct size and ven‑
tricular function, other non‑invasive techniques such as 
CMR [127, 128] and transthoracic echocardiography [117, 
223, 415] have gained increasing interest.
Larger mammal hearts in situ
General considerations
Large animal models, using dogs, pigs, or sheep, have both 
advantages and disadvantages over small rodent models. 
Size and anatomy of the heart and systemic hemodynam‑
ics, notably heart rate, are closer to those of humans, and 
potential interventions in large animal models bear closer 
similarity to potential clinically feasible treatments. Disad‑
vantages of larger animals are the higher costs for purchase 
and housing. Other than the often inbred and more homog‑
enous genotype of small rodents, large animals have a wider 
genetic variation which results in larger variation in hemo‑
dynamic responses and infarct size development, and which 
ultimately requires larger sample sizes to detect differences 
between interventions. Nevertheless, such variability better 
resembles the clinical scenario and favors translation. The 
development of transgenic large animal models is costly, 
time consuming and difficult.
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Animals
Species and strains
While dog models were more frequently used in the past 
[313, 344, 460], pig models are now favored in cardiopro‑
tection research [209]. For pigs, several strains such as Göt‑
tingen, Yorkshire, Yucatan and CLAWN minipigs, but also 
full‑size landrace pigs have been used. So far—unlike in 
mice [171] and rats [28]—there is no evidence that specific 
dog or pig strains are more or less prone to benefit from car‑
dioprotection than others. We recommend dog or pig models 
as those are established in a large number of experimental 
facilities, providing not only a comprehensive portfolio of 
background data (e.g. the expected range of infarct size after 
ischemia/reperfusion) but also the possibility of collabora‑
tion with standardization of protocols across different labs.
Age and sex
Compared to patients, animals are most frequently younger. 
Cardioprotection is more difficult to achieve in very young 
[369] and very old [51] animals, and use of young and old 
animals should be avoided unless age is a specific parameter 
under question. It is yet unclear whether gender influences 
the effect of cardioprotection in larger mammals; in both 
male and female animals, cardioprotection from local and 
remote ischemic conditioning has been validated [129, 312, 
393]. The use of sexually mature animals is recommended; 
thus, dogs aged more than 12 months and pigs aged at least 
6–7 months should be used. In particular, in some pig strains 
such as the landrace, body weight somewhat limits the upper 
age range, as pigs reach about 75% of their mature weight 
at an age of 24 months. To ensure a better long‑term com‑
parability of data, age and body weight should adhere to a 
narrow range. Animals should be housed in a local facility 
for at least 2 and optimally 4 days prior to experiments, as 
transport may induce substantial stress in both, dogs and 
pigs, which can potentially modify their response to cardio‑
protective stimuli within a second window of cardioprotec‑
tion lasting 72–96 h [58].
Pre‑medication and anesthesia
The anesthetic regimen should be carefully selected to meet 
the species‑specific properties of sufficient anesthesia on 
the one hand and the requirements for successful transla‑
tion of the experimental results on the other hand. Local 
authorities often mandate the exclusive use of veterinary 
drugs. As these drugs are not used in patients, unknown side 
effects may interfere with the experimental results. An anes‑
thetic regimen which is also used in clinical cardiovascular 
surgery is preferred [252, 385]. Of note, anesthetic drugs 
may have an impact on the study results. Barbiturate anes‑
thesia is associated with cardiodepressive effects [294], and 
volatile anesthetics are cardioprotective per se [247, 270, 
275]. Propofol interferes with the cardioprotection by remote 
ischemic preconditioning [261]. Such confounding effects 
must be avoided or taken into consideration.
Sedation is induced by intramuscular injection in the 
back/neck or hindlimb (pigs: benzodiazepines, e.g. diazepam 
0.5 mg/kg or flunitrazepam 0.4 mg/kg [252, 385, 394]; azap‑
erone 4 mg/kg can be added to enforce for quicker effect). 
After sedation, a vein on the front paw of dogs or an ear 
vein in pigs is cannulated with an indwelling venous cannula 
for infusion of short‑acting anesthesia (dogs: pentobarbital 
30–40 mg/kg; pigs: etomidate 0.3–0.5 mg/kg with/without 
sufentanil [252, 385, 394]). Anesthesia is maintained by arti‑
ficial ventilation with oxygen enriched air (~ 35%  O2 vol.) 
and volatile anesthetics, e.g. 1.5–2.5% isoflurane, or intrave‑
nous infusion of pentobarbital [248]. Due to the unfavorable 
anatomy of the throat in minipigs, a tracheotomy is an alter‑
native to endotracheal intubation for ventilation.
An alternative anesthetic regimen without potential pro‑
tection by inhaled gasses in pigs uses intramuscular injection 
of ketamine (20 mg/kg), xylazine (2 mg/kg), and midazolam 
(0.5 mg/kg) and is maintained by continuous intravenous 
infusion of ketamine (2 mg/kg/h), xylazine (0.2 mg/kg/h), 
and midazolam (0.2 mg/kg/h) [131, 132, 152, 153].
Experimental preparation and monitoring
Large animal preparations should mimic clinical circum‑
stances. Monitoring of rectal or esophageal temperature, 
end‑expiratory  CO2 levels, arterial blood samples to secure 
sufficient ventilation and physiologic electrolyte levels are 
mandatory to warrant a stable preparation. Irregularities, 
including arrhythmias, should be treated as quickly as pos‑
sible. If the use of drugs cannot be avoided, their poten‑
tial interference with the experimental protocol must be 
considered. Body temperature of dogs and pigs is higher 
(37.5–39.5 °C) than that of humans [221, 317] and must 
be kept constant by use of a heated table and drapes. Con‑
tinuous monitoring of the ECG is not only useful for sur‑
veillance of the preparation, but can also serve to reflect 
the magnitude of injury (ST segment elevation) to assess 
the success of a protective intervention, and to distinguish 
between an ischemic and reperfusion‑related component of 
injury (Fig. 9) [252, 354].
For invasive blood pressure measurement and cardiac 
catheterization, the easiest access is through the internal 
carotid artery, which may be identified by dissection along 
the anterior border of the sternocleidomastoid muscle. The 
internal jugular vein is found alongside the internal carotid 
artery. Alternatively, the percutaneous Seldinger technique 
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has been used to achieve arterial and venous access but 
requires use of ultrasound imaging for guidance. This 
approach is less invasive than the surgical one and recom‑
mended if postoperative recovery of the animals is intended. 
Anticoagulation, particularly when introducing catheter‑
induced infarction, is advised, but increases risk of diffuse 
bleeding. Pigs are somewhat resistant to unfractionated hep‑
arin and, therefore, 300 IU/kg has been recommended [133].
Induction of myocardial ischemia: closed vs. open‑chest 
models
In vivo models use regional myocardial ischemia and thus 
resemble the clinical scenario of STEMI. Regional ischemia 
is induced by temporal occlusion of a large epicardial cor‑
onary artery, commonly the LAD distal to its 1st or 2nd 
diagonal branch. Coronary occlusion can be achieved either 
by direct ligation using a tourniquet (leave in place for later 
demarcation of area at risk, see below) [385] or by an intra‑
coronary balloon, placed under fluoroscopic guidance [131, 
132, 152, 153, 248]. Permanent occlusion of the left circum‑
flex coronary artery can also be achieved by placement of an 
intracoronary coil, which electrically generates a thrombus 
with a subsequently large infarcted area, as well as mitral 
regurgitation and atrial infarction [8]. Ligation by a tourni‑
quet requires a thoracotomy which changes the intrathoracic 
pressures and thus affects hemodynamics, but these effects 
are minor and not prohibitive for precise measurement of 
left ventricular function. Exposure of the heart by either 
sternotomy or left lateral access depends on the body frame 
of the animal. Minipigs do not tolerate a prolonged position 
on their back due to their compact body frame, and lateral 
access is preferred. An obvious advantage of the open‑
chest model is that the area at risk is anatomically precisely 
defined distal to the placement of the ligature and an unin‑
tended closure of side branches is virtually impossible. The 
placement of an intracoronary balloon under fluoroscopic 
guidance makes the determination of area at risk less accu‑
rate. Intracoronary delivery of microspheres (diameter of 
40–50 µm) through a catheter or with direct injection into 
the coronary artery is used to induce microembolization 
[115, 389] to study the effects of coronary microemboliza‑
tion per se [387] and its interference with cardioprotective 
maneuvers [386, 390, 394]. On the other hand, the closed 
chest model with coronary occlusion performed by a balloon 
catheter is clinically more relevant as it mimics the clinical 
procedure for PCI [29, 132].
Hemodynamics, myocardial blood flow and regional 
myocardial function
Placement of open‑end catheters from the internal carotid 
into the left ventricle and through the femoral artery into the 
aorta provides a simple access to measure left ventricular 
and aortic pressures, respectively. A more precise meas‑
urement of ventricular pressure can be achieved by a high‑
fidelity pressure‑tip catheter placed in the left ventricle or by 
a micromanometer implanted into the left ventricular apex. 
Such high‑resolution pressure measurement avoids catheter‑
induced over‑ and undershoots in the pressure signal [241] 
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(PLA). ST‑segment elevation is displayed as amplitude difference 
between two points (vertical red lines) 30 ms before the P wave and 
20 ms after the J‑point, respectively [252]
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which is important in studies investigating complex changes 
in systolic and diastolic ventricular function, e.g. the maxi‑
mal rise of left ventricular pressure during systole and calcu‑
lation of the left ventricular relaxation time constant.
Continuous digital data acquisition systems (e.g. Noto‑
chord, Notocord Systems, Croissy‑sur‑Seine, France; 
Biopac, Biopac systems, Goleta, CA, USA; Labchart, ADIn‑
struments Pty Ltd, New South Wales, Australia) allow off‑
line analysis of hemodynamics, ECG, respiratory param‑
eters, and temperature.
The measurement of regional myocardial blood flow is 
mandatory in species with high collateral blood flow, nota‑
bly in dogs [279], but it is also recommended in species 
with low collateral blood flow, e.g. pigs, where there still 
is an inverse relationship between residual blood flow and 
infarct size [384]. Even the rather small variation in resid‑
ual blood flow during ischemia in pigs is reflected by the 
more frequent occurrence of ventricular fibrillation and by 
larger infarcts [384]. The gold standard for measurement of 
regional myocardial blood flow is the injection of labeled 
microspheres [112] into the left atrium with simultane‑
ous, calibrated withdrawal of blood from the descending 
thoracic aorta [252, 384, 385, 395]. Use of color‑labeled 
microspheres (FluoSpheres, Life Technologies, Eugene, OR, 
USA) is easy, but somewhat labor intensive in the subse‑
quent sample processing [262]. Neutron‑activated micro‑
spheres (BioPal, Worcester, MA, USA) can only be analyzed 
at the manufacturer’s laboratory which induces additional 
costs and delays. Radioactive‑labeled microspheres are now 
obsolete.
Regional myocardial contractile function can be meas‑
ured by transit‑time [418] or Doppler [178] sonomicrometry 
in the area at risk and a remote control area as reference, and 
regional contractile function is usually expressed as systolic 
wall thickening or systolic segment shortening. Calculation 
of these variables requires exact timing of diastolic and sys‑
tolic time intervals which can be derived from high‑fidelity 
left ventricular pressure signals or the ECG [392].
Blood samples, microdialysis, tissue samples/biopsies
Blood and/or tissue samples can be taken at various time 
points of the protocol. In this respect, the larger mam‑
mal heart size is favorable. Accurate timing in relation to 
ischemia/reperfusion and interventions is of utmost impor‑
tance as biologic effects may occur within very limited time 
frames, e.g. in the first few minutes after myocardial reperfu‑
sion [373, 374, 390].
Microdialysis catheters can safely be placed in the ven‑
tricular wall to sample fractions of interstitial fluid during 
an experimental protocol and to evaluate changes in, e.g. 
adenosine, lactate and other metabolites [297, 374].
Large mammal hearts permit multiple sampling of myo‑
cardial tissue from the area at risk and remote areas which 
can serve as an intraindividual Ref. [205, 393]. Using hol‑
low‑core drills with a diameter of 2 mm, transmural tissue 
samples of about 10 mg can be retrieved. Of note, taking 
biopsies from areas with apparent arteries and veins must 
be avoided and sutures must stop bleedings from bore holes. 
Experiments with myocardial tissue samples bear the risk of 
arrhythmias. If large volume blood samples are withdrawn, 
e.g. for preparation of plasma/plasma dialysate [385], the 
volume loss must be compensated with saline.
Imaging
Cardiac imaging can be performed in dogs and pigs with 
protocols similar to human investigations. CMR [60, 315], 
computed tomography, echocardiography [102, 103], posi‑
tron emission tomography [318, 372], single‑photon emis‑
sion computed tomography and fluoroscopy have been 
performed successfully in dogs and pigs. Due to the chest 
shape, it may be difficult to obtain optimal scanning angles, 
which may compromise advanced echocardiographic meas‑
urements, e.g. with tissue Doppler techniques. For the pre‑
cise measurement of ventricular function, we recommend 
invasive methods or CMR.
Ischemic conditioning
Local ischemic pre‑ or postconditioning can be induced 
using an intracoronary balloon or a tourniquet in open‑
chest preparations. Remote ischemic conditioning is mostly 
achieved through intermittent restriction of blood flow in 
a limb. Dissection of the femoral/iliac artery and intermit‑
tently occluding it with a tourniquet can be used to obtain 
intermittent limb ischemia/reperfusion, but external com‑
pression using a strong tourniquet around the proximal part 
of a limb is easier and equally efficient [248, 252, 385]. Veri‑
fication of limb ischemia and successful reperfusion must be 
performed. The timing of ischemic conditioning protocols 
in relation to the index ischemia in the heart is important 
and should be kept strict. The number and duration of the 
conditioning cycles must be kept constant and accurately 
reported. In pigs, three or four cycles of 3–5 min local or 
remote ischemia/reperfusion induce efficient and reproduc‑
ible cardioprotection in most [158, 228, 252, 385, 393], 
but not all studies [29]. In a recent study in pigs, remote 
ischemic perconditioning attenuated ischemic injury even 
before reperfusion, as assessed by attenuated ST‑segment 
elevation during ongoing ischemia [252]. The evolution of 
intracoronary ST‑segment elevation during ischemia can 
also be analyzed, even in the clinical settings to assess car‑
dioprotection during PCI [429].
 Basic Research in Cardiology  (2018) 113:39 
1 3
39  Page 46 of 73
Pharmacologic pre‑, per‑ or postconditioning
Infarct size reduction after ischemia/reperfusion has been 
performed with a number of drugs (e.g. adenosine [452], 
glucagon‑like peptide 1 analogs [121], metoprolol [217], 
and CsA [391]) in dogs and pigs. However, translation to 
clinical use has so far not been successful, and a consistent 
improvement of outcome in patients with STEMI has not yet 
been reported. Such discrepancy may be explained by inter‑
species pharmacokinetic and pharmacodynamic differences, 
but may also be related to the more complex nature of clinical 
ischemia/reperfusion scenarios, often confounded by comor‑
bidities and comedications compared to the rather simplified 
experimental models. Nevertheless, pharmacological studies 
can provide important mechanistic insights [201, 254]. As 
with mechanical conditioning strategies, timing is of major 
importance. Generic drug names, producer, solvents, dos‑
age, timing, and administration route must be clearly reported 
in detail. Measurement of serum levels of the administered 
compound is recommended to secure that a sufficient concen‑
tration is reached. It may be particularly important for future 
experiments to perform studies on novel pharmacological 
targets with a pre‑existing background of  P2Y12 antagonists 
which are now routine clinical anti‑platelet therapy, share 
cardioprotective signaling with ischemic conditioning and 
induce cardioprotection per se [85, 448–450].
Area at risk and areas of no reflow
Prior to euthanasia, it is important to delineate the perfusion 
territory exposed to prolonged ischemia and reperfusion, 
i.e. the area at risk. Direct access to the coronary artery 
is necessary, and if a closed‑chest model has been used, a 
thoracotomy should be performed at this stage and a tourni‑
quet placed around the coronary artery at the best estimate 
of the site of balloon occlusion; perivascular hematoma may 
guide the placement. Commonly, dyes (e.g. Evan’s blue, 
Patent blue, fluorescein) or fluorescent microspheres are 
used to demarcate the area at risk. After re‑occlusion of the 
coronary artery, the dye or microspheres are injected into 
the left atrium, and after staining of remote areas the heart 
is arrested by quick injection of 2 mol/L potassium chloride 
solution or electrical induction of ventricular fibrillation.
Areas of no reflow can be demarcated at the end of an 
experiment by thioflavin S stain which binds to endothe‑
lial cells and thus tissue with intact perfusion at the time 
of injection. One mL/kg body weight of pre‑warmed 4% 
thioflavin‑S solution (Morphisto, Frankfurt, Germany) is 
filtered through a 0.2‑µm pore syringe filter to remove par‑
ticulate debris before slowly infusing it over 2–3 min into 
the left atrium prior to re‑occlusion of the coronary artery. 
In post‑mortem inspection of tissue slices, thioflavin 
S‑stained tissue exhibits a yellow‑green fluorescence when 
examined under ultraviolet light (340–360 nm). Areas of 
no‑reflow remain without fluorescence (thioflavin‑S nega‑
tive) [173, 384]. Fluorescence can be documented by digi‑
tal photography in an ultraviolet‑illuminated light box.
Euthanasia
General advice cannot be given as euthanasia of laboratory 
animals has to comply with national regulations.
Infarct size
After the heart is excised and flushed with cold saline, it is 
cut into slices parallel to atrioventricular grove and meas‑
ured using TTC. Note that the area at risk must be docu‑
mented before TTC‑staining, as the deep red formazan can 
mask the blue stain used to detect the area at risk. A blinded 
observer must quantify infarct size. CMR‑based infarct size 
quantification is a valid alternative to pathology, in particular 
in studies with longer follow‑up in which ventricular func‑
tion is also addressed and scar formation quantified.
Exclusion criteria
Exclusion criteria must be defined prospectively. Exclusion 
is justified by severe anesthetic incidents and surgical faults 
during the initial preparation, by persistent arrhythmias such 
as atrial fibrillation and intractable ventricular fibrillation, 
by higher residual blood flow during ischemia (> 0.06 mL/
min/g in pig myocardium) [252, 384], by large areas of 
non‑reperfused tissue as determined from measurement of 
regional myocardial blood flow at early reperfusion (e.g. 
10 min), by hypo‑ or hyperthermia with more than 1 °C dif‑
ference to normal body temperature, and by obvious errors 
in the timing of the experiment.
The human right atrial trabeculae model 
of simulated ischemia and reperfusion
The human atrial trabeculae model of simulated ischemia/
reperfusion injury was developed by the Yellon group in 
1995 [440]. It uses human atrial trabeculae isolated from 
right atrial appendages harvested at the time of cardiac 
surgery [440]. The human atrial model has proved to be a 
unique translational tool, confirming in humans what has 
been shown in cell models and in vitro/in vivo animal stud‑
ies [253].
Outline of model
Human atrial muscle is taken from patients undergoing car‑
diac surgery following informed consent.
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The exclusion criteria typically consist of
1. Patients over the age of 80.
2. Patients who have had a troponin‑positive event within 
the last 6 weeks of being admitted for surgery.
3. Patients with unstable angina in the last 72 h.
4. Patients in permanent atrial fibrillation or any arrhyth‑
mic episodes such as atrial flutter or ventricular tachy‑
cardia within the last 6 weeks, or on any anti‑arrhythmic 
therapy such as amiodarone.
5. Patients with congestive heart failure (pulmonary edema 
and/or ejection fraction < 50%).
6. Diabetic patients are excluded from all experiments 
except the experiments specifically required for the 
study under investigation.
7. Patients with renal failure.
Sample collection and transport
During surgery, and prior to insertion of the venous can‑
nula of the cardiopulmonary bypass machine, right atrial 
appendages are harvested by placing a purse string suture 
around the base of the appendage. Appendages are imme‑
diately placed in a falcon tube containing 50 mL modified 
Tyrode’s buffer (comprising in mmol/L 118.5 NaCl, 4.8 
KCl, 24.8  NaHCO3, 1.2  KH2PO4, 1.44  MgSO4·7H2O, 1.8 
 CaCl2·2  H2O, 10.0 glucose, and 10.0 pyruvate) oxygenated 
with a 95%  O2–5%  CO2 gas mixture to maintain pH between 
7.35 and 7.45,  pO2 > 55, and  pCO2 between 4.0 and 6.0 kPa. 
In addition, the temperature is maintained at less than 4 °C 
by transporting the falcon tube in a thermos flask containing 
ice as quickly as possible to the laboratory.
Alternatively, appendages are transported and trabecu‑
lae are dissected in cardioplegic buffer (in mmol/L: 100 
NaCl, 10 KCl, 1.2  KH2PO4, 5  MgSO4·7H2O, 50 taurine, 5 
3‑(N‑morpholino)propanesulfonic acid) at 4 °C. The average 
transport time must be kept to a minimum, i.e. from operat‑
ing theater to laboratory.
Dissection of atrial trabeculae
Once in the laboratory, the sample is placed in buffer con‑
tained within a clean sterile Petri dish on a bed of ice. The 
inner surface of the sample is placed upwards and its edges 
pinned down, to expose the atrial trabeculae on the inside 
(Fig. 10a). Trabeculae are then isolated by tying a surgi‑
cal knot at either end of the trabeculae with 5–0 silk. The 
trabeculae are excised and suspended in a 25‑mL water 
jacketed organ bath between two pacing electrodes (Rad‑
noti Glass Technologies, Dublin, IE) containing modified 
Tyrode’s buffer bubbled with a 95%  O2–5%  CO2 gas mix‑
ture, to maintain pH between 7.35 and 7.45,  pO2 > 55, and 
 pCO2 between 4.0 and 6.0 kPa (Fig. 10b). The temperature 
is maintained at 37 °C using a heat exchanger.
Alternatively, measurements of force of contraction are 
performed in a modified four‑chamber myograph (Multi 
Wire Myograph System 610M, DMT, Denmark). Atrial tra‑
beculae are mounted between a fixed and a mobile steel hook 
which is attached to a force transducer. Pacing electrodes 
are inserted in polyvinyl chloride cubs, covering the bottom 
and sides of the chambers. Inserted tubes enable gas sup‑
ply and buffer changes. After pacing atrial trabeculae with 
rectangular pulses (5 ms) and a field stimulation at 1 Hz, 
trabeculae are gradually pre‑stretched to their maximal force 
of contraction [267, 311]. When further stretching does not 
cause greater force of contraction [311], stretch is reduced 
to 90% of the length with such maximal force [99].
Simulation of ischemia and reperfusion
The trabeculae are bathed continuously in the modified 
Tyrode’s buffer coming from a chamber which is oxygen‑
ated with 95%  O2–5%  CO2 gas mixture and maintained 
at 37 °C with the buffer being re‑circulated. Pacing elec‑
trodes in the organ bath are attached to stimulators and the 
trabeculae are paced constantly at 1 Hz. One end of the tra‑
becula is attached to a quad bridge transducer which cre‑
ates an electrical voltage that is proportional to the force 
generated by the muscle strip. A Powerlab (AD Instru‑
ments) then digitizes that voltage and stores the digital 
data on a computer for future analysis with Chart five for 
Windows software. The amplitude of the spike represents 
the force of contraction of the trabeculae. The trabeculae 
are then allowed to stabilize.
At the end of the stabilization period, ischemia is simu‑
lated by replacing the oxygenated glucose‑containing 
Tyrode’s buffer with a hypoxic, glucose‑free buffer (con‑
taining in mmol/L 118.5NaCl, 4.8 KCl, 24.8  NaHCO3, 1.2 
 KH2PO4, 1.44  MgSO4·7H2O, 1.8  CaCl2·2H2O, 7.0 choline 
chloride) from another chamber and stimulation is increased 
from 1 Hz to 3 Hz to deplete ATP levels. The induction of 
ischemia is immediately apparent on the developed tension 
recording chart, as indicated by a reduction in contractile force 
(Fig. 10c). Simulated ischemia is maintained for 60–90 min 
before the trabeculae are reoxygenated (reperfused) with oxy‑
genated modified Tyrode’s buffer and the pacing returned to 
1 Hz during the reoxygenation period (Fig. 10d). This is con‑
tinued for 30–120 min until the end of the experiment. At the 
end of the experiment, the length and width of the trabeculae 
are measured along with the weight in milligrams.
Recovery of function
The amplitude of the contraction spikes, representing the force 
of contraction, is recorded on a spreadsheet at baseline and at 
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various points during the simulated ischemia and reperfusion 
period. The cross‑sectional area of trabeculae is calculated 
by dividing muscle mass by length times density, assuming 
a cylindrical shape and a density of 1.0 mg/mm3. To ensure 
that comparisons of developed force of contraction are not 
affected by variable muscle size, the cross‑sectional area of 
the right atrial trabeculae is used to calculate developed con‑
tractile stress in mN/mm2 [309]. Additionally, the developed 
contractile stress can be expressed as a percent of baseline.
Exclusion criteria:
1. Trabecular diameter greater than 1.2 mm
2. Damaged trabeculae, determined visually
3. Irregularly contracting trabeculae either at baseline or at 
the end of reperfusion
4. Baseline force development less than 4 mN
Critical analysis of the model
The human atrial trabecular model is a functional model that 
uses force of contraction as a measure and recovery of func‑
tion as a surrogate marker of myocardial injury. A drawback 
with this model is that the human myocardium utilized is 
atrial and not ventricular because of the ease of availability 
of atrial tissue as opposed to ventricular tissue.
A B
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Fig. 10  a Atrial trabeculae on the surface of the appendage being 
dissected. b Atrial trabecula mounted between two platinum pacing 
electrodes. c Functional readout from the atrial trabecula showing the 
change in contractile function (difference in tension) during hypoxia 
and reoxygenation. d The recovery of contractile function at the end 
of the experiment is greater in an atrial trabecula that had been pre‑
conditioned prior to hypoxia and reoxygenation
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The human atrial model depends on superfusion as a 
method of delivery of oxygen and solutes to its cells. The 
diffusion of these substances into the inner core of the tra‑
beculae is inversely proportional to the diameter, the cut‑
off value being 1.2 mm. Trabeculae larger than 1.2 mm in 
diameter do not behave the same way when subjected to 
simulated ischemia/reperfusion.
Unbiased “omics” technologies 
for mechanistic studies and identification 
of molecular targets
Problems of reproducibility of mechanistic experimental data 
in cardioprotection studies have become evident by now [255, 
371]. This may be at least in part due to strong hypothesis‑
driven biased selection of molecular mechanisms that may lead 
to lack of proper randomization and biased interpretation of the 
data on top of general biological variations [337, 371]. There‑
fore, studies aiming at acute cardioprotective mechanisms and/
or identification of potentially cardioprotective molecular tar‑
gets may be performed using unbiased “fishing” approaches, 
such as robust “omics” assays, i.e. genomics, epigenomics, 
transcriptomics, epitranscriptomics, proteomics and metabo‑
lomics followed by bioinformatics and systems‑based analysis 
to predict the most relevant pathways or targets [337, 432].
Genomics and epigenomics
Since the completion of the Human Genome Project [268, 
434], a major effort has been undertaken to link this infor‑
mation to a healthy or unhealthy cardiac phenotype. How‑
ever, it has become evident by now that several additional 
mechanisms related to epigenomic, transcriptomic, epitran‑
scriptomic, proteomic, and metabolomic regulations might be 
crucial to determine the pathological phenotype of myocar‑
dial ischemia/reperfusion injury and cardioprotection. As the 
genetic sequence is largely static from birth, genomics have 
little chance to reveal molecular targets for acute cardioprotec‑
tion. However, the relatively fast epigenomic alterations may 
be relevant for cardioprotection. So far, there is a paucity of 
studies in this field due to technical limitations to measure all 
epigenetic changes [337]. As an example, in mice subjected to 
ischemic preconditioning, histone H3 lysine 9 demethylation 
(H3K9me2) levels were increased in the area at risk compared 
to remote myocardium, and this epigenetic mark was pro‑
posed to be involved in the cardioprotective effect of ischemic 
preconditioning through regulation of autophagy [160].
Transcriptomics and epitranscriptomics
While transcriptomics refers to the characterization of 
gene expression at the ribonucleic acid (RNA) level, 
epitranscriptomics refers to post‑transcriptional RNA modi‑
fications; the most frequent ones are pseudouridine (also 
called the “fifth nucleoside”) and N6‑methyladenosine [192]. 
Currently, transcriptomics seems to be useful for unbiased 
mechanistic studies at the transcript level, including coding 
or non‑coding RNAs, since current technologies allow full 
and accurate assessment of all transcripts in biological sam‑
ples [333, 337, 432, 433]. Transcriptomics can be performed 
by different techniques [337]. Since these techniques require 
special and rapidly changing technologies (e.g. deep sequenc‑
ing, DNA microarray, nanostring, etc.), such measurements 
are suggested to be outsourced to specialized core facilities 
or R&D companies. However, proper sample collection and 
handling, RNA isolation, quality check of the RNA isolate, 
transport, and omics data evaluation are key issues to obtain 
reproducible data [337].
Not much is known on the potential role and regulation 
of epitranscriptomics in cardioprotection. Several technical 
constraints have to be overcome before more insight can be 
obtained.
Sampling and storage
Different types of samples can be used for transcriptomics 
analysis, from liquid biopsies to cardiac tissue samples. It 
is important to follow simple recommendations and to limit 
the variations between the collection procedures to ensure 
sampling quality and consistency of results. Liquid biopsies 
have to be collected in tubes devoid of any heparin, since 
this anti‑coagulant is able to inhibit, even in low concentra‑
tion, downstream applications such as the most widely used 
polymerase chain reaction for gene expression analysis [53]. 
Platelet‑free plasma samples have to be stored at − 80 °C in 
aliquots and assayed as soon as possible, but no later than 
after a very few years. Before aliquoting, it is essential to 
homogenize the centrifugation supernatant of the blood 
samples to ensure homogeneity between aliquots. Plasma 
samples can be stored at − 20 °C for maximally 1 month to 
avoid RNA degradation. Storage has to be done in RNase‑
free tubes, and repeated freeze–thaw cycles must be avoided 
since, unlike miRNAs, not all RNAs are resistant to tem‑
perature variations.
Whole blood samples are also used for transcriptomic 
biomarker discovery [104]. Whole blood samples must be 
collected in special tubes containing a RNA‑stabilizing solu‑
tion, thereby allowing recruitment of patients and collection 
of blood at any time of the day without the need for imme‑
diate processing. These tubes, providing the blood is cor‑
rectly homogenized with the stabilizing agent by at least ten 
inversions, can remain at room temperature for up to 3 days 
before long‑term storage at − 20 or − 80 °C.
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Heart tissue samples have to be collected in RNase‑free 
tubes filled with RNA stabilization solution and stored at 
− 80 °C and assayed for transcriptome as soon as possible 
but no later than after a very few years.
Unfortunately, there are no valid data on the long‑term 
stability of different transcripts, some being more stable 
than others. Therefore, time‑matched sampling and storage 
time as far as possible are recommended. This is even more 
relevant to epitranscriptomics studies since the stability of 
many RNA modifications has not been determined.
RNA isolation and quality check
After collection of biological samples, a variety of commer‑
cially available RNA isolation kits enable RNA isolation. 
Due to the different kind of kits, it is not recommended to 
use different kits in the same study, since some will favor the 
isolation of short RNAs while others will enrich the RNA 
fraction with long molecules. RNA isolates must be stored 
at − 80 °C in RNase‑free tubes, in several aliquots when 
the quantity of RNA is sufficient. Before sending the RNA 
isolates for transcriptomic assays, the quality of RNA iso‑
lates should be checked to make sure that the total RNA 
concentration and the RNA integrity number are suitable 
for the actual transcriptomics technologies used [27]. Some 
techniques to assess RNA expression are less sensitive than 
others to RNA degradation. Undegraded RNA, however, is 
mandatory to obtain reliable results.
Data evaluation
Raw data should be obtained from the transcriptomics assay 
location, and data evaluation should be done by a bioinfor‑
matics professional, or by the application of user‑friendly, 
validated, commercial bioinformatic tools for transcriptomic 
data analysis and target pathway predictions based on, e.g. 
microRNA expression fingerprint or full messenger RNA 
expression profiling [7].
Validation of transcriptomic data
Transcriptomic data and bioinformatic predictions based on 
such data must be always validated experimentally by targeted 
real‑time polymerase chain reaction analyses at the RNA level 
and/or at the protein level by antibody‑based assays or tar‑
geted proteomics [337]. Replication of findings in another 
set of animal experiments or in independent patient cohorts is 
paramount to obtain reliable and reproducible findings.
Proteomics
Proteomics address a large‑scale characterization of pro‑
tein species in biological samples. However, unlike in 
transcriptomics, a protein equivalent of the polymerase 
chain reaction does not exist, such that amplification of 
minute samples is not possible. This results in the major 
limitation of unbiased proteomics analysis, i.e. the large 
abundance proteins mask the changes of low‑abundance 
proteins which also make a significant contribution to cel‑
lular signalling. Discovery proteomics using high‑reso‑
lution mass spectrometry gives the most unbiased view 
of proteins; however, quantification especially of low‑
abundance proteins is very limited. Targeted discovery or 
targeted proteomics focusing on selected panels of pro‑
teins gives more accurate quantification of low‑abundance 
proteins, but loses the unbiased feature of proteomics. 
Moreover, when analyzing cardiac tissue samples, blood 
contamination with plasma proteins and other intracellular 
high‑abundance proteins significantly masks any possible 
changes in low‑abundance proteins and post‑translational 
modifications [165]. Currently available techniques to 
remove top or medium abundance proteins are not sophis‑
ticated enough to exclude depletion of low‑abundance 
proteins of interest. Moreover, protein function is largely 
affected by more than 300 post‑translational modifica‑
tions at over 500,000 post‑translational modification sites. 
However, proteins with post‑translational modifications 
are typically low‑abundance proteins—again no unbi‑
ased technique is available for their detection. Therefore, 
targeted proteomics with special techniques and further 
chemical modifications or labeling are required [277]. In 
conclusion, so far proteomics show several limitations that 
restrict the use of this technology for unbiased discov‑
ery for all proteins, especially with their posttranslational 
modifications, but the technologies are rapidly developing 
[280]. Similarly to transcriptomics, discovery proteomic 
results should be experimentally validated by targeted pro‑
teomics and/or antibody‑based assays.
Metabolomics
Metabolomic technologies based on mass spectrometry or 
NMR techniques after pre‑analytical chromatography sam‑
ple preparation to reduce metabolite diversity can measure 
thousands of small molecule metabolites from biological 
samples. Given the total number of small molecule metabo‑
lites in humans (estimated up to 100.000 in Human Metabo‑
lome Database) and the fact that only a fraction of them can 
be measured by high‑throughput metabolomic technologies 
(typically measuring around 1000 molecules even in full 
scan discovery mode at a time) so far metabolomics are not 
useful for unbiased analysis of all metabolites [73]. Never‑
theless, targeted metabolomics may serve as a reflection of 
protein functional activity and be useful for validation of 
proteomic data at the metabolite level (Fig. 11).
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Multiomics
Taken together, the transcriptomics approach fulfills the 
term of unbiased target discovery as this technology allows 
measurement of theoretically all transcripts in biological 
samples. Targeted proteomics and metabolomics are very 
useful tools for validation of molecular targets identified 
from transcriptomics data. Nevertheless, pulling together 
transcriptomic, proteomic and metabolomic data by multi‑
omics approach, based on the concepts of systems biology, 
will open up a new field to identify biomarkers and molecu‑
lar targets for complex diseases, such as ischemic heart dis‑
ease, and eventually cardioprotection [26, 337]. Some pre‑
liminary data using multiomics recently gained more insight 
into mechanisms of cardiac remodeling in mice. The authors 
used integration of transcript abundance, protein abundance, 
and protein turnover data, leading to 75% gain in discovered 
disease gene candidates in six genetic strains of mice [272]. 
Analysis of multiomics data (target predictions, pathway 
analyses) needs excessive bioinformatic expertise. However, 
user‑friendly software is rapidly emerging, but their diversity 
in mathematical models and source data do not yet allow 
accurate comparison of different results.
Proof‑of‑concept clinical phase I/II trials 
with surrogate endpoints
Although phase I/II studies defining dosing, timing and 
safety of cardioprotective interventions may appear to be a 
straightforward task, the field of cardioprotection by not only 
mechanical but also pharmacological interventions is char‑
acterized by a surprising lack of adequate phase I/II studies. 
While animal studies allow the establishment of an optimal 
algorithm of cardioprotective treatments by studying the influ‑
ence of number and duration of cycles, influence of effector 
organ mass and timing of remote ischemic preconditioning 
on infarct size [228, 393] and such studies are also feasible 
in larger animals, they are more challenging in the clinical 
setting, because dose–response studies using infarct size or 
myocardial salvage require acute settings and a large number 
of patients, regardless of whether the endpoint is determined 
from a biochemical injury marker or an imaging modality.
Surrogate endpoints: peripheral circulation
Hence, the translation to human proof‑of‑concept stud‑
ies frequently requires use of surrogate endpoints. Studies 
should be initiated in healthy volunteers and subsequently 
transcriptomics
(relevant for unbiased full 
scale analysis) 
proteomics
(technical limitations for
unbiased discovery) 
metabolomics: 
(technical limitation for 
unbiased analysis)
genomics
(no relevance for acute 
cardioprotection)
target validation
(at mRNA, protein, and 
metabolite levels) 
prediction of 
molecular targets
(including RNA modifications) epitranscriptomics
(technical limitations for 
unbiased discovery) 
epigenetic
mechanisms
epigenomics
(technical limitations for 
unbiased discovery)
proteins
(including post-translational
modifications)
metabolites
DNA
non-coding RNA coding RNA
Fig. 11  Different omics approaches from the genome to metabolome. 
Current technologies so far allow unbiased analysis of all genes and 
transcripts. Based on transcriptomic fingerprints, in silico prediction 
of molecular targets can be achieved. Predicted targets must always 
be validated at the protein level. Other omics technologies are rapidly 
emerging; however, their use is currently limited to assess only frac‑
tions of the total epigenetic/transcriptomic, proteomic and metabo‑
lomic pool
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proceed to basal conditions [343] or an acute ischemia/rep‑
erfusion equivalent that may be precipitated by exercise, 
pharmacologically induced myocardial ischemia, or elective 
percutaneous coronary intervention (PCI) in patients with 
stable coronary artery disease [213]. During elective PCI, 
measurements of biochemical myocardial injury markers can 
be used, whereas studies in healthy volunteers and patients 
with stable coronary artery disease not undergoing coro‑
nary interventions require alternative endpoints. Because 
ischemia/reperfusion induces endothelial dysfunction, the 
most frequently used surrogate endpoint is endothelial 
ischemia/reperfusion injury of the human forearm induced 
by 20 min of upper limb ischemia by inflation of a blood 
pressure cuff to 200 mm Hg followed by reperfusion [248]. 
Forearm blood flow in response to acetylcholine at base‑
line and 15 min after reperfusion can be assessed by venous 
plethysmography [248]. Alternatively, high‑resolution ultra‑
sound can be used to measure the diameter of the superfi‑
cial brachial artery at rest, during reactive hyperemia (with 
increased flow causing endothelium‑dependent dilatation), 
and after sublingual glyceryl trinitrate (causing endothe‑
lium‑independent dilatation) [67]. The latter model requires 
measurements on at least two occasions before and after any 
intervention, to optimize the probability of showing a sig‑
nificant effect from any potentially beneficial therapy [398].
The finger hyperemia index correlates with values of flow‑
mediated dilatation by means of brachial artery ultrasound 
scanning [264]. This modality measures fingertip pulse‑
volume amplitude to calculate a reactive hyperemia index, 
assessed as a measure of peripheral microvascular endothelial 
function. Finger reactive hyperemia is evaluated noninvasively 
in the index finger of the left hand of participants using, e.g. 
the EndoPAT 2000 device (Itamar Medical, Caesarea, Israel). 
A beat‑to‑beat plethysmographic recording of the arterial 
pulse wave is obtained over 5 min of rest. Brachial arterial 
occlusion is then induced by inflating an upper arm cuff to 
suprasystolic pressure (60 mmHg above systolic pressure) for 
5 min and released to elicit reactive hyperemia. Pulse ampli‑
tude responses to hyperemia are calculated from the hyperemic 
fingertip as the ratio of the postdeflation pulse amplitude to the 
baseline pulse amplitude and adjusted for the corresponding 
ratio in the right control hand and expressed as finger reac‑
tive hyperemia [266]. Although these studies bring impor‑
tant insights into our understanding of the pathophysiology 
of ischemia/reperfusion injury, one must be aware that they 
may not reflect or predict the actual impact of a given puta‑
tively “protective” intervention to be tested on the “ultimate” 
insult, i.e. irreversible myocardial injury following a prolonged 
coronary artery occlusion [207]. None of the above‑mentioned 
variable/surrogate endpoints is indeed predictive of clinical 
outcomes in patients with acute myocardial infarction, i.e. truly 
indicative of “cardioprotection” (which is primarily infarct size 
reduction).
Surrogate endpoints: coronary circulation
The coronary circulation is a major target for cardioprotec‑
tive strategies [198]. Blood flow velocity in the LAD can 
be assessed non‑invasively by transthoracic Doppler echo‑
cardiography before and after a cardioprotective interven‑
tion [461]. Doppler signals of coronary blood flow should 
be recorded at baseline and 1, 3, 6 and 9 min after the car‑
dioprotective intervention in three cardiac cycles. The ECG 
must be continuously monitored to register changes in heart 
rate. Outcome variables include the mean coronary blood 
flow velocity, peak diastolic velocity, mean diastolic velocity, 
peak systolic velocity and mean systolic velocity. Follow‑
ing a baseline blood flow velocity measurement, intravenous 
adenosine infusion of 140 μg/kg/min for 90 s allows coronary 
blood flow reserve quantification and hence assessment of 
microvascular function. However, caution should be exerted 
about repetitive measurements with short intervals because 
adenosine per se exerts cardioprotective effects [281], so that 
measurements on separate days are advisable to avoid inter‑
ference between a cardioprotective treatment and adenosine.
The epicardial endothelial and endothelium‑independent 
vascular function [87] and the impact of coronary collaterals 
[20] can be studied in patients with stable coronary artery 
disease undergoing a coronary intervention. To avoid any 
interference, the discontinuation of the patient’s long‑acting 
antianginal medication is recommended 48 h prior to the 
investigation. Endothelium‑dependent vasodilator function 
is assessed preferentially both in a stenotic target and a non‑
stenotic non‑target coronary artery during incremental intra‑
coronary acetylcholine doses at 1, 3, 10, and 30 μg/min for 
2 min at each dose. Non‑endothelium‑dependent vasodilator 
function is measured subsequently using intracoronary nitro‑
glycerine, 0.40 mg. Coronary luminal diameter is assessed 
by quantitative coronary angiography and coronary blood 
flow velocity measured by Doppler. The influence of any 
cardioprotective treatment on coronary blood flow reserve 
can be determined using intracoronary adenosine 40 and 
80 μg in the right and left coronary artery, respectively. As 
with non‑invasive studies, venous blood sampling before 
and after the cardioprotective procedure or sham should be 
added, as circulating markers yield additional information on 
inflammatory, (e.g. myeloperoxidase, interleukin‑6) coagula‑
tory, (von Willebrand factor, asymmetric dimethylarginine) 
and fibrinolytic (tissue plasminogen activator) function. As 
with non‑invasive studies, results obtained by repetitive 
measurements must be interpreted in the light of the fact 
that adenosine per se exerts cardioprotective effects [86].
Invasive results relate to the epicardial coronary artery 
[208] and they only reflect the coronary microcirculation 
when coronary flow reserve is quantitated using adenosine 
(intravenous infusion of 140 μg/kg/min for 90 s). Positron 
emission tomography allows quantification of myocardial 
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blood flow before and after a cardioprotective intervention 
in patients with stable angina pectoris, and positron emis‑
sion tomography imaging enables regional visualization 
of non‑ischemic and reversibly and irreversibly ischemic 
myocardial areas so that therapeutic effects on the “true” 
cardioprotection target (namely infarct size) can be assessed 
separately in these regions [343].
ST segment elevation myocardial infarction
Patients
STEMI patients recruited for cardioprotection studies 
must meet the absolute indication for revascularization, 
i.e. chest pain, < 12 h since symptom onset, ST‑segment 
elevation in at least two contiguous leads (≥ 2.5 mm in 
men < 40 years, ≥ 2 mm in men ≥ 40 years, or ≥ 1.5 mm in 
women in leads V2–V3 and/or ≥ 1 mm in the other leads) in 
the first ECG.
The recruitment of patients depends on the conditions, and 
patient selection may vary. Selected patients, who are most 
likely to benefit from a novel cardioprotective strategy [57], 
can be identified prior to admission, when a large anterior 
infarction presents on the ECG or at the catheterization labo‑
ratory or when the LAD is occluded proximally. An unselected 
group to determine efficacy in dependence of infarct location, 
vessel patency, collateral status, etc. may be preferred to clarify 
the influence of these confounders. Baseline characteristics 
should include the variables specified in Table 4.
Outcome measures
In proof‑of‑concept clinical studies, it may be sufficient to 
measure serum cardiac enzymes, i.e. CK‑muscle/brain (CK‑
MB) and troponin‑T (TnT) or TnI. However, a more robust 
surrogate clinical endpoint is infarct size (measured by 
myocardial nuclear scanning or CMR). Ultimately, clinical 
outcome measures such as (cardiac) mortality and/or hospi‑
talization for heart failure must be determined.
Surrogate endpoints
Imaging data Two experienced nuclear cardiology inves‑
tigators blinded to treatment assignment and clinical data 
must analyze the data independently. Images can be ana‑
lyzed with a commercially available automatic program. In 
case of failure of the automatic quantification algorithm, 
methods to mask extracardiac activity or to define the valve 
plane and apex of the left ventricle, or both, can be used. If 
the difference in infarct size between the readers exceeds 
3%, a consensus reading is recommended from the two or 
additional readers.
Quantification of  area at  risk CMR: This technique has 
been used extensively in recent years to quantify the areas 
of edema as a surrogate to area at risk. It cannot be recom‑
mended to use CMR to retrospectively quantify area at risk, 
for the reasons given in the section "Quantitation of infarct 
size by morphology, biomarkers and imaging" [210].
SPECT: Before reperfusion therapy is started, 700 MBq 
(±  10%) 99Tc‑sestamibi is administered intravenously; 
within 8 h of injection of the radionuclide, SPECT must be 
performed with a high‑resolution parallel‑hole collimator 
dual headed rotating gamma camera, see section "Quantita‑
tion of infarct size by morphology, biomarkers and imaging".
Table 4  Baseline characteristics for STEMI patients included in car‑
dioprotection trials
Age
Gender
Risk factors
 Smoking
Comorbidities
 Dyslipidemia
 Hypertension
 Diabetes mellitus
 History of coronary artery disease
 Previous MI
Preinfarction angina within 1 week before the index event
Infarct‑related artery
 Left anterior descending artery
 Circumflex artery
 Right coronary artery
 Not identifiable
Number of other vessels with clinically significant disease
Symptom‑to‑balloon time
TIMI flow grade at admission
 0/I/II/III
Stenting of culprit lesion by pPCI
TIMI flow grade after procedure
 0/I/II/III
History of medication
 Beta‑blockers
 Statins
 ACE‑inhibitors
 AT‑blockers
 Calcium channel blockers
 Long acting nitrates
 Metformin
 Insulin
 Other antidiabetic drugs
Drugs given at time of pPCI
 Heparin
 Aspirin
 P2Y12‑inhibitors
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Quantification of  infarct size CMR: LGE–CMR imaging 
must be performed to quantify infarct size 10–15 min after 
intravenous administration of 0.20 mmol of gadopentetate 
dimeglumine contrast agent per kg of body weight, see sec‑
tion "Quantitation of infarct size by morphology, biomark‑
ers and imaging".
SPECT: infarct size is quantified using the same protocol 
as for the area at risk quantification 30 days after the STEMI 
event.
Biomarkers of myocardial injury Extending section "Quan‑
titation of infarct size by morphology, biomarkers and imag‑
ing", CK or preferably high‑sensitive troponins (TnT or 
TnI) are measured at 0, 6, 12, 24, 48 and 72 h following the 
revascularization procedure for establishment of a 72 h area 
under the curve. Attention must be paid to use a unique kit 
for one assessment of these biomarkers.
Clinical endpoints Cardiac mortality and readmission for 
heart failure at 30 days and 1 year are the most important 
clinical outcome endpoints. All‑cause mortality at 30 days 
and 1 year should also be recorded, as well as MACCE at 
30 days and 1 year.
The cardioprotective intervention
More than a few cardioprotective studies have been forced 
rapidly from inadequate preclinical experiments to clinical 
trials that may have been premature [56, 181, 184, 196]. 
To overcome the obstacles in translating new cardioprotec‑
tive strategies discovered in the laboratory into the clinical 
setting for patient benefit, the strategy should be founded 
on solid experimental, preclinical, and translational data, 
including in vitro models in established animal models of 
ischemia/reperfusion injury and including human myocar‑
dial tissue models of simulated ischemia/reperfusion injury 
as described above. The preclinical translation studies 
should not only include experiments, which involve a variety 
of confounding factors that may modify the efficacy of the 
cardioprotective strategy, but also reflect the polypharma‑
ceutical environments in which the cardioprotective strat‑
egy will be employed in clinical trials, e.g. on the current 
background of current medical therapy for STEMI patients 
including opiates and  P2Y12 inhibitors which share cardio‑
protective signaling with ischemic conditioning and induce 
cardioprotection per se, as discussed in section "Larger 
mammal hearts in situ" [85, 450]. Dose–response studies 
are not only required in pharmacological studies but also in 
studies of mechanical conditioning such as remote ischemic 
conditioning. Such studies may be challenging because a 
direct cardioprotective effect in humans relies on surrogate 
markers, most frequently endothelial ischemia/reperfusion 
injury, and available methods are not sufficiently sensitive to 
measure minor differences between doses. A hybrid method 
using different cycle numbers and durations of ischemia/rep‑
erfusion in humans with subsequent transfer of cardioprotec‑
tive plasma samples to a mouse, rat or rabbit heart exposed 
to ischemia/reperfusion injury in a Langendorff mode may 
be recommended for establishing human dose–response 
studies. Of note, the conditions of reperfusion by PCI may 
also influence the efficacy of the supposedly protective inter‑
vention, including use of direct stenting or “pre‑dilatation” 
or “post‑dilatation” that may per se trigger inadvertent post‑
conditioning and bias the final analysis [196].
Cardiac surgery
Patients
Overall, outcome following cardiac surgery is favorable [6]. 
The majority of complications relate to mechanical obstacles 
or bleeding that may not be significantly modified by cardio‑
protective strategies. Nevertheless, perioperative myocardial 
damage attributed to ischemia/reperfusion injury has been 
associated with increased perioperative morbidity and mor‑
tality [111, 422]. The risk of perioperative myocardial dam‑
age is increased in patients with a EuroSCORE (European 
System for Cardiac Operative Risk Evaluation) > 5, and car‑
dioprotective efficacy is thought to be enhanced in patients 
with left ventricular hypertrophy or impaired left ventricular 
systolic function, patients undergoing three‑vessel coronary 
artery bypass graft with/without valve surgery or redo coro‑
nary artery bypass graft surgery and patients with diabetes 
mellitus. Hence, the investigation of a new cardioprotective 
strategy should focus on such patients. Baseline charac‑
teristics should include the variables specified for STEMI 
patients, except those specifically relating to culprit lesion 
treatment in STEMI patients.
Outcome measures
In proof‑of‑concept clinical studies, perioperative release 
of cardiac ischemic biomarkers, such as CK, preferably as 
the myocardial fraction CK‑MB, TnT or TnI is the only way 
to assess the efficacy of the novel cardioprotective strategy 
on myocardial injury [186, 420, 421]. One must, however, 
be aware that cardiac surgery including myocardial inci‑
sion or coronary clamping (e.g. coronary bypass) will per 
se cause cardiac enzyme release, hence alter interpretation 
of the data. Other clinical endpoints include: inotrope score, 
duration of mechanical ventilation, length of intensive care 
unit and hospital stay, left ventricular ejection fraction, acute 
kidney injury, cognitive function, cardiovascular mortality, 
and hospitalization for heart failure at 30 days and 1 year. 
Although there is no direct link between perioperative 
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cardioprotection and the need for coronary revasculariza‑
tion, and although heart failure is not included, a frequently 
used clinical endpoint is a composite endpoint of the rate of 
MACCE (death from cardiovascular causes, nonfatal myo‑
cardial infarction, coronary revascularization, or stroke), 
assessed within 12 months after randomization [182]. An 
independent event validation committee must validate all 
primary events.
Anesthesia
Inhaled anesthetic agents such as isoflurane and sevoflurane, 
the recommended first choices in patients at risk of myocar‑
dial ischemia [455], and intravenously administered propofol 
have all been reported to confer cardioprotection during cor‑
onary artery bypass graft surgery in preclinical and clinical 
studies [410]. It is important that any novel cardioprotective 
strategy is shown to be effective in the presence of routine 
medical therapy. Even so, it is necessary to take interference 
with cardioprotective strategies into consideration. Propofol 
seems no more cardioprotective than isoflurane per se, but in 
contrast to isoflurane and sevoflurane, propofol specifically 
abrogates the protection by remote ischemic conditioning 
in patients undergoing elective coronary artery bypass graft 
surgery [32, 260, 261, 454], and seems to be a common 
denominator of all studies that failed to see protection with 
remote ischemic conditioning [204, 302]. So, propofol must 
be avoided specifically in studies investigating the efficacy 
of remote ischemic conditioning.
Concomitant medication
While it may be possible to standardize the anesthetic 
regimen, concomitant medication in clinical cardioprotec‑
tion studies may vary significantly. Providing the study is 
adequately powered and properly randomized, confound‑
ing factors should be distributed equally between the study 
intervention and the standard treatment groups. When it 
is difficult to perform a large clinical study without stand‑
ardization of concurrent medical therapy, stratification 
of the study with respect to confounding factors must be 
considered.
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